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Abstract
Introduction
According to the World Health Organisation, antimicrobial resistance (AMR) is one of
the major threats to human health in the twenty-first century. Many of the advances of
modern medicine, such as cancer treatments and complex surgeries, are being threatened
by the development of AMR. Antimicrobial overuse has been associated with the
development of AMR. This has resulted in a situation where previously treatable
infections can now become life-threatening. To address these risks, antimicrobial
stewardship (AMS) has been developed as an important strategy for improving the use of
antimicrobials. AMS aims to improve patient outcomes, reduce adverse effects, and
alleviate AMR. Most of the available literature on AMS has been derived from single site,
metropolitan teaching hospitals with on-site infectious diseases, pharmacy and
microbiology support. There remains an evidence gap for AMS strategies that are
applicable to non-metropolitan and multisite hospital settings.

The aims of this thesis were threefold: (1) to develop and evaluate educational strategies
for improving antimicrobial use in different clinical settings, such as infection prevention,
treatment of infection, and side effects of antimicrobial use; (2) to develop methods for
AMS education and evaluation that are applicable to non-metropolitan and multisite
settings, and; (3) to develop, apply and evaluate technology in AMS, including the role of
clinical decision support software and innovative educational tools such as interactive elearning for health professional education.
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Methods
This research project consisted of a series of interconnected studies that addressed AMS
education and evaluation strategies at the individual, departmental, hospital and health
district level. Quantitative and qualitative approaches were used to evaluate the impact of
the interventions. A focus was placed on measurement of patient outcomes related to
antimicrobial use, such as length of hospital stay, readmission rate and mortality. An
interactive e-learning tool for health professional education on the antibiotic vancomycin
was also developed and evaluated.

Results
Improvements in antimicrobial use supported by timely audit and feedback methods were
demonstrated, without evident harm to patients. Those included discontinuation of the
antibiotic gentamicin for prophylaxis around hip and knee replacement surgeries, a
reduction in the duration of therapy for community-acquired pneumonia, and a reduction
in broad spectrum antimicrobial use across multiple hospitals sites resulting from
implementation of AMS. A clinical decision support system was shown to be a successful
tool for supporting implementation of AMS across multiple sites. A novel web-based elearning tool that adopted serious game design concepts was also developed for education
of health professionals. Successful change to the culture of antimicrobial use from the
individual to the health district level was demonstrated.

Discussion
The results suggest that educational strategies, supported by technology and antimicrobial
restriction, can be effective in improving antimicrobial use in a network of hospitals with
16

disparate geography and resources. The application of similar techniques across different
settings created economies of scale, which allowed support of smaller sites by larger,
better resourced hospitals. Future research aims to demonstrate the effect of changes to
antimicrobial use patterns on AMR, and to further elaborate novel educational strategies
for improving antimicrobial use.
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1 General introduction
1.1 Preamble

The World Health Organisation (WHO) has described antimicrobial resistance (AMR) as
one of the main threats to human health in the twenty-first century (World Health
Organisation, 2014). Governments around the world have recognised that an international
effort is required to curb AMR, whereby overuse of antimicrobials has led to a situation
where previously treatable infections can now become life-threatening. In Australia,
management of infections in hospitals forms a key component of the strategy for
addressing AMR (Australian Government, 2015). In 2010, the first edition of
Antimicrobial Stewardship in Australian Hospitals was published by the Australian
Commission on Safety and Quality in Health Care (ACSQHC), which offered a
framework for improving the treatment and prevention of infections through more
judicious use of antimicrobials (Duguid and Cruickshank, 2010).

This introductory chapter provides a brief background on strategies for improving
antimicrobial use, with a focus on evaluating strategies for education at the individual,
department, hospital and health district level. It identifies that there is limited published
evidence for these strategies in the non-metropolitan setting where health care facilities
experience geographic and resource disparities. The specific aims of the research and an
outline of the thesis structure are also provided.
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1.2 Background

Antimicrobial stewardship (AMS), or antibiotic stewardship, is defined as a set of
strategies intended to improve the use of antimicrobials (Duguid and Cruickshank, 2010).
Antimicrobial stewardship programs (ASPs) are a required component for accreditation
according to ACSQHC standards, which have been introduced to drive safety and quality
in public and private health care organisations in Australia (Australian Commission on
Safety and Quality in Health Care, 2011). ASPs are implemented with the goals of
treating and preventing infections more effectively, while curbing AMR and reducing
adverse outcomes for patients (Ashiru-Oredope et al., 2012). Previously reported patientrelated outcome measures used to evaluate AMS include mortality, length of hospital stay
(LOS) and readmission rates (Khadem et al., 2012). Various approaches for establishing,
maintaining and measuring the success of ASPs include: implementation of clinical
guidelines; formulary restriction and approval systems; education on appropriate
prescribing of antimicrobials; and audit with intervention and feedback to the prescriber
(Dellit et al., 2007; Duguid and Cruickshank, 2010).

High rates of inappropriate antimicrobial prescribing in Australian hospitals have been
described in the literature (Robertson et al., 1999; Robertson et al., 2002; Radford et al.,
1999; To et al., 1999). Improving appropriateness of prescribing according to accepted
antimicrobial guidelines is a key strategy for ASPs (Dellit et al., 2007). Furthermore,
ASPs have been effective in reducing AMR in selected settings (Yong et al., 2010;
Khadem et al., 2012). Organisms commonly targeted as part of these programs include
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methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci
(VRE) and multidrug resistant Gram-negative species (Khadem et al., 2012).

Improvements in the quality of antimicrobial prescribing have been associated with:
improved cure rates, reduced adverse events, Clostridium difficile infection (CDI),
reduced LOS and reduced infection-related mortality (Davey et al., 2013). Some ASPs
have demonstrated reduced costs without causing harm to patients (Dellit et al., 2007;
Carling et al., 2003). A common limitation of many AMS studies is their uncontrolled
before-and-after design, with some studies not accounting for external factors such as
changes in drug-acquisition costs and infection control practices (Vettese et al., 2013;
McGowan, 2012). To compensate for the potential methodological shortcomings of
pragmatic clinical research, interrupted time series (ITS) analysis, or analysis of change in
trend attributable to an intervention, has been used as an effective evaluation tool (van
Kasteren et al., 2005).

1.3 Evaluating educational strategies

A number of methods have been developed for improving antimicrobial prescribing. A
Cochrane review of interventions to improve antimicrobial prescribing for hospital
inpatients categorised interventions into three groups: persuasive (or educational),
restrictive and structural (Davey et al., 2013). Examples of persuasive interventions
include printed educational material, reminders, audit and feedback, and educational
outreach in the form of academic detailing and recommending change. Restrictive
interventions include compulsory order forms, requirement for expert approval, stock
restriction (removal of antimicrobials from clinical areas), and “review and make change”
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strategies. Restrictive interventions have demonstrated greater initial effects on
antimicrobial use whereas educational interventions may be more durable over time.
Structural interventions include computerised clinical decision support systems (CDSSs)
and introduction of quality monitoring mechanisms (Davey et al., 2013). The updated
Cochrane review by Davey and colleagues (2017) identifies “enabling” interventions as
audit and feedback, educational outreach and reminders. Evaluation of educational
interventions forms the main theoretical framework for this research, whereby education
is supported by restrictive and structural interventions.

When developing educational AMS strategies, it is necessary to recognise concepts such
as medical hierarchy, targeting of opinion leaders and unwillingness of prescribers to alter
prescriptions started by medical colleagues (Charani et al., 2011). Study designs for
improving antimicrobial use should include multiple quality improvement methods,
developing an understanding of the target audience’s motivations (Charani et al., 2011;
Gaynes et al., 2009; Antoine et al., 2006). It is also necessary to recognise differences in
learning styles between junior and senior medical staff (Gaynes et al., 2009). Prospective
audit with educational feedback is an important component of AMS education (Duguid
and Cruickshank, 2010). Timely feedback allows for meaningful changes to the therapy
of the individual patient, in addition to providing quality improvement data (Griffith et
al., 2012).

It has been proposed that a strategy for health care quality improvement should include
the following: measurement that is practical and goal-oriented; gathering baseline data on
small numbers initially and checking findings; improving the delivery process while
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gathering data; and following these up with graphical representation of data and
measurement of key outcomes over time (Nelson et al., 1998). Emphasis on usefulness
rather than perfection is readily applicable to AMS methodology as the focus should be
on making measurable improvements to processes and outcomes that are relevant to
patient care. Outcome measures for ASPs should include balancing measures, or
unintended consequences of changes to antimicrobial use (Davey et al., 2013; Davey et
al., 2017).

This research project employs a series of Plan-Do-Study-Act (PDSA) cycles as a
pragmatic methodological approach to improving antimicrobial prescribing practices
(National Health Service Institute for Innovation and Improvement, 2008). ITS analysis is
used as a pragmatic quasi-experimental technique to evaluate the impact of AMS
interventions (Fowler et al., 2007), where the immediate clinical need for change may
hamper the application of more robust research methodologies.

1.4 Rural and regional hospitals

Much of the literature supporting AMS has been produced in metropolitan teaching
hospitals with on-site access to infectious diseases (ID), microbiology and pharmacy
expertise (Dellit et al., 2007). There is little primary evidence on ASPs in small, rural or
regional hospitals. Approaches to AMS in those settings have included education, clinical
review, and implementation of clinical guidelines (LaRocco, 2003). Antimicrobial
restriction has typically been reported in response to infection outbreaks such as CDI
(Kuntz et al., 2007; Schabas et al., 2012). Barriers to successful implementation and
evaluation of ASPs in those sites include a lack of human resources for education and
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research, large distances from AMS experts and microbiology laboratories, and the
potential for small numbers to limit conclusions about any interventions. It is necessary
for hospitals to tailor approaches to their specific needs and level of resources (Patel,
2010). Of the 1345 hospitals in Australia, 753 are public hospitals, comprising 80
principal referral hospitals, 40 large hospitals and 589 hospitals defined as medium-sized
or smaller (Australian Institute of Health and Welfare, 2013). With such a large number
of smaller Australian hospitals, there is a need to address the evidence gap on pragmatic
approaches to improving antimicrobial use in these settings.

1.5 Use of technology to support AMS education

Use of computerised clinical decision support systems (CDSSs)
CDSSs are software tools that bring together patient-specific data and knowledge bases
(Thursky, 2006). In the setting of AMS, this commonly refers to provision of evidencebased guidelines for selection and dosing of antimicrobials for a specific infection. As
prescribing is a complex task that involves integrating information (often incomplete)
from a variety of sources, and potential time pressure, a CDSS may be employed to
reduce the cognitive effort required to prescribe (Sintchenko and Coiera, 2003). A CDSS
also offers improved potential for education through provision of links to guidelines, and
improved monitoring and reporting of antimicrobial use (Baysari et al., 2016).

Use of email as a communication strategy in clinical research
Given the geographic disparity of some hospital locations within the health districts
studied (Australian Institute of Health and Welfare, 2016), provision of timely clinical
audit feedback using face-to-face methods can be challenging. Email is described as a
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tool to report research findings at an individual and department level, and to provide links
to knowledge and attitude surveys. However, low response rates have been reported in the
literature, with lack of time and survey burden described as the main reasons for nonresponse (Cunningham et al., 2015). An investigation into the utility of email as a
communication method for clinical quality improvement is explored in this research
project.

Novel strategies for health professional education
The use of internet-based learning (IBL), or web-based learning, for health professional
education is an emerging field (Cook et al., 2008). As an educational approach, IBL can
overcome some of the barriers that are experienced by traditional educational methods,
such as increased clinical demands preventing face-to-face teaching (Cook et al., 2010).
Web-based e-learning tools that adopt serious game concepts such as interactivity and
entertainment have the potential to improve health professional education (Graafland et
al., 2012). In AMS, smartphone availability may also drive novel educational approaches
for health professionals (Goff, 2012). Novel IBL approaches also provide opportunities
for AMS research.

1.6 Aims

This research project aims to contribute new knowledge regarding the best methods of
education and evaluation to improve antimicrobial use in a multisite hospital setting, and
to inform future AMS research.
The specific aims of this research are:
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1. To develop and evaluate educational strategies for improving antimicrobial use in
different clinical settings:


prevention of infection (surgical prophylaxis; Chapter 2)



treatment of infection (community-acquired pneumonia [CAP]; Chapter 3)



adverse effects of antimicrobial overuse (CDI; Chapters 4 and 5)



dosing, administration and therapeutic drug monitoring (TDM;
vancomycin; Chapters 6 and 7)

2. To develop methods for AMS education and evaluation that are applicable to nonmetropolitan and multisite settings, including:


use of timely audit and feedback (Chapters 2, 3 and 4)



appropriate evaluation of outcome measures such as mortality, LOS,
duration of therapy, and health costs (Chapters 3, 4 and 5)



use of ITS methodology for evaluation of AMS research (Chapters 4 and
5)

3. To develop, apply and evaluate technology for improving antimicrobial use,
including:


the role of a CDSS as a tool for implementing an ASP and supporting
quality improvement initiatives (Chapters 3, 4 and 5)



the utility of email as a method of feedback and education for clinicians
(Chapters 2, 3, 4 and 7)



innovative methods for health professional education such as a web-based
e-learning tool (Chapters 6 and 7)
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1.7 Structure of the thesis

This thesis has been prepared in the format of journal article compilation. This was
considered to be the most appropriate style for the thesis content due to the common
education and evaluation themes between chapters. Chapters 2 through 7 comprise six
articles; five have been published or are in press, one has been submitted for editorial
review. Although the articles are formatted according to the guidelines of each journal,
the referencing style has been changed to Harvard style for consistency throughout the
thesis, with references placed at the end of each chapter. In order to enhance the
coherence of this thesis by compilation, a brief summary of each chapter is provided
below.

Chapter 2 reports on an initiative to improve antimicrobial use for prevention of
infections related to prosthetic hip and knee replacements. Quality improvement
methodology is employed, using the combination of departmental education with timely
audit and feedback to individual prescribers. Use of email to overcome communication
barriers with senior doctors is described. The article was written by the candidate with coauthors Craig Boutlis, Stuart Jansen and Spiros Miyakis, and was published in the
Australian New Zealand Journal of Surgery (Bond et al., 2016a).

Chapter 3 provides a model for improving the antimicrobial treatment of communityacquired pneumonia (CAP), one of the most common and serious infections. A similar
educational framework as used in Chapter 2 is described, including the use of timely
email feedback of audit results. Education for decision makers (senior medical staff) and
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at the departmental level on appropriate use of antimicrobials was central to the
improvement methodology. The CDSS was used as a tool to assist the data collection
process. The article was written by the candidate with co-authors Craig Boutlis, Wilf Yeo
and Spiros Miyakis, and was published as a brief communication in Internal Medicine
Journal in 2017 (in press) (Bond et al., 2017a).

Chapter 4 describes a research project on an adverse effect from inappropriate
antimicrobial use, CDI. A multisite methodology for reducing inappropriate use of
causative antimicrobials is described, including use of timely email feedback to senior
clinicians and a CDSS for monitoring of antimicrobial use. The chapter also reports
hospital costs and LOS as key AMS outcome measures. The article was written by the
candidate with co-authors Craig Boutlis, Wilf Yeo, William Pratt, Megan Orr, and Spiros
Miyakis. It was published in the Journal of Hospital Infection in 2016 (Epub ahead of
print) (Bond et al., 2016b).

Chapter 5 provides an overview of implementation and evaluation of an ASP across
multiple hospital sites, with antimicrobial use, CDI, antimicrobial costs, LOS and
mortality as indicators of improvement. Hospitals from two health districts and a
specialist children’s hospital are included in the report. A centrally deployed CDSS and
various educational strategies are explored as tools for implementing and evaluating a
multisite ASP across hospitals with varying resources, including those in regional and
rural areas. The article was written by the candidate with co-authors Adriana Chubaty,
Suman Adhikari, Spiros Miyakis, Craig Boutlis, Wilf Yeo, Marijka Batterham, Cara
Dickson, Brendan McMullan, Mona Mostaghim, Samantha Li-Yan Hui, Kate Clezy, and
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Pamela Konecny. The article was published in the Journal of Antimicrobial
Chemotherapy in 2017 (in press) (Bond et al., 2017b).

Chapter 6 reports on the design and implementation of a novel web-based e-learning tool
for health professional education on antimicrobial use. The specific antimicrobial tested is
vancomycin, used for treatment of serious infections caused by MRSA. The Vancomycin
Interactive (VI) is proposed as a useful approach where the multiple hospitals within a
health district are spread across a large geographic area, thereby addressing a barrier to
ongoing education. Through its hosting on an open website, the game can also be easily
used in smaller rural and regional hospitals. Qualitative survey methodology is employed
to report on knowledge and attitudes related to the intervention. The article was written
by the candidate with co-authors Shelley Crowther, Suman Adhikari, Adriana Chubaty,
Ping Yu, Jay Borchard, Craig Boutlis, Wilf Yeo, and Spiros Miyakis. The article was
published in Journal of Medical Internet Research in 2017 (in press) (Bond et al., 2017c).

Chapter 7 further explores the use of the VI for health professional education, through
comparison with a standard email intervention. As in Chapters 3, 4 and 5, the CDSS is
used to support evaluation of the initiative. Further research on evaluation of the elearning tool is also described. The article was written by the candidate with co-authors
Shelley Crowther, Suman Adhikari, Adriana Chubaty, Ping Yu, Jay Borchard, Craig
Boutlis, Wilf Yeo, and Spiros Miyakis. The article was under review in Journal of
Medical Internet Research: Medical Education in March 2017.

44

Chapter 8 provides a summary of project findings followed by a discussion on the
implications, strengths and limitations of the research. Suggestions for future research and
thesis conclusions are also presented.

A full list of collaborators, their roles and areas of expertise are provided in Table 1.1
below.
Table 1.1: Research collaborators for this thesis
Research

Site

Position

Areas of expertise

Wollongong

Professor of Medicine;

Research planning,

Hospital;

thesis supervisor

data analysis, critical

collaborator
Wilf Yeo

UOW
Craig Boutlis

review

Wollongong

ID physician;

AMS, data collection

Hospital;

thesis supervisor

and analysis,

UOW
Spiros Miyakis

Stuart Jansen

scientific writing

Wollongong

ID physician;

AMS, research

Hospital;

Associate Professor of

planning, manuscript

UOW

Medicine; thesis

review and

supervisor

submission

Wollongong

Wollongong Hospital

Project

Hospital

Orthopaedic surgeon

implementation,
manuscript review
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William Pratt

Megan Orr

Shoalhaven

General/ ID physician;

AMS, project design

Hospitals;

health district lead for

and implementation,

UOW

AMS

manuscript review

Shoalhaven

AMS pharmacist

AMS, data collection,

Hospitals
Adriana Chubaty

Prince of

manuscript review
AMS pharmacist

AMS, project design,

Wales

data collection and

Hospital

analysis, manuscript
review

Suman Adhikari

St George

AMS pharmacist

Hospital

AMS, data collection
and review, project
implementation;
critical review

Marijka Batterham

Cara Dickson

UOW

St George

Associate Professor of

Project design,

applied statistics

statistics

Performance analyst

Data collection and

Hospital
Brendan McMullan

analysis

Sydney

Paediatric ID

AMS, project

Children’s

physician

implementation,

Hospital
Mona Mostaghim

Sydney

Paediatric AMS

AMS, project

Children’s

pharmacist

implementation,

Hospital
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manuscript review

manuscript review

Samantha Li-Yan

Prince of

CDSS administrator

AMS, CDSS support,

Hui

Wales

pharmacist

coordination of data

Hospital
Kate Clezy

Pamela Konecny

Prince of

collection
ID physician

AMS, project design

Wales

and implementation,

Hospital

manuscript review

St George

ID physician

Hospital

AMS, literature
review, manuscript
review

Shelley Crowther

Wollongong

District educator

Survey design, project

Hospital

pharmacist

design and
implementation,
manuscript review

Ping Yu
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Associate Professor of

Survey design, study

Health Informatics

design, manuscript
review

Jay Borchard
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Hospital

Clinical researcher

Statistical analysis,
manuscript review
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2.1 Summary statement

This chapter offers a model for improving antimicrobial use related to prevention of
infection around orthopaedic surgery. Educational themes explored as part of this project
include: use of timely audit and feedback, departmental education with subsequent
reporting of post-intervention results by email, and tailoring of an educational strategy to
senior surgical staff through the use of peer education. Those themes are further explored
in Chapters 3 and 4.
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2.2 Abstract

2.2.1 Background

Gentamicin has historically been used prior to insertion and removal of indwelling
urinary catheters (IDCs) around elective joint replacement surgery to prevent infection;
however, this indication is not recognised in the Australian Therapeutic Guidelines:
Antibiotic and the paradigm for safe use of gentamicin has shifted.

2.2.2 Methods

The AMS team of a 500 bed tertiary regional hospital performed a retrospective clinical
study of gentamicin IDC prophylaxis around total hip and knee arthroplasties. Results
were presented to the orthopaedic surgeons. A literature review identified no guidelines to
support gentamicin prophylaxis and only a very low risk of bacteraemia associated with
IDC insertion/removal in patients with established bacteriuria. Consensus was reached
with the surgeons to discontinue this practice. Subsequent prospective data collection was
commenced to determine effectiveness, with weekly feedback to the Department Head of
Orthopaedics.

2.2.3 Results

Data from 137 operations pre-intervention (6 months) were compared with 205
operations post-intervention (12 months). The median patient age was 72 years in both
groups. Following the intervention, reductions in gentamicin use were demonstrated for
IDC insertion (59/137 [42%] to 4/205 [2%], p<0.01) and removal (39/137 [28%] to 6/205
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[6%], p<0.01). No gentamicin use was observed during the final 40 weeks of the postintervention period. There were no significant differences between the groups for preoperative bacteriuria, surgical site infections (SSIs) or acute kidney injury (AKI).

2.2.4 Conclusions

A collaborative approach using quality improvement methodology can lead to an
evidence based reappraisal of established practice. Regular rolling audits and timely
feedback were useful in sustaining change.

2.2.5 Keywords

Antibiotic prophylaxis, gentamicin, arthroplasty, in-dwelling catheters, surgical site
infection
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2.3 Introduction

Urinary catheterisation is common during the peri-operative period and is associated with
increased risk of bacteriuria and symptomatic urinary tract infection (UTI) (Marschall et
al., 2013). In contrast, bacteraemia from IDC manipulation is rare, even when indwelling
times are longer (Polastri et al., 1990; Jewes et al., 1988; Bregenzer et al., 1997). A causal
link has not been established between peri-operative asymptomatic bacteriuria,
bacteraemia and subsequent haematogenous seeding of the prosthetic joint (Sousa et al.,
2014). Studies have reported either no effect (Britt et al., 1977) or modest reduction (Jaffe
et al., 1985; Mountokalakis et al., 1985; Romanelli et al., 1990; Esposito et al., 2006;
Pfefferkorn et al., 2009; Petronella et al., 2012; van der Wall et al., 1992) in rates of
bacteriuria and UTIs from antibiotic prophylaxis around short term IDC use. Several
limitations applied: small sample sizes, none examined aminoglycosides, and the effect
on antibiotic resistance was not routinely examined. In addition, the studies were not
performed in the setting of orthopaedic surgery, and did not examine the impact on SSIs.

Gentamicin is an aminoglycoside antibiotic administered intravenously for the treatment
of Gram-negative infections (Leong et al., 2006). Gentamicin is also recommended as
prophylaxis for surgery with high risk of Gram-negative infections, such as urological
procedures (Antibiotic Expert Group, 2010). Due to concerns over side effects such as
ototoxicity and nephrotoxicity, even after a single dose (Ahmed et al., 2012; Coroners
Court of Victoria, 2012), there has been a shift in the paradigm of safe gentamicin use
(Australian Commission on Safety and Quality in Health Care, 2015). Two recent studies
examining the combination of gentamicin with a beta-lactam antibiotic for orthopaedic
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surgical prophylaxis gave conflicting results on the risk of AKI (Bell et al., 2014; Craig et
al., 2012). Both highlighted the presence of additional potentially nephrotoxic factors
(e.g. older age, fractures, volume loss, anti-hypertensive medications and analgesics).

The Australian Therapeutic Guidelines: Antibiotic (Antibiotic Expert Group, 2010)
recommend against the routine use of gentamicin in the setting of peri-operative IDC
insertion and removal and this recommendation has not changed in the latest update
(Antibiotic Expert Groups, 2014). Despite guideline recommendations, gentamicin had
been used as peri-operative prophylaxis in around one third of orthopaedic patients in our
hospital. Some surgeons were initially reluctant to abandon gentamicin use, due to
concerns about a potential increase in SSI rates and medico-legal considerations related to
not following an established historical practice.

Education and quality improvement are fundamental aspects of AMS in hospitals (Davey
et al., 2013). Recent evidence suggests that feedback as a component of the change
management process is more effective when it is: frequently presented; delivered by a
peer; and aims to decrease a specific behaviour (Ivers et al., 2014). Our study analysed
the effect of education with rapid-cycle audit and feedback, a method that may be
effective where clinicians have previously agreed to review their practice (Ivers et al.,
2012). The importance of engaging with stable staff groups such as consultant surgeons
and anaesthetists became evident. We assessed the impact of a group of interventions that
aimed to reduce prophylactic gentamicin use during IDC insertion and removal in
orthopaedic surgery, without increasing SSI rates. This quality improvement initiative
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could constitute an effective model for management of change in the setting of limited
background data.

2.4 Methods

2.4.1 Setting

We initially performed a retrospective clinical study at Wollongong Hospital, a regional
500 bed university teaching hospital in New South Wales (NSW), Australia. The AMS
team (pharmacist and ID physician) identified the use of gentamicin as prophylaxis for
IDC insertion and removal during a routine retrospective audit of systemic antibiotic
prophylaxis around total hip and knee arthroplasties and revisions. IDC use was routine in
this setting. The decision to administer gentamicin and its dose were at the discretion of
the surgeon and there was not a departmental policy.

2.4.2 Intervention

This study employed PDSA quality improvement methodology (National Health Service
Institute for Innovation and Improvement, 2008). The timeline of observations and
interventions is shown in Figure 2.1. The guideline recommendations for routine surgical
prophylaxis were the same for both the pre- and post-intervention groups (cephazolin
routinely, with or without vancomycin following risk assessment for MRSA) (Antibiotic
Expert Group, 2010). Notably, there was discussion with the surgeons and anaesthetists
around guideline-concordant prescribing during the time interval (March 2012 to January
2013) from the presentation of initial findings until the main intervention point.
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Discussion also occurred at the AMS committee meetings (which included a surgeon
representative) during this time.

2.4.3 Definitions

SSIs were defined according to standard definitions (Australian Council on Healthcare
Standards, 2014) and reported by mandate to the NSW Ministry of Health. AKI was
defined by the Kidney Disease Improving Global Outcomes criteria as a >50% rise above
baseline serum creatinine (Kidney Disease Improving Global Outcomes, 2012).
Assessment for vestibular toxicity was available, as dictated by patient symptoms.

2.4.4 Outcomes

The effect of the intervention was assessed using the following measures: prevalence of
gentamicin use for insertion and removal of IDCs; comparative SSI rates; proportion of
patients with AKI 48-72 hours post-operation.

2.4.5 Data sources

A retrospective dataset of total hip and total knee arthroplasties was obtained from
medical records for the period 1 January to 30 June 2011. Gentamicin use was assessed
from anaesthetic and medication charts, and serum creatinine measurements were
retrieved from the electronic medical record (eMR; Cerner Powerchart™). Arthroplasty
data were collected prospectively during the post-intervention period (February 2013 to
February 2014) from the eMR and ward list. The infection control service provided SSI
rates.
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Figure 2.1: Timeline of study observations and interventions

2.4.6 Statistical analyses

Statistical analyses were performed using Stata statistical software: Release 14 (Statacorp
LP, College Station, TX, USA). Chi-square and Fisher’s exact tests were used as
appropriate. A Shapiro-Wilk test was used to check for normal distribution, and MannWhitney U-test was used for continuous variables. Statistical significance was accepted as
p<0.05.
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2.4.7 Ethics

This study was approved by the University of Wollongong (UOW) and Illawarra
Shoalhaven Local Health District (ISLHD) Human Research Ethics Committee:
HE11/103 (Appendix B).

2.5 Results

Data from 137 operations pre-intervention (6 months, retrospective) were compared with
205 operations post-intervention (12 months, prospective; Table 2.1). Patient age and
weight were similar in both groups; however, there were marginally more males in the
post-intervention sample (31% vs. 42%, p=0.048). There were more positive preoperative MRSA screening cultures in the pre-intervention group (3% vs. 0.5%,
p=0.047). No differences were observed in the number of positive pre-operative urine
samples (Table 2.1). Gentamicin doses ranged from 80mg to 240mg.
A significant reduction in gentamicin use was demonstrated post-intervention (Table 2.2).
From week 12 of the post-intervention period (Figure 2.2), no further doses of gentamicin
were administered for IDC manipulation.

No significant differences were found between the numbers of superficial hip, deep hip,
superficial knee, or deep knee infections (Table 2.2). There were no significant changes in
the rates of AKI (Table 2.2), and no reports of vestibular toxicity following gentamicin
use.
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Table 2.1: Patient characteristics and pre-operative screening

Median age, yrs

Pre-intervention

Post-intervention

p value

72 (40-91)

72 (35-87)

0.79

43 (31)

86 (42)

0.048

82 (40-142)

82 (44-143)

0.79

116/137 (87)

188/205 (92)

0.13

58/137 (42)

70/205 (34)

0.13

4/122 (3)

1/204 (0.5)

0.047

25/123 (20)

28/198 (14)

0.15

11/25 (44)

8/28 (29)

0.24

(range)
Male, n (%)
Median weight†, kg
(range)
Cephazolin as skin
prophylaxis‡, n (%)
Hip arthroplasty§, n
(%)
MRSA screening
swab positive
Pathogen isolated in
pre-operative urine
sample║, n (%)
Pre-op positive urines
treated with
antibiotics║, n (%)
†

Data available from 133 patients pre-intervention; 202 post-intervention; ‡Data available from 134 patients

pre-intervention, 205 post-intervention; §Includes revisions; ║Includes mixed and single pathogen growth.
The remainder of the urine samples were reported as “no growth” or “no significant growth”.
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Table 2.2: Gentamicin use, surgical site infections and acute kidney injury, n (%)
Pre-

Discussion and

Post-intervention

intervention

planning

(12 months)

(6 months)

period

n = 205

n = 137

(20 months)

p value

n = 605
Gentamicin for

59 (42)

N/A

4 (2)

<0.01

39 (28)

N/A

6 (3)

<0.01

0 (0)

7 (1.2)

1 (0.5)

0.59

1 (0.7)

3 (0.5)

0 (0)

0.45

2 (2)

N/A

1 (1)

0.35

IDC insertion
Gentamicin for
IDC removal†
Surgical site
infections, deep
Surgical site
infections,
superficial
Post-operative
acute kidney
injury‡
†

Data available from 137 patients pre-intervention, 204 patients post-intervention ‡defined as >50% rise in

baseline serum creatinine
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Figure 2.2: The proportion of patients receiving gentamicin for catheter insertion and
removal over the 6 month pre-intervention period and during each week postintervention. The discussion and planning period is shown in grey.

2.6 Discussion

Our study showed that a combined intervention of education and discussion with audit
and timely feedback was effective in withdrawing the practice of prophylactic gentamicin
for IDC insertion and removal in orthopaedic surgery. No significant changes were
observed in the rates of SSI or AKI, although the study was not powered adequately to
detect those. Most importantly, this study offers a model for a sustained quality
improvement initiative in the setting of limited background data and contributes to
emerging evidence on the beneficial role of AMS in improving antibiotic use.
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The majority of infections in orthopaedic surgery are caused by Gram-positive skin flora,
for which cephazolin and vancomycin (where appropriate) provide adequate prophylaxis
(Antibiotic Expert Group, 2010). The potential risks and lack of clinical benefit from
gentamicin in this setting formed the basis of our intervention. Rates of gentamicin use
were reducing during the planning and discussion period, highlighting that the ongoing
interaction resulted in gradual practice change. This was consolidated to a withdrawal of
gentamicin prescribing in the study sample. The importance of directly addressing
medico-legal concerns and providing written support for practice change was also
recognised.

To our knowledge, this is the first study that has examined the impact of a change to IDC
prophylaxis on clinical outcomes for orthopaedic surgery patients. A Cochrane review of
antibiotic prophylaxis for short term IDC bladder drainage in adults showed that the
primary outcome of bacteriuria was lower in the prophylaxis group (Lusardi et al., 2013).
There is no evidence linking insertion and/or removal of an IDC with Gram-negative
bacteraemia and seeding of a newly implanted prosthesis. Although a recent study has
demonstrated that asymptomatic bacteriuria was an independent risk factor for prosthetic
joint infection, preoperative antibiotic treatment did not show any benefit and infecting
organisms were frequently different to those isolated prior to surgery (Sousa et al., 2014).
Studies reporting bacteraemia from IDCs in the setting of chronic catheterisation reported
low rates of established infection (Polastri et al., 1990; Jewes et al., 1988; Bregenzer et
al., 1997).

67

There were no deep SSIs during the pre-intervention period and only one (0.5%) postintervention. During the intervening period the SSI rate was low at 1.1%, comparable
with existing literature (Kurtz et al., 2008; Havelin et al., 2000). These differences were
not statistically significant. Studies powered to detect changes in rare outcomes such as
SSI rates typically require larger sample sizes (Havelin et al., 2000; Kurtz et al., 2008; AlMulhim et al., 2014).

The rate of peri-operative AKI in our study was 1-2%. Rates have been previously
reported at 11% for orthopaedic surgeries with routine gentamicin prophylaxis, but with
different gentamicin doses (Bell et al., 2014). The lower rate in our study may be due to
the lower doses of gentamicin for IDC prophylaxis than for routine skin prophylaxis.

A focus on immediate clinical outcomes (gentamicin toxicity) rather than parameters that
appear later (antibiotic resistance) may have stronger influence on prescribing behaviour
(Broom et al., 2014). Other strategies to reduce the risk of IDC-related UTI in the perioperative setting include: intermittent or no catheterisation, early mobilisation (that
shortens the period when the IDC needs to remain in place), training for insertion
techniques, good IDC care and consideration of IDC materials (Gould et al., 2010). Male
patients receiving epidural anaesthesia may be at greater risk of urinary retention in the
setting of orthopaedic surgery (Griesdale et al., 2011; Hollman et al., 2015; Lingaraj et
al., 2007).

There were several limitations to our study. These included confounding factors that may
influence SSI rates (skin preparation, surgical technique, patient comorbidities) and the
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significantly larger proportion of male patients in the post-intervention sample (probably
resulting from variation in data collection methods). The study was not powered to detect
changes in SSI rates and those were not followed up long term, meaning that late deep
infections may have been missed. The indication for gentamicin use was not routinely
documented on the anaesthetic records and drug charts. The study did not follow the
prescribing habits of individual surgeons, so some of the change in gentamicin use may
have been due to changes in staff. There were; however, minimal staff changes at a senior
level during the study period. We believe that interpersonal interactions, the prevailing
local culture of quality improvement and strong leadership of the units involved have
contributed to the successful outcomes of this study. Those features were furthermore
strengthened during the interactive audit and feedback process; generalisability to other
settings needs to be tested. Audiometry was not available on site to test for gentamicin
toxicity. Although we used a methodology common in pragmatic AMS research,
introduction of bias may be inherent, outside a randomised controlled environment.

2.6.1 Conclusions

We have shown that a group of robust multi-disciplinary AMS interventions effected
durable practice change without obvious evidence of harm. Further studies are required to
demonstrate validity in other settings, as well as the impact of gentamicin prophylaxis on
renal function in other types of surgery.
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3.1 Summary statement

This chapter addresses treatment of a common infection, CAP, using an educational
strategy with common links to Chapters 2 and 4. Email was used as a method for
providing clinical feedback and education to individual prescribers, along with combined
educational interventions at the departmental level. As CAP treatment traverses the
emergency department and numerous medical specialties, a hospital-wide approach was
also required. Monitoring of antimicrobial prescribing was supported by a CDSS, which
when combined with email feedback has applicability to multiple sites within the rural
and regional health district. The multisite and rural/regional themes are further explored
in Chapters 4, 5, 6 and 7.

3.2 Abstract

3.2.1 Background

CAP is the second commonest indication for antibiotic use in Australian hospitals and is
therefore a frequent target for AMS interventions. The recommended duration of
combined intravenous and oral empiric therapy for CAP in the Australian Therapeutic
Guidelines (2014) is seven days. The aim of this study was to improve appropriateness of
antibiotic prescribing for CAP.

3.2.2 Methods

We performed a single-centre prospective study in a regional referral hospital comparing
management of adult inpatients with presumed CAP before and after an AMS
intervention (pre-intervention 1 June to 30 November 2013; post-intervention 1 June to
30 November 2014). Post-intervention, individual case feedback was emailed to the
attending medical officer (AMO). The primary outcome measure was duration of
antibiotic therapy. Secondary outcome measures included appropriateness of therapy,
LOS, 30 day readmission rate and in-hospital mortality.

3.2.3 Results

Post-intervention, median duration of therapy decreased from 11 days (n=34) to 9 days
(n=79; p=0.04). The number of patients with non-severe CAP receiving the third
generation cephalosporin, ceftriaxone (indicated for severe CAP) decreased from 74%
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(14/19) to 45% (18/40; p=0.04). There were no significant differences in LOS, 30 day
readmission rate or in-hospital mortality.

3.2.4 Conclusions

Our AMS intervention was successful in reducing duration of therapy and unnecessary
exposure to ceftriaxone. The use of timely audit and feedback can foster improvement. As
CAP therapy is responsible for a large proportion of antibiotic use in Australian hospitals,
interventions are recommended to address initial choice and duration of therapy.

3.2.5 Keywords

Community-acquired pneumonia, antibiotics, duration of therapy, antimicrobial
stewardship
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3.3 Introduction

CAP causes significant morbidity and mortality (Maxwell et al., 2005; Postma et al.,
2015) and is the second commonest indication for antibiotic prescribing in Australian
hospitals, following surgical prophylaxis (Australian Commission on Safety and Quality
in Health Care, 2015). Ceftriaxone (a third generation cephalosporin) plus azithromycin
(a macrolide) is recommended as first-line treatment of severe CAP in non-tropical
regions of Australia (Antibiotic Expert Group, 2010; Antibiotic Expert Groups, 2014),
whereas benzylpenicillin plus doxycycline is recommended for moderate-severity CAP.
These recommendations are based on susceptibility data for Streptococcus pneumoniae,
the commonest causative pathogen of CAP in Australia (Charles et al., 2008), which is
almost uniformly susceptible to benzylpenicillin for non-central nervous system (CNS)
isolates (Newton, 2013).

Prescribing for CAP is a common target for hospital-based ASPs, due to the potential for
overuse of the combination of ceftriaxone plus azithromycin for treatment of non-severe
disease (Australian Commission on Safety and Quality in Health Care, 2011; Antibiotic
Expert Group, 2010; Maxwell et al., 2005). Unnecessary use of those antibiotics may be
associated with increased cost; the emergence of resistant pathogens such as MRSA
(Paterson, 2004), extended spectrum beta-lactamase (ESBL) producing
enterobacteriaceae (Paterson, 2004), and Streptococcus pneumoniae (Musher and
Thorner, 2014); as well as CDI (Paterson, 2004).
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The requirement to rapidly identify and treat sepsis in emergency departments (EDs)
(Clinical Excellence Commission, 2015; Burrell et al., 2016) may drive use of broad
spectrum antibiotics for initial treatment of CAP. Initial antibiotic prescribing in EDs is
often continued on the wards, possibly due to a culture of non-interference among
medical staff (Charani et al., 2013). Clinicians may also perceive that development of
AMR is a low priority and a distant consequence of prescribing (McCullough et al.,
2015).

A number of studies have demonstrated no difference in outcomes for patients with mild
to moderate CAP treated with up to seven days of total antibiotic therapy compared with
prolonged courses of greater than seven days (Athanassa et al., 2008; Choudhury et al.,
2011; Li et al., 2007). Avdic et al (2012) reported a reduction of three days in median
duration of CAP therapy using education and direct oral feedback to treating teams at a
large metropolitan hospital. A reduction in time between measurement and feedback, and
a high level of stakeholder buy-in (such as from senior medical staff) may result in better
audit outcomes (Ivers et al., 2012).

We evaluated whether an intervention involving education with timely audit and emailed
feedback would lead to a more appropriate duration of antibiotic therapy and a reduction
in the number of patients with non-severe CAP receiving a ceftriaxone-based regimen.
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3.4 Methods

3.4.1 Setting

We performed a prospective pre- and post-intervention study of patients presenting to the
ED of Wollongong Hospital, a 550-bed regional tertiary referral hospital in NSW,
Australia. Treatment of adult (≥18 years) patients with a final diagnosis of CAP was
compared between pre-intervention and post-intervention cohorts (1 June - 30 November
2013 vs. 1 June - 30 November 2014).

3.4.2 Participants

Firstnet® ED software (Cerner, Kansas City, MO, USA) was viewed prospectively for
admissions containing any of the following keywords in the “diagnosis” column:
pneumonia; lower respiratory tract infection; chest infection. Patients in whom
pneumonia was suspected were also screened where an AMO consult was requested from
respiratory, general or geriatric medicine. Patients who received initial antibiotics directed
at CAP were initially screened, with a final diagnosis of CAP on the discharge summary
being required for study inclusion. Exclusion criteria were as follows: <18 years of age;
immunosuppressed (i.e., concurrent chemo- or immunosuppressant therapy or human
immunodeficiency virus [HIV] positive); cystic fibrosis; bronchiectasis; empyema;
exacerbation of chronic obstructive pulmonary disease (COPD) or asthma if not involving
pneumonia; suspected or confirmed tuberculosis; aspiration or hospital-acquired
pneumonia; readmitted to hospital within 14 days; transferred from another hospital.
Duration of antibiotic therapy was determined from the medication charts and pharmacy
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dispensing data. The remaining course of oral antibiotics was supplied to the patient on
discharge.

A reference SMART-COP severity score was calculated for each patient by the AMS
pharmacist to assess compliance with national antibiotic guidelines (Antibiotic Expert
Group, 2010). The SMART-COP score and occasionally the CORB and CURB-65
severity scores were used by prescribers. Regimens suggested in the antibiotic guidelines
broadly aligned with the mild, moderate and severe categories of CAP identified by the
severity scores. Guideline compliance was recorded as: “complete” if, after accounting
for allergy, all drugs matched the treatment of CAP according to SMART-COP score;
“partial” if some of the drugs given matched the score; and “not at all” if none of the
antibiotics matched. Ongoing monitoring of broad spectrum antimicrobial use on AMS
rounds was facilitated by a CDSS, Guidance MS® (Guidance Group, 2013).

In the pre-intervention group, 42 patients were initially screened for inclusion. The use of
a patient admissions report (i.PM, CSC, Wilmington, DE, USA) during the postintervention phase, resulted in a greater number of patients included (n=99). The same
screening definitions applied in both groups. Data analysis was performed on those
patients with a final diagnosis of CAP on discharge summary. A CAP diagnosis was
made in 34/42 (81%) assessable patients pre-intervention and 79/99 (80%) postintervention (Figure 3.1).
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Figure 3.1: Study flowchart

3.4.3 Intervention

Pre-intervention results were presented to emergency, respiratory and general medicine,
infectious diseases, pharmacy, and nursing meetings (April - May 2014). Education
points included: use of severity scores; initial choice of antibiotics; change of antibiotic
regimen; duration of intravenous (IV) and total therapy; and Streptococcus pneumoniae
antibiograms. During the post-intervention phase a summary of each case was emailed by
the AMS pharmacist to the AMO and junior staff, typically within two weeks of
discharge. Initial antibiotic choice, subsequent treatment and duration of therapy were
described in the email. The response rate of AMOs was assessed and responses were
grouped as follows: (1) containing clinical feedback, (2) basic acknowledgement, or (3)
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defensive. The time to collect data and send the email was approximately 30 minutes per
patient. This was incorporated into the existing role of the AMS pharmacist.

3.4.4 Outcomes

The primary outcome measure was total duration of combined IV and oral antibiotic
therapy. Secondary outcomes included proportion of non-severe CAP patients receiving a
ceftriaxone-based regimen, documentation of severity scores; appropriateness of
antibiotic therapy according to severity score; LOS; 30 day readmission rate; and inhospital mortality.

3.4.5 Statistical analyses

Statistical analyses were performed using Stata® statistical software (Release 14,
Statacorp LP, College Station, TX, USA). A chi-square test was used to compare
proportions (Fisher’s exact test was used when an expected cell value was less than 5),
and Wilcoxon rank-sum test for comparison of continuous variables involving duration of
antibiotic therapy and duration of IV therapy. All statistical tests were two tailed,
differences were considered significant at p<0.05.

3.4.6 Ethics

Ethics approval was granted by our institutional Human Research and Ethics Committee,
approval number HE11/377 (Appendix B).
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3.5 Results

Demographic characteristics were similar between the two groups (Table 3.1). Parameters
for calculation of a SMART-COP score were available in 97/113 (86%) cases with a final
diagnosis of pneumonia. There were no significant differences between the proportion of
patients with mild, moderate and severe CAP according to SMART-COP score, and a
similar number of patients received antibiotics prior to admission in both cohorts.
Respiratory medicine and general medicine accounted for 101/113 (89%) cases. Penicillin
allergy was slightly more common in the pre-intervention group (p=0.11).

There were no significant differences in the proportion of microbiology investigations
between the two cohorts. Streptococcus pneumoniae was the commonest organism
identified in both groups.
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Table 3.1: Demographic characteristics and disease severity of patients with a final
diagnosis of community-acquired pneumonia
Characteristic

Pre-

Post-

p

intervention

intervention

value

(2013; n=34)

(2014; n=79)

Male, n (%)

16 (47)

48(61)

0.18

Age, median (range), yrs

83 (20-93)

78 (18-95)

0.08

Penicillin allergy, n (%)

9(26)

11(14)

0.11

Antibiotics prior to ED, n (%)

9(26)

27(34)

0.42

SMART-COP 0-2 (mild), n (%)

11(32)

27(34)

0.85

SMART-COP 3-4 (moderate), n (%)

13(38)

29(37)

0.88

SMART-COP 5-11 (severe), n (%)

10(29)

23(29)

0.98

Abbreviations: ED, emergency department; SMART-COP, reference clinical severity score

The median duration of antibiotic therapy decreased from 11 days pre-intervention to 9
days post-intervention (p=0.04; Table 3.2). The median duration of directed therapy in
patients with a positive microbiological test was 11 days pre-intervention and 10 days
post-intervention. The proportion of patients with non-severe CAP treated with
ceftriaxone-based therapy (with penicillin allergy cases excluded) decreased from 14/19
(74%) patients pre-intervention to 18/40 (45%) post-intervention (p=0.04). Among those
patients, ceftriaxone was continued beyond 48 hours in only 2/14 cases pre-intervention
and in 3/18 cases post-intervention; in all other cases ceftriaxone was either deescalated
to oral therapy or ceased (data not shown). In the pre-intervention period, therapy was
escalated in 1/34 (3%) cases following the results of the laboratory investigations,
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compared to 6/79 (8%) cases post-intervention (p=0.35). Where there was not a final
diagnosis of CAP (n=28), 12 patients (3/8 pre-intervention, 9/20 post-intervention)
received initial treatment with a ceftriaxone-based regimen.

Documentation of severity scores and compliance of initial antibiotic choice with the
guidelines (according to severity score) increased post-intervention, compared with the
pre-intervention levels, but those differences did not reach statistical significance (Table
3.2). Where antibiotic therapy did not match guidelines, 7/9 (78%) patients received
ceftriaxone plus azithromycin in non-severe pneumonia pre-intervention, compared with
11/17 (65%) post-intervention. Benzylpenicillin was administered for severe CAP once in
each cohort, where the guidelines recommended ceftriaxone. There were no significant
differences in LOS, 30-day readmission rate or in-hospital mortality between the two
groups (Table 3.2). One included patient was treated by a study investigator (WY).
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Table 3.2: Outcomes in patients with a final diagnosis of community-acquired
pneumonia
Variable

Pre-intervention

Post-

p

(2013) (n=34)

intervention

value

(2014) (n=79)
11 (9-13)

9 (7-10)

0.04

3 (2-5)

3 (2-5)

0.74

Severity score documented, n (%) ‡

11 (32)

35 (44)

0.22

Mild-mod receiving initial ceftriaxone,

14 (74)

18 (45)

0.04

11 (30)

32 (41)

0.41

2 (6)

12 (15)

0.22

Length of stay, median (IQR) days

6 (3-10)

6 (3-12)

0.74

30 day readmissions, n (%)

4 (12)

13 (16)

0.77

In-hospital mortality

2 (6)

4 (5)

1

Total duration of antibiotic therapy, median
(IQR), days
Duration of intravenous antibiotic therapy,
median (IQR), days†

n (%) –excluding penicillin allergy§
Initial antibiotics guideline compliant
(“completely”), n (%)
Therapy escalated by admitting team,
n (%) ¶

†31 known pre-intervention, 79 post-intervention; ‡34 known pre-intervention, 78 known postintervention; §19 known pre-intervention, 40 known post-intervention; ¶pre-intervention, benzylpenicillin
to ceftriaxone (n=1), ceftriaxone to meropenem (n=1); post-intervention, benzylpenicillin to ceftriaxone
(n=6), ceftriaxone to piperacillin/tazobactam (n=4), ceftriaxone to ciprofloxacin (n=2); 30 day
readmissions, 1 for pneumonia pre-intervention, 2 for pneumonia post-intervention.
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Email responses were received for 20 of 99 sent emails; 6 from AMOs and 14 from junior
medical staff. The responses either contained clinical feedback (17/20) or acknowledged
the email (3/20); there were no defensive responses.

3.6 Discussion

Our study demonstrated that an intervention combining education with audit and email
feedback was associated with a significant reduction in the median duration of total
antibiotic therapy from 11 to 9 days that was driven by shorter courses of oral therapy.
The number of patients with non-severe CAP receiving a ceftriaxone-based regimen also
decreased significantly (74% to 45%). Increases of almost 30% in documentation of
severity score and compliance with guidelines were observed, although these did not
reach statistical significance.

Previous AMS studies have reported similar reductions in duration of IV (Fine et al.,
2003; Carratala et al., 2012) and total antibiotic therapy (Avdic et al., 2012). Our study
differed in that we targeted emergency medicine to address initial treatment, and
admitting teams for ongoing therapy. We also demonstrated an approach applicable to
rural and regional hospitals, through use of a CDSS-supported ASP, the eMR and email
feedback. Feedback of results was provided on an individual case basis, which may be
more effective if clinicians have previously agreed to review practice (Ivers et al., 2012).
Emails to doctors were broadly well received.
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Our study had several limitations, including its single-centre design and small number of
patients. The change to data collection methodology post-intervention may have resulted
in a change to patient demographics, even though the same screening criteria were used.
Discharge dispensing data were obtained from pharmacy and outpatient compliance was
not evaluated. Parameters for calculation of SMART-COP scores were not available in
14% of cases, thus disease severity may have been underestimated in those patients.
Patients with treatment limitations were not excluded, which may have resulted in worse
patient outcomes; however, antibiotics are typically not withheld in those patients, and
inclusion criteria did not change between study periods. The response rate to emails was
low; however, email was not used as the only feedback method, with departmental
meetings and daily AMS rounds forming part of the education strategy.

The intervention demonstrated a reduction in duration of therapy that was driven by
shorter courses of oral antibiotics. Median duration of total therapy remained long at 9
days, indicating that further interventions are required to address both duration of therapy
and LOS. Post-intervention, some patients still received ceftriaxone for non-severe CAP
but the frequency was significantly reduced. Although the exact reasoning behind
ceftriaxone overuse cannot be inferred from our data, possible reasons include its once
daily administration, broad spectrum, lack of requirement for dose adjustment and
existence of sepsis guidelines. Although it was recognised that therapy should be
reviewed following discharge from ED, there may still have been some prescribing
etiquette shown by admitting medical teams, with an unwillingness to change a therapy in
an improving patient (Charani et al., 2013).
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3.6.1 Conclusions

We have demonstrated significant reductions in total duration of CAP therapy and of
inappropriate ceftriaxone-based therapy for non-severe CAP following a targeted
intervention that combined education with audit and feedback. This approach addressed
initial and ongoing prescribing, and may be readily transferred to other settings. Ongoing
education with timely feedback of audit results is recommended to foster sustainability.
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4.1 Summary statement

The themes of multisite and rural/regional applicability of AMS initiatives are explored in
this chapter, which relates to CDI, a serious adverse effect of antimicrobial use. Using a
multisite approach, the outcomes of patients complicated by healthcare-associated CDI
are investigated. The widespread use of antimicrobials across the health district, and
geographic disparity of the hospitals, necessitated the use of email feedback and
education, which builds on those themes described in Chapters 2 and 3. The use of
technology (CDSS and e-learning tool) to provide pragmatic AMS education is further
explored in Chapters 5, 6 and 7.
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4.2 Abstract

4.2.1 Objective

CDI is a major cause of healthcare associated (HCA) diarrhoea in industrialised countries
and is associated with considerable morbidity and mortality. No data exist on the burden
of HCA-CDI in multisite non-metropolitan settings. This study examined the introduction
of an ASP in relation to HCA-CDI rates and the effect of HCA-CDI on LOS and hospital
costs.

4.2.2 Methods

A before-and-after intervention comparative study of patients aged 16 years and over with
HCA-CDI from December 2010 to April 2016 across the nine hospitals of a nonmetropolitan health district in NSW, Australia. The intervention comprised a multisite
ASP supported by a CDSS, with subsequent introduction of email feedback of HCA-CDI
cases to AMOs. Main outcome measures: HCA-CDI rates; comparative LOS and hospital
costs; prior antimicrobial and proton-pump inhibitor (PPI) use; appropriateness of CDI
treatment.

4.2.3 Results

HCA-CDI rates rose from 3.07 to 4.60 cases per 10,000 occupied bed days (OBDs) preintervention, and remained stable at four cases per 10,000 OBDs post-intervention
(p=0.24). Median LOS (17 vs. 6 days, p<0.01) and hospital costs (AU$19,222 vs. $7,861,
p<0.01) were significantly greater for HCA-CDI cases (n=91) than for matched controls
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(n=172). Half of the patients with severe HCA-CDI (4/8) did not receive initial
appropriate treatment (oral vancomycin).

4.2.4 Conclusions

HCA-CDI placed a significant burden on our regional and rural health service through
increased LOS and hospital costs. Interventions targeting HCA-CDI could be employed
to consolidate the effects of ASPs.

4.2.5 Keywords

Clostridium difficile infection, antimicrobial stewardship, antibiotics, length of stay,
hospital costs
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4.3 Introduction

CDI is a major cause of HCA diarrhoea in industrialised countries and is associated with
considerable morbidity and mortality (Valiquette et al., 2007). In Australia, the annual
incidence of hospital-identified CDI was 4.03 cases/10,000 patient days in 2012
(Slimings et al., 2014). Risk is increased by antimicrobial use and/or immunosuppression
(Cheng et al., 2011). Other putative risk factors include gastrointestinal surgery, gastric
acid-suppressive therapy and prolonged hospital stay (Cheng et al., 2011).

HCA-CDI has been associated with increased LOS, additional costs from hospitalisation
(Gabriel and Beriot-Mathiot, 2014) and antimicrobial treatment (Cheng et al., 2011), and
indirect costs such as productivity losses (McGlone et al., 2012).

Most antimicrobials have been related to occurrence of CDI, with lincosamides (e.g.
clindamycin), third generation cephalosporins (e.g. ceftriaxone), and broad-spectrum
penicillins (e.g. amoxycillin/clavulanic acid) showing strong associations (Slimings and
Riley, 2014). Fluoroquinolones have been particularly associated with the hypervirulent
NAP1/027 strain (Vardakas et al., 2012). There is probable association between PPI use
and CDI, with the combination of PPIs and antimicrobials carrying a greater risk than
either alone (Kwok et al., 2012).

ASPs should be employed to reduce the incidence of HCA-CDI (Valiquette et al., 2007).
Despite HCA-CDI being an outcome measure for ASPs, increasing community
acquisition of CDI may cloud interpretation of HCA-CDI rates (Slimings et al., 2014).
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AMS interventions targeting HCA-CDI have predominantly been conducted in
metropolitan teaching hospitals, at single sites or within a defined clinical area (Talpaert
et al., 2011; Feazel et al., 2014; Vonberg et al., 2008; Thomas and Riley, 2003; Brumley
et al., 2016). Very limited data exist on the burden of HCA-CDI in Australia, particularly
in regional and rural settings (Riley et al., 1995). To our knowledge this is the first study
to examine a multisite ASP in relation to HCA-CDI rates in the non-metropolitan setting.

The aims of our study were: to describe HCA-CDI rates before and after an ASP; to
measure LOS and hospital costs in HCA-CDI patients across multiple hospital sites; to
compare prior antimicrobial and PPI use in HCA-CDI patients with the background use;
and to assess appropriateness of HCA-CDI antimicrobial treatment according to
guidelines.

4.4 Methods

4.4.1 Setting

From December 2010 to April 2016, a study on the burden of HCA-CDI was performed
across the nine public hospitals (1000 total beds) of ISLHD in south eastern NSW,
Australia. The district services 390,000 residents across a catchment that begins one hour
south of Sydney, and extends 250km along a coastal strip. The three largest hospitals
comprise one principal referral hospital (550 beds), a large acute hospital (150 beds) and
a medium acute hospital (100 beds). The remaining six hospitals are either small acute or
mixed sub- and non-acute (Australian Institute of Health and Welfare, 2015). This study
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employed PDSA quality improvement methodology (National Health Service Institute for
Innovation and Improvement, 2008).

4.4.2 Antimicrobial stewardship

In May and June 2012, an ASP supported by a CDSS (GuidanceMS®) (Guidance Group,
2013) was uniformly implemented across the district’s nine hospitals. The CDSS enabled
monitoring of antimicrobial use and facilitated regular AMS rounds where advice on
appropriate antimicrobial use could be offered by an ID physician and pharmacist (postprescription review). In addition to the CDSS, the ASP involved a restriction policy,
whereby broad spectrum antimicrobials were only stocked in pharmacy (with supply
contingent on CDSS approval) or specialist areas (i.e. intensive care unit [ICU], ED,
haematology/oncology ward). Those antimicrobials included third generation
cephalosporins, intravenous beta/lactamase inhibitor combinations and fluoroquinolones.
Additional restriction (prior ID/microbiology approval required) was placed on reserve
antimicrobials such as linezolid, daptomycin, tigecycline and colistimethate sodium. An
education campaign involved regular departmental presentations, and an intranet webpage
was established to improve access to guidelines. In addition to regular AMS rounds at the
three largest hospitals, and an antimicrobial advice telephone hotline was established
across the district to support the smaller hospitals without onsite AMS clinicians. See
Figure 4.1 for the study flowchart. There were no major changes to infection control
policies related to either Clostridium difficile or hand hygiene during the study period.
Patients in whom Clostridium difficile was detected were routinely isolated in single
rooms, and personal protective equipment (disposable gown and gloves) was mandated
by infection control policy.
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Following a review of HCA-CDI rates, in April 2013 the AMS team (infectious diseases
doctors and pharmacists) introduced a targeted CDI intervention. The AMS pharmacist
audited all CDI cases for the following: patient demographics, risk factors, antimicrobial
treatment, features indicating severe disease (Cheng et al., 2011), ICU admission, surgical
intervention, and NAP1/027 strain. A feedback email was then sent to the attending
medical officer (AMO) within two weeks (Figure 4.2). Qualitative analysis of email
responses determined the level of acceptance by AMOs. Responses were categorised as
clinical feedback, basic acknowledgement or defensive. The appropriateness of HCACDI treatment (Cheng et al., 2011) was assessed during AMS rounds or retrospectively
from medical notes. Results were presented to the AMS, drug and therapeutics, and
infection control committees.

4.4.3 Clostridium difficile laboratory testing

From December 2010, our laboratory protocol subjected all diarrhoeal stools to
Clostridium difficile testing. First line testing targeted glutamate dehydrogenase (GDH)
antigen and toxins A and B (C. Diff Quik Chek Complete®, Techlab, Blacksburg, VA,
USA). If those tests were discordant, then a polymerase chain reaction (PCR;
GeneXpert®, Cepheid, Sunnyvale, CA, USA) test was employed, which could also detect
the NAP1/027 strain. During the period June to November 2015, HCA Clostridium
difficile stool samples were sent to a reference laboratory for molecular typing as part of a
larger project examining HCA-CDI rates. No clonal similarities were identified, and
molecular epidemiology was similar to other parts of NSW (data not shown).

101

Figure 4.1: Study flowchart
Abbreviations: ASP, antimicrobial stewardship program; CDSS, clinical decision support system; HCA,
healthcare associated; LOS, length of stay; risk factors, anti-peristaltic use, gastrointestinal surgery,
immunosuppression; PPIs, proton pump inhibitors; HCA-CDI, healthcare associated Clostridium difficile
infection; DRG, diagnosis-related group; background use, whole hospital prevalence data on antimicrobial
use
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Dear Doctor,

As part of routine antimicrobial stewardship activities we are conducting a prospective
audit into all episodes of C. diff diarrhoea across the district.

Your patient X (MRN: 111111) was diagnosed with C. diff diarrhoea on dd/mm/yyyy.

Potential risk factors for your patient included:

(As appropriate)


Proton pump inhibitor use –



Anti-peristaltic use –



Prior GI surgery –



Immunosuppression –



Antimicrobial use within one month prior to diagnosis –

Details of antimicrobial treatment of CDI.
I’ve attached a copy of the audit form for your information. Please don’t hesitate to
contact me if you have any questions.

Regards,
AMS pharmacist

Figure 4.2: CDI exemplar feedback email to admitting medical officer
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4.4.4 Effect of HCA-CDI on LOS and hospital costs

LOS and hospital cost analysis was performed only for the three acute hospitals due to a
shortage of matched controls and other confounders for LOS at smaller hospitals (e.g.
nursing home availability, social factors). The two definitions for HCA-CDI were: HCAhealthcare facility onset, diarrhoea onset >48 hours after admission; HCA-community
onset, diarrhoea onset in the community or <48 hours after admission, but within four
weeks of last discharge (Healthcare Associated Infection Technical Working Group,
2013). Demographic data for HCA-CDI cases did not differ significantly between
hospitals, or between the two types of HCA-CDI (data not shown), so all HCA-CDI cases
were included for further analysis, including healthcare facility (n=103) and community
onset (n=17; Figure 4.1).

A post hoc analysis of LOS and hospital costs was conducted for those HCA-CDI cases
identified from 1 April 2013 to 30 April 2014. Matched controls were identified from
diagnosis-related group (DRG) data (Australian Institute of Health and Welfare, 2016) for
HCA-CDI cases (n=103). Controls were identified from 1 January 2013 to 30 June 2014.
Two controls were matched to each case by site, sex, age (+/- 5 years), and DRG (81
cases). Where two matched controls were not available, one control was identified (10
cases), resulting in 91 cases and 172 controls (Figure 4.1). DRGs were grouped and the
most common DRGs were reported. Additional analysis was performed on those HCACDI cases and controls with LOS of ≥8 days to address time-dependent biases (8 days
equalled the median time to HCA-CDI onset).
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4.4.5 Antimicrobial and PPI use

Antimicrobial use within one month prior to diagnosis among HCA-CDI patients was
compared with background antimicrobial use data, regularly collected in Australia as part
of standard surveillance reports. Those data (defined daily doses [DDDs] per 1000 OBDs)
from the three acute hospitals were derived from the Australian National Antimicrobial
Utilisation Surveillance Program (NAUSP; from pharmacy software) and the Australian
National Antimicrobial Prescribing Survey (NAPS; point prevalence survey in November
2013, seasonally corrected, antimicrobial class use as a percentage of total use). PPI use
was also compared with background use (point prevalence survey 2013).

4.4.6 Statistical analyses

ITS analysis (Linden, 2015) was used to assess HCA-CDI rates at the three large
hospitals (due to comparability of acute OBD data). Data were included from December
2010 (earliest time point with current CDI testing methods) to April 2016, with the
intervention point defined as May 2012 (introduction of multisite ASP). Separate analyses
were performed for May 2012- Mar 2013 and April 2013 onwards (targeted CDI
intervention). Since those periods did not reveal any significant differences (data not
shown) the post-intervention period was reported as one interval. A chi-square test was
used for proportions or Fisher’s exact test where appropriate. A Mann-Whitney U-test
was used to compare continuous variables such as LOS and hospital costs. Stata®
Statistical Software Version 14 was used (Statacorp, College Station, Texas, USA).
Significance was accepted as p<0.05.
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4.4.7 Ethics

Ethics approval was received from the joint UOW and ISLHD Human Research Ethics
Committee, approval number HE13/137 (Appendix D).

4.5 Results

Figure 4.3 shows ITS analysis of monthly HCA-CDI rates. The model-predicted HCACDI rate in December 2010 was 3.07 cases/10,000 OBDs. Prior to introduction of the
ASP, the model-predicted rate was 4.6 cases/10,000 OBDs. Following the ASP’s
introduction, and including the targeted email intervention, HCA-CDI rates remained
stable at 4 cases/10,000 OBDs. None of those differences reached statistical significance,
demonstrating an overall stable rate of HCA-CDI during the study period. The principal
referral hospital accounted for two thirds of the health district’s inpatient activity, and so
largely drove the overall HCA-CDI rate. There was larger monthly variability in HCACDI rates at the smaller sites, but no significant differences in overall rates between sites.
Detailed ITS data are provided in Table 4.1.

During the targeted intervention phase from April 2013 to April 2014, 120 primary HCACDI cases were identified. The median age was 73 years (IQR 63-81yrs) and 51/120
(43%) of patients were male. Antimicrobials one month prior to HCA-CDI diagnosis
were received by 107/120 (89%) patients. Severe disease was identified in 8/120 (7%)
cases; there were 8/120 (7%) ICU admissions, no surgical interventions, and no
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NAP1/027 strains. Following a positive test for Clostridium difficile, all patients were
isolated in single rooms according to policy.

Figure 4.3: HCA-CDI rates for the three acute hospitals in Illawarra Shoalhaven Local
Health District, Australia from December 2010 to April 2016
Vertical line, implementation of antimicrobial stewardship program; HCA-CDI, healthcare associated
Clostridium difficile infection; OBD, occupied bed day.
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Table 4.1: HCA-CDI rates before and after implementation of an ASP
Pre-ASP

Post-ASP

(Dec 2010 to April 2012)

(May 2012 to April 2016)

Initial

Initial

p

Change

p

Change

p

level

trend

value

in level

value

in trend

value

HCA CDI per

3.07a

0.09a

0.23

-0.83a

0.24

-0.08a

0.26

10,000 OBDs, n

(1.51-

(-0.06-

(-2.25-

(-0.24-

(LCI, UCI)

4.65)

0.24)

0.58)

0.07)

Initial level, number of cases of HCA-CDI per 10,000 occupied bed days per month; initial trend, rate of
increase per month; change in level, immediate difference between pre-intervention and post-intervention
cases; change in trend, difference between pre-intervention and post-intervention trend by month; ASP,
antimicrobial stewardship program, detail described in Methods; HCA-CDI, healthcare associated
Clostridium difficile infection, data included for the three large acute hospitals of the health district; OBDs,
occupied bed days; LCI, lower 95% confidence interval; UCI, upper 95% confidence interval; aadjusted for
first order autocorrelation;

Of the emails sent to AMOs for 120 HCA-CDI cases from April 2013-14, 23 responses
were received (19% response rate). Of those responses, 10 contained clinical feedback, 13
contained basic acknowledgement, and there were no defensive responses. Examples of
clinical feedback responses were: “...in the setting of immune suppression and...other
complications with chemo I am treating C diff…”; and, “the (antibiotic) was for
aspiration… the PPI (was) longstanding…”.
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Median LOS was 11 days greater for HCA-CDI patients (n=91; 17 days [IQR 8-27]) than
their matched controls (n=172; 6 days [IQR 3-12]; p<0.01). Also, median hospital cost
was estimated at AU$11,361 higher for the HCA-CDI group ($19,222 [IQR $7,817 $41,337]) compared to controls ($7,861 [IQR $3,477 - $14,553]; p<0.01). The median
time to onset of HCA-CDI was 8 days (IQR 4-14).

The median hospital cost for 48 HCA-CDI patients with LOS ≥ 8 days was AU$17,832
(IQR 9,472-28,840) vs. AU$12,563 (9,072-20,086) for 70 controls with LOS ≥ 8 days
(p=0.17). For patients with LOS ≥ 8 days, the median LOS was 16 days (IQR 10-26) for
HCA-CDI cases vs. 15 days (IQR 12-26) for controls. After excluding non-treated
patients (n=6) with available controls (n=11), the difference between HCA-CDI patients
and controls persisted for median LOS (18 vs. 7 days; p<0.01) and cost (AU$20,245 vs.
$8,924; p<0.01). The five most common primary DRGs among 263 HCA-CDI cases and
controls were: gastrointestinal (n=18 for cases, n=36 for controls), haematological
malignancy (n=9, n=17), orthopaedic surgery (n=8, n=15), abdominal surgery (n=6,
n=10), and cardiac (n=5, n=9).

Antimicrobial use among the HCA-CDI group at the three acute hospitals was compared
with background antimicrobial use (Figure 4.4). Over-represented in HCA-CDI patients
were third generation cephalosporins (e.g. ceftriaxone; 34% of total use in HCA-CDI
patients vs. 11% of background use; p<0.01), beta-lactamase inhibitor combinations (e.g.
piperacillin/tazobactam; 58% vs. 36%; p=0.01), nitroimidazoles (e.g. metronidazole; 28%
vs. 11%; p<0.01), and glycopeptides (e.g. vancomycin; 23% vs. 6%; p<0.01). Underrepresented in HCA-CDI patients were beta lactamase resistant penicillins (e.g.
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flucloxacillin; 7% vs. 18%; p=0.02), beta lactamase sensitive penicillins (e.g.
benzylpenicillin; 2% vs. 9%; p=0.03), extended spectrum penicillins (e.g. ampicillin; 14%
vs. 33%; p=0.03), macrolides (e.g. azithromycin; 4% vs. 19%; p<0.01), and tetracyclines
(e.g. doxycycline; 4% vs. 38%; p<0.01). Implementation of the multisite ASP was
associated with an overall decrease in use of broad spectrum antimicrobials (e.g. third
generation cephalosporins, fluoroquinolones and intravenous beta/lactamase inhibitor
combinations; data not shown). Reporting on temporal changes to antimicrobial use
patterns was beyond the scope of this study.

Figure 4.4: Antimicrobial use for HCA-CDI cases compared with background
antimicrobial use
†Denotes statistical significance
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Vancomycin and metronidazole were over-represented in HCA-CDI patients, but are also
recommended for CDI treatment. Those two classes were further analysed. For
vancomycin, the most commonly co-prescribed antimicrobial was piperacillin/tazobactam
(11/25) with febrile neutropenia the commonest known indication (9/11). Vancomycin
use was intravenous in all of those cases. For metronidazole, the most commonly coprescribed antimicrobial was ceftriaxone (13/35), predominantly for abdominal infections
(10/13). There was an overall decrease in use of broad spectrum antimicrobials following
implementation of the multisite ASP (data not shown). PPI use was documented in
83/120 (69%) HCA-CDI patients compared with 343/730 (47%) patients audited as part
of a local 2013 point prevalence survey (p<0.01).

In non-severe HCA-CDI treated at the acute hospitals (n=95), oral metronidazole was
initiated in 78 (82%) cases. Oral vancomycin plus oral metronidazole was used in eight
(8%) cases, where metronidazole alone would have sufficed (Cheng et al., 2011). No
therapy was given in nine non-severe cases, due to cessation of diarrhoea with or without
identification of an alternative correctable cause. In the severe HCA-CDI group (n=8),
oral metronidazole was initiated in 4 (50%) cases, where oral vancomycin, intravenous
metronidazole or a combination was indicated. In those cases a relevant AMS
intervention was made.

4.6 Discussion

Our study describes the relationship between HCA-CDI rates and a multisite ASP
supported by a CDSS, education and antimicrobial restriction combined with targeted
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audit and feedback. The effect of the ASP on HCA-CDI rates did not reach statistical
significance, demonstrating that HCA-CDI rates remained stable during the study period.
Targeted interventions may help to combat the waning of the initial impact of a program
over time. We found that in an Australian non-metropolitan setting, LOS and hospital
costs were significantly increased in HCA-CDI patients when compared with matched
controls. Increased antimicrobial and PPI use in patients with HCA-CDI were consistent
with previous reports (Slimings and Riley, 2014; Kwok et al., 2012). Although the initial
treatment of non-severe HCA-CDI cases predominantly matched guidelines, there was
concerning use of oral metronidazole in half of the severe cases (albeit with small
numbers). This was similar to previous findings elsewhere (Jury et al., 2013), likely
resulting from under-recognition of severity criteria (Cheng et al., 2011; Trubiano et al.,
2016).

HCA-CDI has been associated with increased LOS and hospital costs (Gabriel and
Beriot-Mathiot, 2014). Most studies evaluating these effects were either epidemiological
studies (Pakyz et al., 2011; Campbell et al., 2013) or performed in the metropolitan
setting (Feazel et al., 2014). To our knowledge this is the first study to combine
evaluation of the burden of HCA-CDI with multisite ASP implementation in a regional
and rural setting. Comparison with matched controls allowed for a pragmatic approach to
identifying additional LOS and hospital costs associated with HCA-CDI (Kyne et al.,
2002; Vonberg et al., 2008). For those patients with LOS ≥ 8 days, there was a 42%
increase in hospital costs in HCA-CDI patients compared with controls, despite similar
LOS in those groups. This highlighted the increased cost of caring for HCA-CDI patients
additional to greater LOS, and alleviated the potential for time-dependent biases.
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There were several limitations to this study. We included all positive Clostridium difficile
tests during the targeted intervention phase, as the frequency of daily diarrhoeal episodes
was unreliably documented. Alternative causes of diarrhoea may have been present in
some patients carrying Clostridium difficile. We could not attribute the increase in LOS
and hospital costs to HCA-CDI alone. Alternative statistical methods such as multi-state
modelling (van Kleef et al., 2014) to account for time-dependent biases, and propensity
matching (Gabriel and Beriot-Mathiot, 2014) to accurately estimate the impacts of CDI
have been proposed. To account for those limitations, we applied the case-control
methodology in two additional subsets: the “long-stay” patients (≥8 days, the median
time-to-onset of HCA-CDI) and only those treated for HCA-CDI. Those results were in
line with our primary evaluation, emphasising the high LOS and cost burden of HCACDI. As expected, gastrointestinal DRGs were overrepresented. In some cases the
primary DRG may have been allocated to gastrointestinal due to CDI severity or duration.

Community cases could not be accurately assessed with the current study resources. Of
120 HCA-CDI cases, only 91 were eventually analysed for LOS and cost. Assessing the
impact on HCA-CDI rates might have been confounded for antimicrobials (e.g.
metronidazole, vancomycin) often given to treat CDI or co-administered with
antimicrobials associated with HCA-CDI. Intravenous vancomycin has been associated
with CDI (Hecht and Olinger, 1989); however, vancomycin was associated with CDI in
this study only when combined with other antimicrobials. We did not evaluate
appropriateness of prior antimicrobial use, in order to define avoidable HCA-CDI cases.
Detailed demographic data and prior antimicrobial use were not collected for controls, as
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this dataset was collected to allow for a post hoc analysis. Using background
antimicrobial and PPI data allowed for larger numbers and accounted for the potential of
bias due to under-reporting of those agents in control patients in whom CDI was not
considered. However, detailed characteristics of patients from whom the background use
data were derived were not available. The largest hospital accounted for two thirds of the
total OBDs; hence its infection rate largely determined the overall rate. The response rate
to emails was only 19%, limiting conclusions about their impact; however, responses
were not requested in the initial email, and still some useful clinical feedback was
received. Due to the hospitals’ geographic disparity, email remained the most pragmatic
feedback method.

Patient complexity in our hospitals may be lower compared with larger metropolitan
hospitals, limiting generalisability to those settings. Further studies combining evaluation
of ASPs with targeted CDI interventions would be useful, particularly in multisite and
non-metropolitan settings. In this study we identified high risk antimicrobial classes that
have formed targets for ongoing AMS activities.

4.6.1 Conclusions

Our study demonstrates the high burden of HCA-CDI in a non-metropolitan setting.
While it confirms the association between high-risk antimicrobial use and HCA-CDI, it
also identifies the possibility of under-recognition of CDI severity criteria during
treatment initiation. Targeted audit and feedback interventions may be a useful way of
consolidating the effects of a multisite ASP, contributing to sustainability, which remains
one of the major challenges of contemporary AMS.
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5.1 Summary statement

This chapter provides an insight into the challenges associated with evaluating ASP
implementation (involving an education campaign) across multiple hospital sites and
health districts. The theme of multisite AMS education supported by technology is further
explored in Chapters 6 and 7. Varying resources between hospitals necessitated a
combined approach, whereby implementation was based around a CDSS and allowed for
AMS support to be provided to the smaller and more remote sites with less on-site
expertise. An evidence gap was identified around centrally-deployed decision support

technology to facilitate improved antimicrobial use. At a multi-health district level, CDI,
infection-related LOS and mortality were examined as outcome measures for the ASP.
Measurement of outcomes related to antimicrobial use was also explored in Chapter 2
(renal toxicity and SSIs), Chapter 3 (30 day readmission rate and in-hospital mortality),
and Chapter 4 (CDI).
All results tables are provided at the end of the chapter (pages 148-161).

5.2 Abstract

5.2.1 Objective

Studies evaluating ASPs supported by CDSSs have predominantly been conducted in
single site metropolitan hospitals. This study aimed to examine outcomes of multisite
ASP implementation supported by a centrally deployed CDSS.

5.2.2 Methods

An ITS study of a CDSS-supported multisite ASP was conducted across five hospitals in
NSW, Australia from 2010 to 2014. Outcomes analysed were: effect of the intervention
on targeted antimicrobial use, antimicrobial costs, HCA-CDI rates, infection-related LOS,
and standardised mortality ratios (SMRs).

5.2.3 Results

Post-intervention, antimicrobials targeted for increased use rose from 223 to 293
DDDs/1000 OBDs/month (+32%, p<0.01). Conversely, antimicrobials targeted for
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decreased use fell from 254 to 196 DDDs/1000 OBDs/month (-23%; p<0.01). These
effects diminished over time. Antimicrobial costs decreased initially (-AU$64,551/month;
p<0.01), then increased (+AU$7,273/month; p<0.01). HCA-CDI rates decreased postintervention (-0.2 cases/10,000 OBDs/month; p<0.01). Proportional LOS reductions for
key infections (respiratory 4.8 to 4.3 days, p<0.01; septicaemia 6.8 to 6.1 days, p<0.01)
were similar to background LOS reductions (2.1 to 1.9 days). Similarly, infection-related
SMRs (observed/expected deaths) decreased in line with background rates (respiratory
1.1 to 0.75; septicaemia 1.25 to 0.8; background rate 1.19 to 0.90).

5.2.4 Conclusions

Implementation of collaborative multisite ASP supported by a centrally deployed CDSS
was associated with changes in targeted antimicrobial use, decreased antimicrobial costs,
decreased HCA-CDI rates, and no observable increase in LOS or mortality. Ongoing
targeted interventions are suggested to promote sustainability.

5.2.5 Keywords

Antimicrobial stewardship, computerised clinical decision support system, health costs,
Clostridium difficile, length of stay, mortality rate
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5.3 Introduction

ASPs aim to improve appropriateness of antimicrobial prescribing with the goals of more
effectively treating and preventing infections, while curbing AMR and reducing adverse
effects (Duguid and Cruickshank, 2010; Barlam et al., 2016). Studies examining the
impact of ASPs have primarily been conducted in tertiary metropolitan hospitals (Cairns
et al., 2013; Sick et al., 2013; Standiford et al., 2012; Nowak et al., 2012; Baysari et al.,
2016; Schuts et al., 2016). There is limited literature describing clinical outcomes from
collaboratively implemented ASPs across multiple hospital sites (Ostrowsky et al., 2014;
Lai et al., 2016; Cosgrove et al., 2012; Schuts et al., 2016). Previous single site ASP
studies have demonstrated benefits using a CDSS, antimicrobial restriction, and
prospective audit and feedback (Cairns et al., 2013; Sick et al., 2013; Nowak et al., 2012;
Standiford et al., 2012; Davey et al., 2013). These benefits include a reduction in targeted
antimicrobial use (Davey et al., 2013; Carling et al., 2003; Sick et al., 2013),
antimicrobial drug acquisition costs (Ansari et al., 2003; Carling et al., 2003; Sick et al.,
2013), and HCA-CDI rates (Aldeyab et al., 2012; Carling et al., 2003). An evidence gap
exists for implementation of ASPs across multiple sites using a centrally deployed CDSS
(Barlam et al., 2016).

Metrics for evaluating ASPs include antimicrobial use, drug costs, adverse effects such as
HCA-CDI and AMR, LOS, and mortality (Morris et al., 2012; Khadem et al., 2012).
Infection-related outcomes related to CAP, skin and soft tissue infections and septicaemia
have been also been recommended (Morris et al., 2012). Although there are confounders
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associated with their use as ASP metrics, LOS and mortality are useful balancing
measures to address potential unintended consequences (Davey et al., 2013).

To our knowledge, no studies of multisite ASPs using a centrally deployed CDSS have
included non-metropolitan hospitals. The aims of this study were to evaluate the impact
of a CDSS-supported, multisite ASP on antimicrobial use, antimicrobial costs, HCA-CDI
rates, infection-related LOS, and SMRs.

5.4 Methods

5.4.1 Setting

In 2012 a multisite ASP supported by a centrally deployed CDSS was implemented in 12
hospital sites (Figure 5.1) across the South Eastern Sydney and Illawarra Shoalhaven
Local Health Districts, and Sydney Children’s Hospital, all in NSW, Australia. These
districts cover a geographic area of 6,331 square kilometres and have an estimated
population of 1.17 million, extending from central Sydney to three hours’ drive south
(New South Wales Health, 2010). Comparable adult metrics were available for analysis in
five hospitals, comprising 1900 beds, as shown in Figure 5.1. The remaining hospitals
were not included in the study for the following reasons: small size, ASP implementation
outside of study period, specialist (i.e. obstetrics, paediatrics) or subacute admissions
(Figure 5.1). Those attributes would not allow comparison of outcomes such as
antimicrobial use, LOS or HCA-CDI. The specialist paediatric hospital contributed to the
development of guidelines for paediatric services within the other hospitals. Hospitals
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shared AMS strategies, including a centrally deployed CDSS (Guidance MS®,
Melbourne Health) (Guidance Group, 2013), educational material and similar
antimicrobial formulary restrictions. Further information on case complexity and case
mix of the included study hospitals is provided in Table 5.1.

5.4.2 Intervention

An ITS study was conducted combining data from five acute hospitals. The intervention
point for the ASP was defined as the go-live date of the CDSS with concurrent
dissemination of standardised antimicrobial prescribing guidelines at each site (May-July
2012). This occurred in the setting of a 6-month lead-in period of prior education and
antimicrobial guideline development (Figure 5.1). The fully modifiable CDSS, Guidance
MS® is an intranet browser-based CDSS that guides prescribers on appropriate use and
generates approvals for antimicrobials (Guidance Group, 2013). Antimicrobial restriction
(a key component of our ASP) within the CDSS is determined on the basis of spectrum of
action, potential toxicity or cost (Guidance Group, 2013). Implementation of the CDSS
used project methodology (PRINCE2®, ILX Group, Mulgrave, Victoria, Australia) and
was overseen by a multidisciplinary committee of medical, pharmacy, information
technology (IT), and executive staff. The committee met monthly via teleconference and
collaborated closely throughout the project implementation period (May 2011 - May
2012). This period was critical to optimise organisational readiness for implementation of
a CDSS-supported ASP (Duguid and Cruickshank, 2010).
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Figure 5.1: Population, clinical setting, nature and timing of interventions
†Phone-based AMS with formulary restriction implemented Nov 2008
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Figure 5.1 (cont): *Exclusions: delayed implementation, hospital sites had delayed recruitment of
specialist staff and inadequate reporting of antimicrobial benchmarking data; data not comparable,
specialist children’s and women’s hospitals with non-comparable patient and case mix; small sample size,
antimicrobial use and cost data not reported to the National Antimicrobial Utilisation Surveillance Program
(NAUSP); CDI, LOS and mortality data not analysed due to small sample size and high proportion of subacute admissions

Antimicrobial guidelines were based on national guidelines (Antibiotic Expert Group,
2010), then standardised across the hospitals and incorporated into the CDSS. The
development of guidelines, educational content and decision support was shared by adult
and paediatric ID physicians and AMS pharmacists. This allowed for a standardised
intervention that was tailored to hospital size and level of acuity (Figure 5.1), thereby
reducing individual hospital workload, allowing access to clinical expertise at smaller
sites and ensuring timely consensus on CDSS clinical content. Staffing (ID physicians,
pharmacists and microbiologists) varied across the hospital sites, so intranet-based
guidelines and an antibiotic advice hotline were used to promote access to program
resources. Standardised bimonthly nationally benchmarked antimicrobial usage audits
were reported to respective hospital AMS committees (South Australian Health, 2016).
Prior to the study, AMS activities were restricted to phone-based advice, formal ID
consults, selective antimicrobial sensitivity reporting, restriction of antifungals and
reserve antibacterials (e.g. linezolid, tigecycline, colistin and daptomycin), and a phonebased approval system at one study hospital (Figure 5.1).

Study investigators classified the most commonly used antimicrobial classes into two
categories, either targeted for increased or decreased use. Categorisation was based on the
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following factors: local AMR patterns, local use compared with benchmarked hospitals
(South Australian Health, 2016), risk of HCA-CDI and other side effects, compliance
with antibiotic guidelines (Antibiotic Expert Group, 2010), and cost. Antimicrobials
targeted for increased use were benzylpenicillin, doxycycline and aminopenicillins,
whereas antimicrobials targeted for decreased use were third generation cephalosporins,
macrolides, anti-pseudomonal beta-lactam/beta-lactamase inhibitor combinations,
fluoroquinolones, and carbapenems. Additional antimicrobials were targeted for increased
use in some settings, but decreased use in others. For example, local quality audits
identified underdosing in surgical prophylaxis, but unnecessarily long duration of therapy
in other settings such as cellulitis (data not shown). Such antimicrobials (i.e. first
generation cephalosporins, flucloxacillin, aminoglycosides, and vancomycin) were only
included in the overall antimicrobial use analysis.

The infection control policies related to Clostridium difficile and hand hygiene were not
subject to any major changes during the study period. Infection control measures
recommended by local policies included: isolation in single rooms; use of disposable
gowns and gloves; hand hygiene with alcohol-based hand rub and/or soap and water; and
terminal cleaning with chlorine-based disinfectant. Diagnostic testing methods for
Clostridium difficile were comparable across the health districts’ three main laboratories
from May 2010, and included first line testing with targeted GDH antigen and toxins A
and B (e.g. C. Diff Quik Chek Complete®, Techlab, Blacksburg, VA, USA). Discordant
results occasioned the use of a PCR (e.g. GeneXpert®, Cepheid, Sunnyvale, CA, USA)
test. All diarrhoeal stools were subjected to testing from December 2010 (seven months
after the beginning of the pre-intervention period). A subset of the CDI data has been
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published previously in a different context (Bond et al., 2016). Those data have been
included here to allow comparison in the multisite setting.

5.4.3 Outcomes

The effect of the intervention was assessed by: (1) change in antimicrobials targeted for
increased use (benzylpenicillin, doxycycline and aminopenicillins) expressed as DDDs
per 1000 OBDs; (2) change in antimicrobials targeted for decreased use (third generation
cephalosporins, macrolides, anti-pseudomonal beta-lactam/beta-lactamase inhibitor
combinations, fluoroquinolones, and carbapenems; DDDs/1000 OBDs) (World Health
Organisation, 2017); (3) change in total monthly antimicrobial costs (AU$). High cost
antifungals (liposomal amphotericin, anidulafungin, caspofungin, posaconazole, and
voriconazole) were analysed separately to the main antimicrobial group due to small
variations in use accounting for large cost variations; (4) change in HCA-CDI rates,
defined as a positive laboratory test for toxigenic Clostridium difficile plus diarrhoea
onset greater than 48 hours after hospital admission (HCA-CDI cases per 10,000 OBDs)
(Australian Council on Healthcare Standards, 2014); and (5) change in LOS and inhospital SMR for respiratory tract infections, cellulitis, kidney and urinary tract
infections, and septicaemia, compared with background figures for all conditions
(infectious and non-infectious combined). Confounders for each of the above measures
were also investigated and reported where appropriate. Those included infection
outbreaks, updated guidelines, changes to drug acquisition costs and administrative
changes.
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5.4.4 Data sources

Adult inpatient data were included from May 2010 to July 2014. Antimicrobial use and
acquisition cost data were obtained from pharmacy dispensing software, iPharmacy®
Versions 5.5 and 5.6 (CSC, Sydney, Australia). Antimicrobial use data were processed by
NAUSP (South Australian Health, 2016) using WHO classifications. OBD data were
sourced from the hospitals’ performance units. HCA-CDI numbers were provided by the
infection control teams in line with standardised surveillance and reporting (Australian
Council on Healthcare Standards, 2014). LOS (using Australian refined DRGs)
(Australian Institute of Health and Welfare, 2016) and SMRs (using principal diagnosis
codes, based on International Classification of Diseases, 10th revision, Australian
modification) (Australian Institute of Health and Welfare, 2016) were provided by the
performance units for the following key infections: respiratory infections/inflammations
(predominantly pneumonia), cellulitis, and kidney and urinary tract infections. Those
were the commonest treatment indications for antimicrobials in the 2014 Australian
NAPS (Australian Commission on Safety and Quality in Health Care, 2015). Septicaemia
was also included due to its high mortality (Gauer, 2013). LOS and SMRs were compared
for the time periods 1 July 2010 – 30 June 2012 and 1 July 2012 – 30 June 2014, as only
data aligned with Australian financial years was available. Analysis of overall LOS
excluded day case haemodialysis admissions. Comparative case complexity and case mix
of the study hospitals was reported using National Weighted Activity Units (NWAUs)
(National Health Funding Pool, 2016) and DRGs (Table 5.1) (Australian Institute of
Health and Welfare, 2016).
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5.4.5 Statistical analyses

ITS analysis with segmented linear regression was used to examine the impact of the
intervention on monthly antimicrobial use, costs and HCA-CDI, estimating the immediate
effects of the intervention and changes in trend (Linden, 2015). To account for seasonal
variations, 24 time points one month apart were used pre- and post-intervention (Ansari et
al., 2003). To allow for statistical analysis of two years pre- and two years postintervention, the intervention point (go-live date of CDSS-supported ASP) was aligned
for the five hospitals, with individual hospital data provided in Table 5.5 and Table 5.6.
Definitions for ITS were: (1) initial level, model-predicted level (antimicrobial use, cost,
HCA-CDI) 24 months pre-intervention; (2) initial trend, model-predicted monthly trend
pre-intervention; (3) change in level (immediate effect), model-predicted difference
between the level at the end of the pre-intervention period and commencement of the
post-intervention period (Cairns et al., 2013); (4) change in trend, model-predicted
difference between initial (pre-intervention) monthly trend and post-intervention trend.
Autocorrelation using Newey-West approximation for standard errors was investigated
and an appropriate lag was used when necessary, in order to assess for similarity between
observations (Linden, 2015). LOS was assessed using Mann-Whitney U-test. A logistic
regression model was used to calculate the number of expected deaths using: age; sex;
admission type (emergency or acute); admission source (acute transfer or other); principal
diagnosis, and Charlson Comorbidity Index (0, 1-2, or 3+) (Charlson et al., 1987).
Additional variables used in the expected deaths analysis related to vascular surgery,
cardiac surgery, neurosurgery, trauma and transplant. Those figures were then used to
calculate infection-related and total SMR (actual deaths/expected deaths). SMRs (pre131

and post-intervention) were expressed with 95% confidence intervals (CIs). Statistical
significance was considered p<0.05. Statistical analyses were performed using Stata®
Statistical Software: Release 14 (Statacorp 2015; College Station, TX, USA).

5.4.6 Ethics

Ethics approval was obtained from the districts’ Human Research Ethics Committees,
approval number HE13/137 (Appendix E).

5.5 Results

5.5.1 Antimicrobial use

Following the intervention, a rise in antimicrobials targeted for increased use of 70
DDDs/1000 OBDs (+32%; p<0.01) was observed, followed by a decline in trend of 3.5
DDDs/1000 OBDs per month (p<0.01). A concomitant reduction in antimicrobials
targeted for decreased use of 58 DDDs/1000 OBDs (-23%; p<0.01) was observed,
followed by a rise in trend of 3.4 DDDs/1000 OBDs per month (p<0.01;Figure 5.2). No
significant change in level or trend was observed for overall antimicrobial use. There was
a national shortage of benzylpenicillin in 2010-11; ampicillin was recommended as an
alternative for most benzylpenicillin indications during this time. The national
antimicrobial guidelines (Antibiotic Expert Group, 2010; Antibiotic Expert Groups, 2014)
were updated in 2010 and again in 2014.
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Figure 5.2: Impact of the AMS intervention on antimicrobial use
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Figure 5.2 (cont): Abbreviations: DDDs, defined daily doses; OBDs, occupied bed days
Targeted for increased use: benzylpenicillin, doxycycline, aminopenicillins (amoxycillin and ampicillin);
targeted for decreased use: third generation cephalosporins (ceftriaxone, cefotaxime), macrolides
(azithromycin, clarithromycin, erythromycin, roxithromycin), anti-pseudomonal penicillins
(piperacillin/tazobactam, ticarcillin/clavulanic acid), fluoroquinolones (ciprofloxacin, moxifloxacin,
norfloxacin); carbapenems (ertapenem, doripenem, imipenem/cilastatin, meropenem) total antimicrobials,
all antimicrobials excluding antifungals and antivirals; vertical line is introduction of a CDSS-supported
ASP, including antimicrobial restriction and education.

5.5.2 Antimicrobial costs

There was a significant reduction in total monthly antimicrobial costs of AU$64,551 (17%; p<0.01) post-intervention, followed by an increase in trend of AU$7,273 per month
(p<0.01; Table 5.3). This corresponded to a reduction of AU$1.70/OBD post-intervention
(-20%; p<0.01), with a subsequent increase in trend of AU$0.26/OBD per month
(p<0.01). High cost antifungals demonstrated an immediate cost reduction (p<0.01), with
no significant increase in trend. Some changes in acquisition costs were noted prior to the
intervention, most notably a reduction in meropenem acquisition costs in mid-2011.

5.5.3 HCA-CDI rates

HCA-CDI rates were increasing pre-intervention from 2.8 to 6.2 cases/10,000 OBDs per
month (p<0.01). A reduction was demonstrated post-intervention (-1.2 cases/10,000
OBDs/month, p=0.15), followed by a decrease in trend (p<0.01; Table 5.3; Figure 5.3).
There were no systemic changes to hand hygiene and cleaning policies during the study
period. The rate of hand hygiene compliance had increased across facilities following
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national initiatives prior to 2009. There were no notable HCA-CDI outbreaks from 20102014.

Figure 5.3: Impact of the AMS intervention on HCA-CDI rates
Abbreviations: HCA-CDI, healthcare associated Clostridium difficile infection
Two years of monthly HCA-CDI rates pre- and post-intervention; vertical line is introduction of a CDSSsupported ASP.

5.5.4 LOS

Median LOS was reduced for respiratory infections (4.8 to 4.3 days, p<0.01), cellulitis
(3.2 to 2.9 days, p<0.01), urinary and kidney infections (3.3 to 2.9 days, p<0.01), and
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septicaemia (6.8 to 6.1 days, p<0.01; Table 5.4). Over the same time period, median LOS
for all hospital admissions also decreased from 2.1 to 1.9 days (p<0.01).

5.5.5 In-hospital SMR

SMRs decreased for respiratory infections (1.10 [95%CI 1.01-1.20] to 0.75 [0.68-0.82]
observed/expected deaths), urinary and kidney infections (0.78 [0.52-1.10] to 0.63 [0.420.91]), and septicaemia (1.25 [1.12-1.38] to 0.80 [0.72-0.89]). Reductions in those
infection-related SMRs were in line with the reduction in background SMR (1.19 [1.151.23] to 0.90 [0.87-0.93]; Table 5.4). A small increase was observed for cellulitis (0.55
[0.28-0.95] to 0.66 [0.38-1.05]).

5.6 Discussion

To our knowledge, this is the first study to evaluate implementation of a multisite ASP
supported by a centrally deployed CDSS. We found improvements in antimicrobial use,
demonstrated by changes in antimicrobials targeted for increased and decreased use.
There were significant reductions in antimicrobial costs and HCA-CDI rates. Safety of
the intervention was supported by decreased or unchanged LOS and SMRs for key
infections during the study period. The long-term impact of the intervention on
antimicrobial use and cost diminished over time, which suggests that ongoing program
reinforcement and targeted interventions may be required to alleviate “AMS fatigue”.
Changes in overall antimicrobial use prior to the main intervention probably resulted from
an intensive education campaign to optimise antimicrobial use across the hospitals, with
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heightened awareness of the impending change among clinicians. The importance of
readiness assessments prior to implementation was recognised, along with shared
interventions across the study hospitals. Those included AMS ward rounds with postprescription review and feedback, consensus guidelines, departmental education, and
antimicrobial restriction.

Some studies have evaluated ASPs across multiple hospital sites (Ostrowsky et al., 2014;
Antoine et al., 2006; Schuts et al., 2016) and the utility of an individual site CDSS for
improvement in antimicrobial prescribing (Cairns et al., 2013; Kaushal et al., 2003;
Buising et al., 2008; Thursky, 2006); however, the combination of these two approaches
is novel. Furthermore, this collaborative ASP was applied to non-metropolitan settings
with an established structure of support from a larger hospital. Pooling data across five
hospitals enhanced the potential to identify effects of the ASP. Few randomised studies
have been conducted to determine the effect of ASPs (Davey et al., 2013; Schuts et al.,
2016). Our study used interrupted time series analysis, which is considered an alternative
pragmatic approach with strong quasi-experimental design (Fowler et al., 2007).
Comparison with control hospitals would have strengthened the study design; however,
there were none available in the health districts due to widespread implementation of the
ASP.

Our study demonstrates that shared knowledge and expertise can be used to effectively
implement an ASP across multiple hospital sites spanning a wide geographic area. The
economies of scale enjoyed by the multisite approach allowed for collective interventions
to be employed with reduced workload at individual hospital sites. Multisite
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implementation also alleviated some of the potential disadvantages of the CDSS, such as
resources required for implementation and maintenance (Barlam et al., 2016). An
additional benefit of extensive multisite intervention was consistency in antimicrobial
prescribing guidelines, facilitating the training of medical officers rotating through the
facilities within the districts’ different hospitals. A consistent, multisite approach was also
anticipated to enhance prescriber confidence and facilitate the quality improvement
culture necessary to effect longer term improvements in antimicrobial prescribing (Broom
et al., 2014; Charani et al., 2011).

ASPs are a key element of the approach to reducing HCA-CDI (Leffler and Lamont,
2015). Importantly, our intervention was associated with a reduction in HCA-CDI rates,
as well as a decrease in trend that persisted over time. This occurred in the context of
increasing community CDI rates (Slimings et al., 2014).

The specialist paediatric hospital and paediatric wards from study sites were not included
in this analysis. Non-comparability of standard adult metrics such as DDDs results in
difficulty benchmarking antimicrobial use in children (Porta et al., 2012). HCA-CDI
cannot easily be assessed in the paediatric population due to asymptomatic carriage in
infants and lower rates of symptomatic CDI in children (Sammons et al., 2013). Although
quantitative paediatric data were not included in this study, paediatric antimicrobial
guideline and CDSS development were important for multisite ASP implementation
across the network of small rural to large metropolitan hospitals.
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Maintaining cost effectiveness is of concern to administrators (McGowan, 2012). Placing
drug costs as the primary measure of cost analysis does not take into account changes in
acquisition costs (e.g. when drugs come off patent). In addition, the most appropriate
antimicrobial is not necessarily the lowest in price. Identifying other methods of cost
benefit analysis is justified, such as the impact of healthcare associated infections, and the
increased cost of treating resistant organisms (Goff, 2011). Some cost savings were
attributed to reductions in drug acquisition costs, such as for meropenem in 2011.
Paradoxically, the intervention was associated with increased drug costs in some
instances. Benzylpenicillin, targeted for increased use, had a daily cost at usual dosing
(1.2g intravenously 6 hourly) of AU$25, compared with ceftriaxone (targeted for
decreased use; AU$1.30 for 1g intravenously daily). In addition, the post-intervention
cost increase may have been driven by high cost antifungal use where treatment of a
small number of patients may result in a significant increase in drug costs. Building
works at some of the sites, leading to increased prophylaxis and treatment of invasive
fungal infections, may have led to this increase. However, antifungals were not a main
target of the collaborative ASP as they were already highly restricted prior to the
intervention. Costs of the intervention were not analysed as part of this study; there were
costs associated with purchasing the CDSS, and additional pharmacy and ID resources in
supporting the ASPs.

There were some other limitations to this study. Antimicrobial use patterns may also have
been affected by unforeseen drug shortages and changes to infection control practices.
There were no systematic changes to the infection control policies across the districts
during the study period, and no recognised outbreaks of CDI occurred during this time.
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Some measures were not included due to a lack of comparable pre- and post-intervention
data across sites; these included the impact of antimicrobial stewardship ward rounds,
point prevalence survey results and AMR patterns. Antimicrobials analysed included only
those targeted for increased (e.g. benzylpenicillin) or decreased (e.g. ceftriaxone) use. Not
all antimicrobial classes were reported individually, such as glycopeptides (e.g.
vancomycin) and first generation cephalosporins (e.g. cephazolin, cephalexin). Although
often targeted in ASPs, based on national guidelines (Antibiotic Expert Group, 2010)
there were instances where these classes were targeted for either increased or decreased
use. As such, it was not clear whether the ASP would result in a change to use. Reserve
antibacterial agents such as linezolid and daptomycin were already highly restricted prior
to the intervention, requiring prior physician approval before use.

The effect of the intervention was not uniform across the sites. Reasons for this variability
may have included differences in maturity of existing antimicrobial stewardship
initiatives prior to the introduction of the CDSS, disparate levels of acuity, and variable
patterns of resistance. Pre-existing AMS initiatives at all sites consisted of selective
microbiology reporting, limited ID and microbiology phone support, and some
departmental education, with one site additionally using a phone-based approval system
(Figure 5.1). Variation in case complexity and case mix between study hospitals (Table
5.1) may have justified some differences in antimicrobial use. Additionally, seasonal
variation was evident in the antimicrobial use patterns. Those confounders may have been
alleviated by using combined antimicrobial use data with sufficient pre- and postintervention time points for the ITS analysis. Data on antimicrobial use, cost and HCACDI data could not be aligned perfectly in time with LOS and mortality data due to report
140

limitations; however, the maximum lag (for one hospital) was only 6 weeks over a 48
month period. Infection-related and overall LOS decreased after the intervention, which
may have been due to increased use of hospital in the home services. There may have
been potential confounders, such as changes to funding and hospital admission models
that affected LOS and SMR during the intervention which were difficult to quantify.
However, LOS and SMR were included as important balancing measures as they could
potentially be negatively impacted by changed patterns of antimicrobial use. Statewide
programs were also introduced by the NSW Clinical Excellence Commission through
2010-2014 to improve management of deteriorating patients (Between the Flags program)
and recognition and management of sepsis (Sepsis Kills program) (Clinical Excellence
Commission, 2016). Those initiatives potentially contributed to the improvements in LOS
and SMR in the post-intervention period.

We anticipate that our findings would be generalisable to healthcare facilities with
potential for utilising shared resources, such as those with existing professional or
political networks. Additional studies using prospective methodological approaches in
different settings would help to validate our results.

5.6.1 Conclusions

Implementation of a multisite ASP supported by a centrally deployed CDSS was
associated with significant changes to targeted antimicrobial use, containment of
antimicrobial expenditure and reduction in HCA-CDI, without obvious adverse effects.
Ongoing targeted interventions involving education and behaviour change are required to
sustain the benefits of ASPs on hospital antimicrobial use.
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5.8 Tables
Table 5.1: Case complexity and case mix of study hospitals for the Australian financial year 2013 – 2014
Hospital

Total acute
NWAU(16)

Prince of Wales

Total
acute
episodes
32,699

Top five DRGs by volume

49,513

Average
NWAU(16) per
acute episode
1.51

Shellharbour

8,213

11,246

1.37

Respiratory infection/ inflammation; schizophrenia disorders; chronic obstructive
airway disease; hernia procedures; personality disorder and acute reactions

Shoalhaven

10,970

12,678

1.16

Uncomplicated neonatal admission; vaginal delivery; respiratory infection/
inflammation; chronic obstructive airway disease; caesarean delivery

St George

39,234

57,138

1.46

Uncomplicated neonatal admission; vaginal delivery; chest pain; respiratory
infection/ inflammation; oesophagitis and gastroenteritis

Wollongong

36,951

50,813

1.38

Uncomplicated neonatal admission; vaginal delivery; respiratory infection/
inflammation; cellulitis; caesarean delivery

Chest pain; cellulitis; other digestive system diagnosis; respiratory infection/
inflammation; injuries

Australian financial year, 1 July 2013 to 30 June 2014; total acute episodes excludes haemodialysis, due to a large number of episodes without significant
antimicrobial use; NWAU(16), National weighted activity unit (2015/16), a measure of comparing and valuing each public hospital service, to determine the
overall complexity and relative resource payment for services funded on an activity basis. DRGs, Australian-refined diagnosis related group.

Table 5.2: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use
Initial
level

LCI

Pre-intervention
UCI
LCI
Initial
trend

Combined targeted
for increased use

182a

170

195

1.7a

Combined targeted
for decreased use

316

298

334

Total antimicrobial
use

1125a

1033

1184

Antimicrobial

Post-intervention
p
Change
value
in trend

UCI

p
value

Change
in level

LCI

UCI

LCI

UCI

p
value

0.7

2.8

<0.01

71a

43

98

<0.01

-3.5a

-5.3

-1.7

<0.01

-2.6

-4.1

-1.2

<0.01

-58

-87

-29

<0.01

3.4

1.4

5.3

<0.01

-3.4a

-8.9

2.1

0.22

-29a

-129

71

0.57

3.55a

-2.6

9.7

0.25

Antimicrobial use (level) expressed as average defined daily doses/1000 occupied bed days for five hospitals, as reported to NAUSP; trends: positive value represents
increase, negative value represents decrease; 95% confidence intervals expressed as LCI (lower confidence interval) and UCI (upper confidence interval); aadjusted for first
order autocorrelation; targeted for increased use: benzylpenicillin, doxycycline, aminopenicillins (amoxycillin, ampicillin); targeted for decreased use: third generation
cephalosporins (ceftazidime, cefotaxime, ceftriaxone); macrolides (azithromycin, clarithromycin, erythromycin, roxithromycin); anti-pseudomonal penicillins
(piperacillin/tazobactam, ticarcillin/clavulanic acid); fluoroquinolones (ciprofloxacin, moxifloxacin, norfloxacin); carbapenems (meropenem, ertapenem, doripenem,
imipenem/cilastatin); individual hospital data provided in Table 5.5.
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Table 5.3: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare associated Clostridium difficile infection
Pre-intervention

Post-intervention

Initial
level

LCI

UCI

Initial
trend

LCI

UCI

p
value

Change
in level

LCI

UCI

p
value

Change
in trend

LCI

UCI

p
value

Totalb costs
($AU)

463375a

417101

509649

-3196a

-5759

-633

0.02

-64551a

-106056

-23044

<0.01

7273a

3899

10649

<0.01

Costs per
OBD ($AU)

9.9

8.7

11.1

-0.07

-0.14

-0.01

<0.01

-1.7

-2.6

-0.8

<0.01

0.26

0.18

0.34

<0.01

Antifungalc
costs ($AU)

92575

67721

117429

2021

376

3666

0.02

-50270

-86637

-13903

<0.01

1117

-1504

3738

0.40

HCA-CDI
per 10,000
OBDs

2.8

1.7

3.9

0.14

0.06

0.22

<0.01

-1.2

-2.8

0.4

0.15

-0.2

-0.3

0.1

<0.01

Variable

Abbreviations: OBD, occupied bed day; $AU, Australian dollars; HCA CDI, healthcare associated Clostridium difficile infection.
a

adjusted for first order autocorrelation; trends: positive value represents increase, negative value represents decrease; bantibacterial, antifungal, antiviral chigh cost

antifungals: liposomal amphotericin, anidulafungin, caspofungin, posaconazole, voriconazole; individual hospital data provided in Table 5.6.
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Table 5.4: Length of stay and standardised mortality ratio by clinical infection group
Length of stay
Outcome
measure

July 10 – June 12
Episodes
Median LOS
(IQR), days

Standardised mortality ratio

July 12 – June 14
Episodes
Median LOS
(IQR), days

p value

July 10 – June 12
Standardised
Actual/
mortality ratio
expected
(95% CI)
deaths

July 12 – June 14
Standardised
Actual/
mortality ratio
expected
(95% CI)
deaths

Respiratory
infections

5,489

4.8 (2.8-7.8)

5640

4.3 (2.5-7.1)

<0.01

1.10 (1.01-1.20)

534/485

0.75 (0.68-0.82)

436/584

Cellulitis

3,696

3.2 (1.6-5.8)

3757

2.9 (1.2-5.0)

<0.01

0.55 (0.28-0.95)

12/22

0.66 (0.38-1.05)

17/26

Urinary and
kidney
infections

4,323

3.3 (1.2-5.2)

4364

2.9 (1.0-5.2)

<0.01

0.78 (0.52-1.10)

30/39

0.63 (0.42-0.91)

29/46

Septicaemia

1,610

6.8 (4.0-11.7)

2441

6.1 (3.5-10.9)

<0.01

1.25 (1.12-1.38)

350/281

0.80 (0.72-0.89)

359/450

224,021

2.1 (0.6-5.6)

242,383

1.9 (0.5-5.0)

<0.01

1.19 (1.15-1.23)

3795/3193

0.90 (0.87-0.93)

3647/4063

Overall

Abbreviations: LOS, length of stay; IQR, interquartile range; CI, confidence interval
Respiratory infections/inflammations, code E62; cellulitis, code J64; urinary and kidney infections, code, L63; septicaemia, code T60; overall LOS excludes haemodialysis
day admissions. Codes for LOS used Australian refined diagnosis related group definitions; codes for SMR used principal diagnosis codes, based on International
Classification of Diseases, 10th revision, Australian modification.
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Table 5.5a: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital
Prince of Wales Hospital

Initial
level

LCI

Pre-intervention
UCI
Initial LCI
trend

UCI

p
value

Change
in level

LCI

UCI

Post-intervention
p
Change
value in trend

LCI

UCI

p
value

Benzylpenicillin
Doxycycline
Aminopenicillins
Combined

19a
10a
146a
175a

11
5
129
148

28
15
163
202

0.5
2
-0.8
1.78

-0.1
1.5
-1.8
0.1

1.2
2.5
0.3
3.4

0.1
<0.01
0.15
0.04

4.9
4.4
3.0
38

-8.6
-6.8
9.3
14.0

18.4
15.6
47.5
61.4

0.5
0.4
<0.01
<0.01

-0.3
-1.8
0.4
-1.68

-1.2
-2.6
-1.0
-4.1

0.6
-0.9
1.7
0.68

0.5
<0.01
0.6
0.15

3rd gen
cephalosporins
Macrolides
Anti-pseudomonal
penicillins
Fluoroquinolones
Carbapenems
Combined

75a

68

83

-0.6

-1.0

-0.3

<0.01

1.7

-4.7

8.2

0.6

0.8

0.2

1.5

0.01

95a
28a

80
23

111
33

-0.6
0.7

-1.6
0.4

0.4
1.0

0.2
<0.01

-13
-4.9

-35
-13

8.8
3.3

0.2
0.24

0.4
-0.67

-1.2
-1.1

1.9
-0.2

0.6
<0.01

72
25
296

62
17
270

81
34
322

-1.8
0.4
-0.9

-1.4
-0.2
-2.7

-0.2
1.0
0.8

0.01
0.2
0.3

-0.2
3.4
-13

-12
-7.4
-47

12
14
21

0.98
0.5
0.4

0.1
-0.5
0.1

-1
-1.3
-2.4

1.1
0.3
2.5

0.87
0.25
0.9

Total antimicrobial
1078 1140
-3.2
1.6
0.5
20
119 <0.01
-0.8
8.1
1109a
0.8
69
3.6
use
Antimicrobial use (level) expressed as average defined daily doses/1000 occupied bed days, as reported to NAUSP; 95% confidence intervals expressed as LCI (lower

0.1

Antimicrobial

Targeted for
increased
use

Targeted for
decreased
use

confidence interval) and UCI (upper confidence interval); trends: positive value represents increase, negative value represents decrease.
a

adjusted for first order autocorrelation; aminopenicillins, amoxycillin, ampicillin; third generation cephalosporins, ceftriaxone and cefotaxime; macrolides, azithromycin,

clarithromycin, roxithromycin, erythromycin; anti-pseudomonal penicillins, piperacillin-tazobactam and ticarcillin-clavulanic acid; fluoroquinolones, ciprofloxacin,
moxifloxacin and norfloxacin; carbapenems, ertapenem, doripenem, imipenem/cilastatin, meropenem.
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Table 5.5b: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital
Shellharbour Hospital

Initial
level

LCI

Pre-intervention
UCI
Initial LCI
trend

UCI

p
value

Change
in level

LCI

UCI

Benzylpenicillin
Doxycycline
Aminopenicillins
Combined

13
22a
98a
132a

-1.1
8
80
96

26
35
117
168

0.17
5.2
-0.2
5.2

-0.8
3.9
-1.6
2.5

1.2
6.5
1.2
7.8

0.7
<0.01
0.75
<0.01

35
74
53
162

17
33
25
99

53
115
81
226

<0.01
<0.01
<0.01
<0.01

3rd gen
cephalosporins
Macrolides
Anti-pseudomonal
penicillins
Fluoroquinolones
Carbapenems
Combined

94

78

110

-1.2

-2.9

0.6

0.19

-29

-59

2

295
17

259
13

331
21

-6.1
0.03

-8.7
-0.3

-3.4
0.3

<0.01
0.88

-65
-8

-127
-15

55
5
466

35
2
400

75
7
530

-0.001
-0.05
-7.3

-1.6
-0.2
-13

1.6
0.1
-1.2

1
0.57
0.02

-30
-1.5
-133

1295a

1191

1399

-8

-18

3

0.14

-42

Antimicrobial

Targeted for
increased
use

Targeted for
decreased
use

Total
antimicrobial use

154

Post-intervention
p
Change
value in trend

LCI

UCI

p
value

-1.4
-7
-1.3
-9.9

-2.7
-10
-2.9
-14.2

-0.1
-4
0.3
-5.6

0.03
<0.01
0.1
<0.01

0.06

2.1

0.3

3.9

0.02

-3.4
-1

0.04
0.02

5.7
0.25

2.9
-0.2

8.4
0.7

<0.01
0.28

-58
-5
-245

-1
2
-22

0.04
0.41
0.02

0.7
0.2
8.9

-1.3
-0.1
1.9

2.6
0.5
16

0.5
0.18
0.01

-252

167

0.7

6.7

-5.3

18

0.27

Table 5.5c: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital
Shoalhaven Hospital

Initial
level

LCI

Pre-intervention
UCI Initial LCI
trend

UCI

p
value

Change
in level

LCI

UCI

Benzylpenicillin
Doxycycline
Aminopenicillins
Combined

36
108a
202a
344a

22
71
190
302

49
143
214
387

0.03
0.4
-2.4
-2.0

-1.1
-1.7
-3.3
-4.4

1.2
2.6
-1.5
0.5

1
0.7
<0.01
0.12

9
54
19
82

-13
26
-11
32

31
81
49
131

0.8
<0.01
0.2
<0.01

3rd gen
cephalosporins
Macrolides
Anti-pseudomonal
penicillins
Fluoroquinolones
Carbapenems
Combined

54

42

67

0.3

-0.5

1.0

0.5

-16

-27

-6

170
21

153
16

187
26

-3.2
-0.01

-4.4
-0.3

-1.9
0.3

<0.01
0.97

-40
-5

-84
-12

66
9a
320

57
6
293

75
11
346

-1
-0.2
-4.1

-1.7
-0.3
-5.8

-0.3
-0.01
-2.3

<0.01
0.04
<0.01

-13
-2
-77

1508a

1391

1625

-15

-24

-7

<0.01

-104

Antimicrobial

Targeted for
increased
use

Targeted for
decreased
use

Total
antimicrobial use

Post-intervention
p
Change
value in trend

LCI

UCI

p
value

-0.2
-1.1
2.2
0.8

-1.5
-3.5
0.2
-3.0

1.1
1.3
4.1
4.6

0.7
0.4
0.03
0.68

<0.01

-0.5

-1.4

0.4

0.24

3
1.7

0.07
0.14

5.1
0.63

-0.3
-0.02

11
1.3

0.06
0.06

-30
-6.5
-128

3.4
2.5
-27

0.12
0.37
<0.01

0.85
0.4
6.5

-0.2
0.1
0.9

1.9
0.8
12

0.12
0.02
0.02

-249

40

0.15

17

8

27

<0.01
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Table 5.5d: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital
St George Hospital

Initial
level

LCI

Pre-intervention
UCI Initial
LCI
trend

UCI

p
value

Change
in level

LCI

UCI

Benzylpenicillin
Doxycycline
Aminopenicillins
Combined

20a
1.4a
75a
96a

14
-2.9
69
85

27
5.6
81
107

0.7
1.1
2.0
3.8

0.2
0.84
1.28
2.8

1.2
1.43
2.69
4.9

<0.01
<0.01
<0.01
<0.01

-16
-0.1
8.1
-7.6

-24
-8.5
-6.8
-27.8

-7
8.3
23.0
12.6

<0.01
0.98
0.3
0.45

3rd gen
cephalosporins
Macrolides
Anti-pseudomonal
penicillins
Fluoroquinolones
Carbapenems
Combined

44

37

50

0.5

0

1.06

0.051

-4.0

-14

6.1

80
18a

68
15

90
20

0.9
0.8

-0.1
0.6

1.9
1.0

0.09
<0.01

-6.4
-7

-28
-12

29a
13a
183

24
10
165

34
15
202

0.2
0.1
2.5

-0.1
-0.02
0.8

0.5
0.3
4.3

0.13
0.09
<0.01

-5
3.2
-19

633

590

676

14

11

18

<0.01

-43

Antimicrobial

Targeted for
increased
use

Targeted for
decreased
use

Total
antimicrobial use
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Post-intervention
p
Change
value in trend

LCI

UCI

p
value

-0.1
-1.0
-3.8
-5.0

-0.7
-1.6
-4.7
-6.3

0.4
-0.5
3.0
-3.8

0.6
<0.01
<0.01
<0.01

0.43

-0.9

-1.5

-0.3

<0.01

15
-2

0.56
<0.01

-2.0
-0.08

-3.4
-0.4

-0.7
0.2

<0.01
0.6

-9
-2.4
-54

-1
8.8
15

0.02
0.25
0.27

-0.1
-0.1
-3.3

-0.5
-0.4
-5.4

0.2
0.2
-1.2

0.43
0.5
<0.01

-98

12

0.12

-17

-20

-13

<0.01

Table 5.5e: Impact of a CDSS-supported multisite ASP on monthly antimicrobial use, by hospital
Wollongong Hospital

Initial
level

LCI

Pre-intervention
UCI
Initial LCI
trend

UCI

p
value

Change
in level

LCI

UCI

Benzylpenicillin
Doxycycline
Aminopenicillins
Combined

20
30a
114a
164a

15
19
104
143

26
40
124
186

-0.3
1.2
-1.2
-0.3

-0.7
0.1
-2.1
-2.3

0.06
2.3
-0.3
1.8

0.1
0.03
0.01
0.8

18
35
27
80

11
8
11
39

25
61
44
120

<0.01
0.01
<0.01
<0.01

3rd gen
cephalosporins
Macrolides
Anti-pseudomonal
penicillins
Fluoroquinolones
Carbapenems
Combined

51

42

61

-0.3

-0.9

0.4

0.4

-8

-17

1

123
49a

110
41

137
58

-1.9
-0.3

-3.0
-0.9

-0.9
0.2

<0.01
0.24

-13
-7

-34
-15

73
19a
316

63
15
283

83
23
349

-1
0.01
-3.6

-1.8
-0.2
-6.0

-0.3
0.2
-1.2

<0.01
0.87
<0.01

-16
-3
-48

1081a

1008

1156

-7

-15

0.2

0.06

-22

Antimicrobial

Targeted for
increased
use

Targeted for
decreased
use

Total antimicrobial
use

Post-intervention
p
Change
value
in trend

LCI

UCI

p
value

-0.05
-2.5
0.8
-1.8

-0.6
-4
-0.3
-4.4

0.5
-1
1.9
0.8

0.8
<0.01
0.15
0.18

0.08

0.56

-0.2

1.3

0.12

8.5
1.5

0.23
0.1

1.5
0.7

0.4
0.05

2.5
1.3

<0.01
0.04

-30
-10
-88

-4
3
-7

0.01
0.3
<0.01

1.3
0.6
4.6

0.5
0.2
1.8

2.1
1.0
7.4

<0.01
<0.01
<0.01

-159

114

0.74

6.4

-1.8

14.6

0.12
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Table 5.6a: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection
rates, by hospital
Prince of Wales Hospital

Variable
Total costs ($AU)
Total costs per OBD
($AU)
Antifungalb costs
($AU)
HCA CDI per
10000 OBDs (n)

Initial
level
174984a

LCI
135818

Pre-intervention
UCI
LCI
Initial
trend
214149
-4201
-2006

UCI
188

p
value
0.07

Change
in level
-7440

LCI
-37329

Post-intervention
UCI
p
Change
value in trend
22449
0.62
2853

297

5410

p
value
0.03

14

-0.15

-0.3

-0.003

0.045

-1.5

-3.5

0.5

0.15

0.55

0.35

0.75

<0.01

56110a

-705

2803

87

-1218

1391

0.9

-13288

-34951

8375

0.22

1049

2803

0.23

5.5

3.6

7.5

0.08

-0.05

0.2

0.2

0.4

-3.2

4.0

0.8

-0.24

705
-0.5

-0.01

0.04

adjusted for first order autocorrelation; bhigh cost antifungals, liposomal amphotericin, caspofungin, voriconazole, posaconazole, anidulafungin.
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UCI

10

12

Abbreviations: OBD, occupied bed day; $AU, Australian dollars; HCA CDI, healthcare associated Clostridium difficile infection.
a

LCI

Table 5.6b: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection
rates, by hospital
Shellharbour Hospital

Variable
Total costs ($AU)
Total costs per OBD
($AU)
Antifungalb costs
($AU)
HCA CDI per
10000 OBDs (n)

LCI

Pre-intervention
UCI
Initial
trend
14196
-37

LCI

UCI

-196

-0.02

31
3.4

Initial
level
12274

10351

4.3a

3.5

5.0

-88

-129

1.1

-1.2

Post-intervention
UCI
p value
Change
in trend
657
0.11
36

LCI

UCI

-175

247

p
value
0.73

-2

0.3

0.15

0.05

-0.02

0.11

0.16

-1177

-2893

540

0.17

-49

129

31

0.22

-2.5

-5.6

0.5

0.1

-0.1

-0.3

0.1

0.4

123

p
value
0.65

Change
in level
-2708

LCI
-6074

-0.08

0.05

0.6

-0.85

51

-29

130

0.2

0.1

-0.02

0.25

0.09

159

Table 5.6c: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection
rates, by hospital
Shoalhaven Hospital

Variable
Total costs ($AU)
Total costs per OBD
($AU)
Antifungalb costs
($AU)
HCA CDI per
10000 OBDs (n)

160

LCI

Pre-intervention
UCI
Initial
trend
36238
-624

LCI

UCI

-1037

-0.2

386
3.7

Initial
level
28629

21020

8.5

6.2

109

4409a

23

1.7

-0.3

LCI

Post-intervention change
UCI
p
Change
value in trend
4299
0.97
639

-210

p
value
<0.01

Change
in level
89

LCI

UCI

201

1077

p
value
<0.01

-4122

-0.3

-0.1

<0.01

0.14

-1.1

1.4

0.83

0.24

0.1

0.4

<0.01

-213

-368

-58

<0.01

2225

404

4046

0.02

204

22.5

386

0.03

0.1

-0.04

0.3

0.14

-0.1

-3.6

3.4

0.95

-0.2

-0.4

0.1

0.17

Table 5.6d: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection
rates, by hospital
St George Hospital

Variable
Total costs ($AU)
Total costs per OBD
($AU)
Antifungalb costs
($AU)
HCA CDI per
10000 OBDs (n)

LCI

Pre-intervention
UCI
Initial
trend
124662
1688

LCI

UCI

206

0.19

28689
6.3

Initial
level
104693a

84724

7.1a

5.95

8.33

11112

-6465

4.1

1.9

LCI

Post-intervention change
UCI
p
Change
value in trend
-37694
<0.01
828

3170

p
value
0.03

Change
in level
-61611

LCI

UCI

-873

2529

p
value
0.33

-85528

0.02

0.22

0.02

-4.7

-6.5

-2.9

<0.01

0.1

-0.01

0.23

0.06

1998

390

3606

0.02

-46943

-74954

-18932

<0.01

-300

-2011

1411

0.73

0.2

0.07

0.36

<0.01

-1.9

-4.5

0.7

0.15

-0.4

-0.6

-0.2

<0.01
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Table 5.6e: Impact of a CDSS-supported multisite ASP on monthly antimicrobial costs and healthcare-associated Clostridium difficile infection
rates, by hospital
Wollongong Hospital

Variable
Total costs ($AU)
Total costs per OBD
($AU)
Antifungalb costs
($AU)
HCA CDI per
10000 OBDs (n)

162

LCI

Pre-intervention
UCI
LCI
Initial
trend
162803
-3396
-2218

-1040

Change
in level
7120

-19333

-0.3

-0.1

<0.01

0.5

-1.6

2.6

0.6

98

-713

908

0.8

8912

-6418

24242

0.15

0.06

0.24

<0.01

-1.9

-4.1

0.33

122788

12.3

10.6

14.1

-0.2

21032

-1051

1476

1.6

0.5

2.6

UCI

LCI

Post-intervention change
UCI
p
Change
value in trend
33573
0.6
2917

p
value
<0.01

Initial
level
142796

LCI

UCI

1138

4667

p
value
<0.01

0.27

0.12

0.41

<0.01

0.25

212

-1051

1476

0.74

0.09

-0.08

-0.21

0.06

0.25
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6.1 Summary statement

This chapter investigates a novel e-learning approach for education on antimicrobial use.
The theme builds on the use of technology to enable multisite education as discussed in
Chapter 5. The potential benefits of the e-learning approach include: applicability to rural
and regional settings, availability on mobile devices, and targeting of multiple health
professional groups. Qualitative feedback is also employed, a theme that was additionally
reported in Chapters 3 and 4. Further comparative investigation into the impact of the elearning tool is described in Chapter 7.

6.2 Abstract

6.2.1 Background

Traditional approaches to health professional education are being challenged by increased
clinical demands and decreased available time. Web-based e-learning tools offer a
convenient and effective method of delivering education, particularly across multiple
health care facilities. However, the effectiveness of this model for health professional
education needs to be explored in context.

6.2.2 Objectives

The aims of this study were to (1) determine health professionals’ experience and
knowledge of clinical use of vancomycin, an antibiotic used for treatment of serious
infections caused by MRSA and (2) describe the design and implementation of a webbased e-learning tool created to improve knowledge in this area.

6.2.3 Methods

We conducted a study on the design and implementation of a video-enhanced, web-based
e-learning tool between April 2014 and January 2016. A web-based survey was
developed to determine prior experience and knowledge of clinical vancomycin use
among nurses, doctors, and pharmacists. The Vancomycin Interactive (VI) involved a
series of short video clips interspersed with interactive question and answer scenarios,
where only the correct response allowed for progression to the next section. Dramatic
tension and humor were used as tools to engage users. Health professionals’ knowledge
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of clinical vancomycin use was obtained from website data; qualitative participant
feedback was also collected.

6.2.4 Results

From the 577 knowledge survey responses, pharmacists (N=70) answered the greatest
number of questions correctly (median score 4/5), followed by doctors (N=271; 3/5) and
nurses (n=236; 2/5; p<0.001). Survey questions on target trough concentration range
(75%; 433/577) and rate of administration (65%; 375/577) were answered most correctly,
followed by timing of first level (49%; 283/577), maintenance dose (42%; 242/577), and
loading dose (38%; 219/577). Self-reported “very” and “reasonably” experienced health
professionals were also more likely to achieve correct responses.
The VI was completed by 163 participants during the study period. The rate of correctly
answered VI questions on first attempt was 65% for nurses (N=63), 68% for doctors
(N=86), and 82% for pharmacists (N=14; p<0.001), reflecting a similar pattern to that of
the knowledge survey. Knowledge gaps were identified for loading dose (39% correct on
first attempt; 64/163), timing of first trough level (50%; 82/163), and subsequent trough
levels (48%; 78/163). Of the 163 participants, we received qualitative user feedback from
51 participants following completion of the VI. Feedback was predominantly positive
with themes of “entertaining,” “engaging,” and “fun” identified; however, there were
some technical issues identified relating to accessibility from different operating systems
and browsers.
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6.2.5 Conclusions

A novel web-based e-learning tool with interactive video content was successfully
developed combining game design principles and humor to improve user engagement.
Knowledge gaps were identified for different health professionals that allowed for
targeting of future education strategies. The VI provides an innovative model for
delivering web-based education to busy health professionals in different locations.

6.2.6 Keywords

Nursing education; pharmacy education; medical education; continuing education;
vancomycin; survey methods; anti-bacterial agents.
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6.3 Introduction

6.3.1 Internet-based learning

The development of IBL for healthcare professionals has increased in recent years (Liu et
al., 2016). One reason for advancement of IBL is the existence of barriers associated with
implementation of face-to-face health professional education, including increased clinical
demands and decreased available time (Cook et al., 2010). These barriers become more
evident where education is required across multiple facilities that are separated by long
distances. Consequently, there is a requirement for more effective and accessible ways of
improving knowledge and competence in health professionals (Liu et al., 2016). To date,
IBL approaches have shown positive effects on health education outcomes through
overcoming the above barriers (Cook et al., 2008).

Serious games have been defined as “interactive computer applications, with or without
significant hardware components” that are designed to entertain while achieving changes
in knowledge or skills. Methods to improve their entertainment value include dramatic
tension, humour and challenge (Thompson, 2012). User engagement can also be
improved through the inclusion of a narrative (Lu et al., 2016). Humour as an aid to
nursing and medical education has been described in the literature (Baid and Lambert,
2010; Ziegler, 1999), while the use of games as a medium for humour may increase
learners’ interest and motivation to learn (Baid and Lambert, 2010). As distinct from elearning with limited user interaction (Graafland et al., 2014a), serious games can provide
greater engagement with the educational content.
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Use of serious game methodologies to deliver health professional education has been
reported in previous studies (Graafland et al., 2014b; Wang et al., 2016; Castro-Sanchez
et al., 2014). Educational and design frameworks are recommended for the development
of games for health professional education (Akl et al., 2013; Graafland et al., 2014a).
Strategies include application of knowledge in a safe environment that resembles real life
(Akl et al., 2013), a degree of interactivity (Cain and Piascik, 2015), and entertainment
(Thompson, 2012). These topics were considered in development and assessment of the
e-learning tool in this study.

Most e-learning tools in health care have targeted specific groups, such as medical or
nursing students, physicians or nurses (Boeker et al., 2013; Johnsen et al., 2016;
Williams, 2014; Youngblood et al., 2008). We developed the VI to target nurses, doctors
and pharmacists, the three main groups involved in use of medicines in hospitals. The
specific educational content of the VI was clinical use of the glycopeptide antibiotic,
vancomycin, given intravenously in hospitals for treatment of infections caused by
MRSA. MRSA infections have high mortality and are resistant to conventional treatment
with safer antibiotics such as penicillins, which usually do not require such specific
administration and monitoring. Vancomycin is a commonly used antibiotic for treatment
of MRSA infections (Rybak et al., 2009), but there are problems associated with its use.
Those include the requirement for a loading dose (initial higher single dose) in serious
infections, side effects when administered too rapidly, and the need to monitor
vancomycin plasma levels (Antibiotic Expert Groups, 2014). As part of our ASP (Duguid
and Cruickshank, 2010), local quality improvement activities identified gaps in
competence around clinical use of vancomycin. Three main topics were identified from
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those local activities and from previous studies: (1) dosing, including loading and
maintenance (Swartling et al., 2012; Lomaestro, 2011; Phillips et al., 2016); (2)
administration, such as compatible fluids and rate of infusion (Crowley et al., 2007;
Phillips et al., 2016); and (3) TDM, including appropriate timing of blood sampling,
target trough levels and required actions based on reported levels (Coleman and Wilson,
2015; Phillips et al., 2016; Cardile et al., 2015).

6.3.2 Aims of this study

The aims of this study were: (1) to report the design and implementation of a web-based,
interactive e-learning tool providing education on the dosing, administration and TDM of
vancomycin, (2) to assess health professionals’ pre-intervention knowledge of
vancomycin use in order to inform development of the e-learning tool, and (3) to assess
health professionals’ initial acceptance of the VI.

6.4 Methods

6.4.1 Setting

This prospective design and implementation study of a video-enhanced, web-based elearning tool took place in ISLHD and South Eastern Sydney Local Health District
(SESLHD), located in NSW, Australia. These health districts cover a geographic area of
6,331 square kilometres and have an estimated population of 1.17 million, reaching from
central Sydney to three hours’ drive south (New South Wales Health, 2010). The
districts’ 14 hospitals contain a total of 2500 beds and range from small rural facilities to
169

large tertiary metropolitan hospitals. A timeline of design, implementation and evaluation
is shown in Figure 6.1.

Figure 6.1: Timeline of VI design, implementation and evaluation

6.4.2 Web-based vancomycin knowledge survey

An anonymous open web-based survey was created using Survey Monkey® (Palo Alto,
California, USA) to determine confidence, experience and knowledge of vancomycin,
prior to the VI. The survey was developed locally by the AMS and educator pharmacists
as part of routine activities, with input from the ID team. Clinical content was based on
170

the Australian Therapeutic Guidelines: Antibiotic, Version 15, 2014 (Antibiotic Expert
Groups, 2014) and the Australian Injectable Drugs Handbook, Version 6, 2015 (Society
of Hospital Pharmacists of Australia Publications Reference Group, 2015). Use of these
references was required as part of the Australian hospital accreditation standards
(Australian Commission on Safety and Quality in Health Care, 2011). Survey participants
were nurses, doctors and pharmacists from the two health districts. A four-point Likert
scale was used to determine levels of experience, confidence and knowledge on dosing,
administration and TDM of vancomycin (Table 6.1). The survey was advertised using
email and the districts’ fortnightly newsletters. The survey link was open from 1 February
2015 to 30 June 2015 and participation was voluntary. Only one attempt was allowed on
each question and users were directed to further reading material at completion of the
survey. Nurses were expected to correctly answer questions on fluid compatibility and
administration rate, since they were mainly responsible for administration of medicines in
hospitals. Doctors were anticipated to correctly answer questions relating to dosing and
TDM, arising from their role as prescribers. Pharmacists were expected to have a working
knowledge of all aspects of clinical vancomycin use. The response rate to the survey was
calculated from the number of respondents and the number of recipients on staff email
groups.
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Table 6.1: Vancomycin knowledge survey questions
1.

What is your profession?

2.

How much experience do you have with calculating doses of vancomycin?

3.

What do you think is the correct loading dose for vancomycin?

4.

What is an appropriate maintenance dose for vancomycin for a patient with a

creatinine clearance of greater than 90mL/min?
5.

How confident are you to determine the administration rate for vancomycin?

6.

At what rate should vancomycin be administered to avoid red man syndrome?

7.

How confident are you to provide advice on vancomycin monitoring?

8.

When should the first level be taken for a dose of 1g 12hrly?

9.

What is the usual target range for vancomycin plasma trough levels?

10.

Did you refer to any resources to answer these questions?

6.4.3 Design and implementation of the VI

Similar to the survey, clinical content of the VI was developed locally, based on the
Therapeutic Guidelines: Antibiotic (Antibiotic Expert Groups, 2014) and the Australian
Injectable Drugs Handbook (Society of Hospital Pharmacists of Australia Publications
Reference Group, 2015). The vancomycin knowledge survey informed in part the VI’s
educational content in the post-production phase, allowing finalisation of the multiple
choice questions. An entertaining web-based educational tool was selected in the early
development stage (mid-2013; Figure 6.1) for two reasons. The first was that there was
already a health district requirement for staff to complete between 10 and 20 hours’
mandatory training per year on other topics, and study investigators did not wish to
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contribute to the burden of further web-based mandatory training. Rather, a brief,
targeted, and light-hearted educational tool was thought to be more acceptable and
beneficial for staff. Secondly, large distances between hospital sites meant that face-toface education of health professionals was very resource intensive. The learning
objectives of the VI for target users (nurses, doctors and pharmacists) were to improve
knowledge of vancomycin dosing, administration and TDM. The VI did not address
clinical indications for vancomycin, dosing in specialist areas such as intensive care and
renal dialysis, use of continuous infusions or surgical prophylaxis.

A single interactive video was produced due to financial constraints; there was the
expectation that all professional groups should have rudimentary knowledge of clinical
vancomycin use. The VI (Copyright ISLHD) was hosted on the open website
www.vancomycin.com.au (Bond and Crowther, 2015). Using the serious game design
concepts of interactivity and entertainment, we presented a case study resembling real life
interaction between a patient and a health professional. Dramatic tension between the two
characters created the basis for the plot, along with the unprofessional behaviour of the
modelled health professional. The interaction was also designed to be humorous,
particularly through the special effect of “shrinking” the health professional, and
references to William Shakespeare’s plays (Figure 6.2 and Figure 6.3). The concept was
intended to appeal to health professionals who may feel they are at the mercy of their
patients, a theme that emerged during the script-writing process.
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Figure 6.2: Filming of the VI

The user interface consisted of video clips interspersed with interactive question and
answer scenarios placed at the specific points, so that technical content felt organic to the
narrative (Figure 6.4; Table 6.2). A correct answer allowed progression to the next
section, whereas an incorrect answer resulted in a shaking screen and a sound effect. Data
captured from answers to the interactive questions allowed for subsequent analysis. Only
data from the targeted health professionals were included in the analysis; students and
other participants were excluded. Additional questions in the VI, as distinct from the
survey, related to compatibility of vancomycin with various fluids and clinical actions in
response to different trough levels. Completion of the VI took approximately 10 minutes
based on user testing.
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Table 6.2: Vancomycin Interactive questions
1. What is an appropriate loading dose for Mrs Jones?
2. What is an appropriate regular dose for Mrs Jones?
3. What fluids should vancomycin be administered in? (more than one correct
answer)
4. At what rate do you need to administer the vancomycin?
5. When should the first vancomycin level be taken for a patient receiving 1g
12hrly?
6. What is the target trough level?
7. If the level comes back as 35mg/L what may this mean? More than one answer
may apply.
8. The first level comes back as 20mg/L. What should the next dose for this
patient be and what is the dose interval?
9. If the level comes back as 26mg/L, what should the next dose and dose interval
be for this patient?
10. The course length is likely to be 7 days based on the clinical response of the
patient. When should the next level be taken? More than one answer may apply.
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Figure 6.3: Dramatic tension created the basis for the VI’s plot

Figure 6.4: Example of user interface for an interactive question from the VI

Quotes for production were obtained from three developers in accordance with NSW
Health policy, with financial support provided internally by the Clinical Governance Unit
of the health district. Content development began in April 2014, and the video was filmed
using professional actors in November 2014. Post-production modifications were made to
the video up until release in July 2015. In early 2015 the website was established to
promote improved access to the VI, and to include additional clinical content not
contained in the VI. Testing of content and usability was performed by pharmacists and
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ID doctors (n=8) at the study site, with feedback provided by email to the study
investigators. Feedback from testers predominantly related to accuracy of the clinical
content in the context of the narrative, and informed the final iteration of the VI. The first
phase of dissemination and advertisement (email, newsletters, link on intranet homepage)
to ISLHD staff occurred on 27 July 2015 (Figure 6.1) with the initial target audience
estimated from organisational records to be 1000 staff. General release of the VI outside
of ISLHD occurred on 17 November 2015. The final production cost was AUD$15,000;
time devoted to content development, testing, advertising, implementation, and evaluation
was not included in those costs as it fell within usual activities for the pharmacy and
infectious diseases department staff members involved in development of the VI.

6.4.4 User acceptance evaluation

Following release of the VI, qualitative survey responses were assessed to inform the
investigators about user acceptability and suggestions for improvement. The qualitative
survey was open between 1 December 2015 and 31 January 2016, in order to conclude
prior to the annual intake of new junior doctors in February 2016 (Figure 6.1).

6.4.5 Outcome measures

The primary outcome measure was comparative vancomycin knowledge between health
professions and self-reported levels of confidence and experience. Vancomycin
knowledge responses from website data (not linked at a participant level) were also
assessed and compared with the knowledge survey. In addition, qualitative feedback on
the VI was evaluated using a five-point Likert scale and free text responses that were
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grouped into key themes. Assessments were derived from survey responses and VI
website data. Technical issues around compatibility with desktop and mobile operating
systems and web browsers were also assessed. Reporting of outcomes on quantitative
post-intervention survey data, clinical measures of quality vancomycin use such as
therapeutic vancomycin plasma levels, and clinical outcomes related to vancomycin
treatment was beyond the scope of this study.

6.4.6 Statistical analyses

Chi-square and Fisher’s exact tests were used for proportions. Chi-square for trend was
used to determine trend between professions for knowledge questions. Kruskal-Wallis
and Mann-Whitney U-tests were used to examine total survey scores. For continuous
data, normality was assessed using the Shapiro Wilk Statistic. A skewed distribution was
denoted by p<0.05. Kruskal Wallis and follow up Wilcoxon rank-sum tests were used to
investigate between subjects effects with non-normal distributions. A multivariate
analysis was performed to examine influential factors on correct survey responses. For
each item a logistic regression was conducted followed by a multiple regression on the
total score. For profession, nurses were allocated to the reference group, and self-reported
“no experience/confidence” was used at the reference for the experience analysis.
Statistical significance was accepted as p<0.05. Additionally, a mediation analysis
(Preacher and Hayes, 2008) was carried out to explore the mediating effects of
vancomycin experience on the association between profession and knowledge (reflected
by the total number of correct responses). For the mediation analysis, significance was
determined by the 95% confidence of the regression coefficient, b. If the 95% CI did not
contain 0 it was considered significant. The extent of mediation was reported as a
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percentage, where a higher percentage reflects greater mediation. Statistical analyses were
performed using Stata statistical software: Release 14 (Statacorp LP, College Station, TX,
USA).

6.4.7 Ethics

Ethics approval was granted by the Joint UOW ISLHD Health and Medical Human
Research Ethics Committee (EC00150; approval number HE15/005; Appendix F). The
VI website contained a disclaimer that anonymous data collected from the video could be
used for research purposes.

6.5 Results

6.5.1 Vancomycin knowledge survey prior to release of the VI

The response rate to the survey was 27% (577 responses from 2,147 email recipients).
The response rates by profession were 24% (236/967) for nurses, 25% (271/1,070) for
doctors and 64% (70/110) for pharmacists (p<0.001).

As shown in Table 6.3, the median knowledge survey score for nurses was 2 (IQR 1-3),
compared with 3 (IQR 3-4) for doctors and 4 (IQR 3-4) for pharmacists (p<0.001).
Pharmacists had greater total scores than both doctors (p<0.001) and nurses (p<0.001),
while doctors had greater total scores than nurses (p<0.001). For nurses, the most
correctly answered questions were on administration rate (64% correct) and target trough
range (58% correct), while only 19% of nurses answered the loading dose question
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correctly. The most correctly answered question by doctors was on target trough range
(86% correct). Pharmacists answered all responses correctly greater than 80% of the time.

Table 6.3: Number of correct responses to web-based vancomycin knowledge survey, n
(%)
Survey question

Nurse

Doctor

Pharmacist

n=236

n=271

n=70

Loading dose

46 (19)

112 (41)

59 (84)

<0.001

217 (38)

Maintenance dose

58 (25)

126 (46)

58 (83)

<0.001

242 (42)

Administration rate

152 (64)

160 (59)

62 (89)

<0.001

374 (65)

First level timing

70 (30)

155 (57)

59 (84)

<0.001

284 (49)

Target trough range

136 (58)

234 (86)

65 (93)

<0.001

435 (75)

2 (1-3)

3 (3-4)

4 (3-4)

<0.001

3 (2-4)

Median total score

p value

Total
n=577

(IQR)
Abbreviation: IQR, interquartile range

Multivariate analysis (Table 6.4) showed that for the loading dose question, pharmacists
and doctors were more likely to achieve a correct response than nurses. A smaller
variation between professions was seen for the administration rate question, with the
comparison between pharmacists and nurses reaching significance. In addition, selfreported “very” and “reasonably” experienced health professionals were more likely to
achieve a correct response. Similar associations between professions and experience
levels were seen for maintenance dose, first level timing and trough level range (Table
6.4). Pharmacists self-reported more experience and confidence than doctors or nurses,
which influenced the likelihood of a correct response.
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Table 6.4: Multivariate analysis of vancomycin knowledge survey responses (n=577)
Topic

Profession
Nurse

Doctor

Experience/confidence
Pharm

ref
Loading

OR

dose

(95% CI)

-

1

2

3

4

1.4

4.6

11.1

(0.8-2.7)

(2.4-8.6)

(3.3-36.9)

ref
2.6

16.8

(1.7-4.1)

(7.9-35.7)

-

p value

-

<0.001

<0.001

-

0.25

<0.001

<0.001

Maint

OR

-

2.5

12.1

-

1.0

2.2

3.3

dose

(95% CI)

(1.7-3.8)

(5.9-24.7)

(0.6-1.8)

(1.2-3.8)

(1.1-9.6)

p value

-

<0.001

<0.001

-

0.85

0.01

0.03

Admin

OR

-

1.0

2.9

-

2.1

4.7

5.7

rate

(95% CI)

(0.6-1.4)

(1.3-6.4)

(1.4-3.3)

(2.9-7.6)

(0.2-1.1)

p value

-

0.82

0.01

-

0.001

<0.001

<0.001

Level

OR

-

2.7

8.5

-

3.6

6.8

4.0

timing

(95% CI)

(1.9-4.1)

(4.0-17.7)

(2.1-5.9)

(4.0-11.6)

(1.4-10.9)

p value

-

<0.001

<0.001

-

<0.001

<0.001

0.01

Trough

OR

-

3.9

5.6

-

3.4

5.7

5.7

range

(95% CI)

(2.5-6.1)

(2.1-15.1)

(2.1-5.6)

(3.2-10.0)

(1.2-26.5)

<0.001

<0.001

0.03

p value

-

<0.001

0.001

-

Total

b

-

0.8

1.7

-

correct

(95% CI)

(0.6-1.1)

(1.4-2.1)

<0.001

<0.001

p value

-

0.9a
(1.4-2.1)

-

<0.001

Abbreviations: ref, reference group for multivariate analysis; maint dose, maintenance dose;
admin rate; administration rate; level timing, timing of first level; trough range, target range for
plasma trough level, total correct; Pharm, Pharmacist (all levels); OR, odds ratio; CI, confidence
interval; Experience/confidence: 1, none; 2, a little; 3, moderate; 4, very experienced/confident. b,
regression coefficient; aaverage of responses to three vancomycin experience/confidence
questions, therefore a multiple regression was performed for Total correct.
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Subsequent mediation analysis revealed that vancomycin experience significantly
mediated the effect of profession on total score (total indirect effect: b = 0.63, biascorrected 95% CI 0.44 – 0.85). Approximately 58% of the profession effect was mediated
by experience, where a higher percentage value indicates greater mediation.

6.5.2 Vancomycin Interactive

Responses to the VI were analysed using background website data received from 27 July
to 14 November 2015, with ISLHD as the target population group. The initial dropdown
question asking the user’s profession was answered by 389 participants; 163 health
professionals (42% of those answering the initial profession question) completed all ten
questions (Table 6.5). The rate of correctly answered questions on first attempt was 65%
for nurses, 68% for doctors and 82% for pharmacists, significantly higher in the
pharmacist group (p<0.001). Notably low numbers of correct responses were identified
for the following three questions, averaged over the three professional groups: loading
dose (39% correct), timing of first level (50%), and timing of subsequent levels (48%).
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Table 6.5: Number (%) of correct answers on first attempt by nurses, doctors and
pharmacists from VI data
Question

Nurse

Doctor

Pharmacist

p value

Total

n=63

n=86

n=14

1 – Loading dose

19 (30)

36 (42)

9 (64)

0.047

64 (39)

2 – Maintenance dose

50 (79)

59 (69)

11 (79)

0.32

120 (74)

3 – Compatible fluids

53 (84)

67 (78)

11 (79)

0.76

131 (80)

4 – Administration

56 (89)

55 (64)

14 (100)

<0.001

125 (77)

20 (32)

49 (57)

12 (86)

<0.001

81 (50)

6 – Target trough level

47 (75)

72 (84)

12 (86)

0.34

131 (80)

7 – Level of 35mg/L

43 (68)

68 (79)

14 (100)

0.02

125 (77)

8 – Level of 20mg/L

49 (78)

81 (94)

13 (93)

0.01

143 (88)

9 – Level of 26mg/L

46 (73)

55 (64)

12 (86)

0.20

113 (69)

10 – Subsequent levels

27 (43)

45 (52)

7 (50)

0.52

79 (48)

65%

68%

82%

<0.001

68%

n=163

rate
5 – Timing of first
level

Average score

p-values obtained using Chi-square for trend.

6.5.3 Comparison of responses between VI and web-based survey

The rates of correct response from the VI were significantly higher than the knowledge
survey for maintenance dose (74% VI vs. 42% survey; p<0.001) and administration rate
questions (77% VI vs. 65% survey; p=0.004). There was a slightly higher correct
response rate for the question on target trough level (80% VI vs. 75% survey; p=0.186).
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Uniformly low correct response rates were observed for the questions on loading dose
(39% for VI vs. 38% for survey; p=0.701) and the timing of first level (50% VI vs. 49%
survey; p=0.89). The question on timing of levels subsequent to the first level in the VI
was answered correctly in 48% of cases; there was no equivalent question in the survey.

6.5.4 User acceptance evaluation of the VI

Among the 163 VI participants, 51 (31%) responses were received. Responses were
predominantly positive, as shown in Table 6.6.

Table 6.6: Qualitative responses (%) following participation in the VI
Survey statement/question

Strongly

Agree

Neutral

Disagree

agree

Strongly
disagree

Using the VI has enhanced my knowledge (n=51)

11 (22)

29 (57)

8 (16)

3 (6)

0 (0)

Using the VI has improved my performance

8 (16)

28 (56)

12 (24)

2 (4)

0 (0)

(n=50)

When users were asked, “What’s good about the VI in comparison to other e-learning
modules?” 28 free text responses were received. Four responses (14%) related to not
being able to load the video. Key themes from the remaining 24 responses (86%) were
“entertaining”, “engaging”, “a lighter approach to learning”, “more real life”, and “held
attention”. To the question, “Does the training provided by the VI meet your needs? If
not, what can be improved?”, 23 free text responses were received. Sixteen respondents
(70%) reported, “yes it met needs”; two (10%) stated issues loading VI; three users (13%)
requested printable resources; one user was “not sure”; and one user requested more
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information to be available when answering questions. All qualitative survey responses
are provided in Table 6.7.

Table 6.7: Qualitative survey feedback on the Vancomycin Interactive
What was good about the Vancomycin Interactive in comparison to other elearning modules? (28 responses)
 could not view
 engaging
 entertaining
 Entertaining
 entertaining easy to understand
 fun and immediate answers available
 Funny, not too much information
 held attention. not just boring power point slides
 i learnt stuff
 Informative and entertaining
 Interesting and memorable (due to jokes and cased based learning)
 It concentrated on vancomycin
 It was an entertaining lesson
 it was engaging & entertaining :-)
 It was fun and had a lighter approach to learning which was very nice! It was
still very informative and educational, but the fun nature of Shirley made it
more enjoyable to complete.
 It was short and specific for vancomycin
 it was very knowledgable session. it improves my confidence. the main thing is
we are familiar with this medication and we quiet often uses at ward.
 It wouldnt work on my work computer
 more real life
 no idea it wouldn’t load
 Provides a real world context
 Step by step followed by questions
 Unable to do vancomycin interactive.
 Very entertaining
 Video
 Was interesting and interactive
 Was short and funny
 Was very interesting…..Fun way of learning with the jingle
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Table 6.7 (cont)
Did the training provided by the Vancomycin Interactive meet your needs? If not,
what can be improved? (23 responses)
 yes (n=16)
 a few case studies with some monitoring of levels would be useful
 could not view
 Good to be able to print a chart with formulas and normal levels
 I think so, not sure if available but would like a summary of key points that can
be printed out at end
 It would be better to have more information before questions e.g. for dosing etc.
Or at least have some explanation as to why the questions were wrong.
 no idea it wouldn't load
 not sure

6.6 Discussion

6.6.1 Principal findings

We have reported on the design, implementation and user evaluation of a novel webbased e-learning tool for education of health professionals on clinical use of the antibiotic
vancomycin. The VI was developed for non-commercial use and targeted three health
professional groups across multiple hospital sites. Responses from the survey that
preceded the VI demonstrated a global lack of knowledge on the safe and effective use of
vancomycin among nurses and doctors, justifying an IBL approach that was suitable for
disparate geographical locations. Pharmacists were shown to be more knowledgeable on
clinical vancomycin dosing, administration and TDM.

As expected, self-reported levels of confidence and experience were correlated with
increased likelihood of correct responses to the knowledge survey questions. Responses
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from the web-based knowledge survey and VI data were only similar for three of the five
common questions, loading dose, timing of first level and the target trough level (Table
6.1 and Table 6.2). This may suggest that respondents equally understood those three
questions in the VI and the knowledge survey. Responses to two questions, maintenance
dose and administration rate, were significantly better in the knowledge survey compared
with the VI. This could be caused by the respondents’ different understanding about the
survey questions presented in the two media or difference in knowledge level between the
participants in the two surveys. Following implementation, qualitative survey responses
demonstrated that the VI was well received by users, and was considered to be an
engaging and entertaining method of improving knowledge. A small number of responses
highlighted technical issues relating to not being able to load the video content, which
were generally resolved through software upgrades.

Numerous studies have reported the development and evaluation of serious games for
training health professionals, but few have targeted multiple professions (Wang et al.,
2016; Graafland et al., 2012; Bergeron, 2008; Taekman and Shelley, 2010). One study
reported development of a serious game on appropriate antibiotic use, but this was not
specific to any particular antibiotic (Castro-Sanchez et al., 2014). Vancomycin was
chosen as the topic for our web-based tool due to its frequency of use, and complexities
associated with treatment of serious MRSA infections, the requirement for loading doses,
TDM and subsequent dose adjustment. The VI in this study adopted some principles of
serious game design (Graafland et al., 2014a), including interactivity and entertainment,
and combined those with humour (Ziegler, 1999) to engage multi-professional users.
Knowledge responses from the VI are promising, and further research is needed to
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determine the reasons for difference in responses to questions between the classical
knowledge survey and knowledge responses from VI website data.

Feedback from the majority of the participants suggested that the VI enhanced their
vancomycin knowledge (79%) and improved their performance (72%). This supports the
VI as a resource to provide healthcare professionals with training on clinical use of
vancomycin. Qualitative responses were generally positive, further supporting the use of
the VI for health professional education. The main challenges for implementation of the
VI related to developing clinical content for the video that would remain applicable to all
three professional groups, without creating a tool that would take too long to complete.
Advertising the tool using different media was also challenging, as the tool was made
available across two health districts with multiple hospitals, and the target professional
groups may have preferred to receive alerts regarding content in different ways.

The creation of a brief, web-based, entertaining educational tool was the purpose of the
project, whereby no further mandatory training burden was placed on staff. As distinct
from existing local mandatory learning modules, the VI was intended for use among
clinical staff involved in vancomycin use. Employing serious game design concepts may
provide greater educational benefit than traditional computer-based learning methods
through the use of greater interactivity, entertainment and scoring; however, further
published comparisons are required (Wang et al., 2016). Our results suggest that
pharmacists have the greatest level of knowledge on clinical vancomycin use. Therefore,
in order to deliver the best learning outcomes for health professionals in this area, it is
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recommended to combine face-to-face teaching with VI learning, using pharmacists as
educators in the future.

6.6.2 Limitations of this study

We studied the logistics and design of an web-based e-learning tool incorporating
interactive video content for health professional education relating to clinical use of the
antibiotic vancomycin. Post-intervention knowledge and clinical outcomes were not
reported here; these form the basis of ongoing research that will be reported separately.
The use of an open website allowed for potential diffusion worldwide, since users outside
our organisations may have found the VI using an internet search engine. In August 2015
the website was also shared on a professional network with members outside the targeted
health district. As a result, there was some unintended use of the video prior to its general
release. However, the greatest number of web sessions was from ISLHD, and employees
of the target ISLHD hospitals may not have been physically located in the region while
completing the VI.

Question design within the VI was limited to multiple choice and multiple answer
questions. Further variation in question types such as open questions, as previously
reported (Johnsen et al., 2016), could be made in future versions to improve immersion
and interactivity. The inclusion of a formal testing process immediately before and after
the e-learning tool may also have added some informative value on its effect and could
inform future improvements. In addition, further scoring methodology, such as time
limitation, competition and increasing difficulty could improve the robustness of the
design (Wang et al., 2016). The Hawthorne effect may have introduced bias into the
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study, whereby participants’ behaviour may have been altered through their awareness of
being measured. This bias may have been limited by participation being anonymous, and
the primary intended aim for users being to further their vancomycin knowledge, rather
than participation in a research project. Detailed economic analysis of the study was
limited by the project forming part of usual educational activities for study investigators.
As such, the total project cost was likely greater than the reported production cost.

There was relatively low uptake of the VI among clinical staff during the study period
despite broad advertisement; this limited statistical power of the study and highlighted the
challenge of using a new e-learning tool for delivery of non-compulsory training material
to health professionals. Reasons for this probably related to the following: (1) the VI was
not mandatory learning, so health professionals who did not regularly use vancomycin
may not have been motivated to participate; (2) competing education priorities in those
health professionals not otherwise intrinsically motivated to participate; (3) lack of time
out from clinical responsibilities; (4) the likelihood that multiple staff completed the VI
together, meaning that the VI’s reach might have been greater than the results
demonstrated; (5) the tool was not targeted towards a specific profession; and (6) not
being able to access the VI using hospital computers, which may have hampered
widespread use by health professionals during office hours. However, there were only
four reports of the VI not loading from 51 survey responses, suggesting that the majority
of participants could access the VI. While the free access website allowed for
participation during working hours, there may have been less motivation to perform
work-related education in this setting. It was expected that the greatest amount of
participation would occur during working hours on hospital computers. Clinical
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indications for vancomycin were not addressed by the VI, as its primary purpose was to
improve knowledge once the decision to prescribe had been made.

Our study presented a model for adopting serious game concepts in combination with
humour to develop and conduct web-based health professional education in a lighthearted, interactive and entertaining way. This model may be useful in settings where use
of face-to-face education is limited by resources and geography. As the VI learning
material was made available around the world, it showcased another significant benefit of
open e-learning resources. Health professionals and health care organisations with the
same learning needs can reuse the material we have published rather than expending
resources to develop similar material.

6.6.3 Conclusions

We demonstrated a novel web-based e-learning tool that used humour and some game
design principles to deliver health professional education on the commonly used
antibiotic vancomycin. The VI was well accepted by users, and was thus useful for
delivering the intended health professional education. Future learning needs for different
professional groups were identified through both the web-based knowledge survey and VI
data. This will allow tailoring of face-to-face education programs, in addition to
subsequent versions of the VI that will embed robust gaming methodology. Further
research will be aimed at measuring the effect on knowledge of the VI compared with a
traditional email intervention, and examining the impact of the VI on clinical vancomycin
use.
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7.1 Summary statement

This chapter further investigates the use of technology for providing education to health
professionals in relation to antimicrobial use, a theme that builds on those described in
Chapters 5 and 6. The VI is compared with a standard educational email intervention in
terms of clinical vancomycin knowledge use. The outcome measure of vancomycin
plasma levels is also evaluated in relation to the VI. Clinical outcomes of antimicrobial
use as balancing measures have also been explored in Chapters 2, 3, 4, and 5.

7.2 Abstract

7.2.1 Background

IBL for health professional education is increasing. It offers advantages over traditional
learning approaches, as it enables learning to be completed at a time convenient to the
user and improves access where facilities are geographically disparate. We developed and
implemented the VI e-learning tool to improve knowledge on the clinical use of the
antibiotic vancomycin, which is commonly used for treatment of infections caused by
MRSA.

7.2.2 Objectives

The aims of this study were to evaluate the effect of the VI e-learning tool on: (1) survey
knowledge scores and (2) clinical use of vancomycin among health professionals.

7.2.3 Methods

We conducted a comparative pre-post intervention study across the 14 hospitals of two
health districts in New South Wales, Australia. A knowledge survey was completed by
nurses, doctors and pharmacists before and after release of a web-based e-learning tool.
Survey scores were compared with those obtained following a traditional educational
intervention in the form of an email update. Survey questions related to dosing,
administration and monitoring of vancomycin. Outcome measures were survey
knowledge scores among the three health professional groups, vancomycin plasma trough
levels and vancomycin approvals recorded on a CDSS.
198

7.2.4 Results

Survey response rates were 27% (577/2147) pre-intervention and 8% (177/2147) postintervention. The VI was associated with an increase in knowledge scores among nurses
(mean 1.67 out of 5 to 2.35/5; p<0.001) but not among other professional groups. The
comparator email update was associated with an increase in knowledge scores among the
overall respondent group (mean 2.85/5 to 3.3/5; p=0.02) and among doctors (mean 2.83/5
to 3.29/5; p=0.04). Participants who referred to web-based resources while completing
the e-learning tool achieved higher overall scores than those who did not (p<0.001). The
e-learning tool was not shown to be significantly more effective than the comparator
email in the clinical use of vancomycin, as measured by plasma levels within the
therapeutic range.

7.2.5 Conclusions

The e-learning tool was associated with improved knowledge scores among nurses,
whereas the comparator email was associated with improved scores among doctors. This
implies that different strategies may be required for optimising the effectiveness of
education among different health professional groups. Improvements to design and
evaluation methodology are proposed to increase the likelihood of a demonstrable effect
from e-learning tools in the future.

7.2.6 Keywords

Nursing education; pharmacy education; medical education; continuing education; survey
methods; anti-bacterial agents.
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7.3 Introduction

7.3.1 Internet-based learning

Traditional face to face approaches to health professional education are being challenged
by busy trainee schedules, involving increased clinical demands and decreased available
time (Cook et al., 2010; Wang et al., 2016). These barriers can be addressed through the
use of internet-based learning (IBL) approaches, which can be completed at a time
convenient to the user (Cook et al., 2008). IBL may also be useful where health
professional education is required across geographically disparate hospital locations.
Effective IBL tools should provide entertainment and supply the user with knowledge,
skills or attitudes useful in real life (Bergeron, 2006). Recently there has been
considerable development in novel IBL methodologies for health professional education
(such as serious games) with common topics relating to surgical skills training, critical
care and emergency triage (Graafland et al., 2012; Wang et al., 2016). Some studies
showed improvements in test scores (Wang et al., 2016); however, study design was
heterogeneous, and none focused on the antibiotic vancomycin as an educational target.

7.3.2 Vancomycin education

Vancomycin is the main antibiotic used for treatment of infections caused by MRSA
(Antibiotic Expert Groups, 2014). Problems associated with vancomycin use across
multiple professions include the requirement for a loading dose in serious infections, side
effects when administered too rapidly, and the need to monitor vancomycin plasma levels
(or concentrations) (Antibiotic Expert Groups, 2014). Therefore, several studies have
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described interventions to improve clinical use of vancomycin (Phillips et al., 2016;
Melanson et al., 2013; Swartling et al., 2012; Coleman and Wilson, 2015; Hamad et al.,
2015; Crowley et al., 2007; Dib et al., 2009; Li et al., 2012). Specific topics addressed in
those studies were dosing (Phillips et al., 2016; Swartling et al., 2012; Hamad et al., 2015;
Li et al., 2012), administration (Phillips et al., 2016) and therapeutic drug monitoring
(TDM) (Phillips et al., 2016; Melanson et al., 2013; Swartling et al., 2012; Coleman and
Wilson, 2015; Crowley et al., 2007; Dib et al., 2009). Educational targets were nurses,
doctors, or pharmacists, with one TDM study conducting multidisciplinary interventions
(Crowley et al., 2007). In a previous study we described the design and implementation
process of a web-based e-learning tool (Vancomycin Interactive; VI©) that employed
serious game design concepts including interactivity and entertainment to provide
education on vancomycin (Bond et al., 2017). To our knowledge, the current study is the
first to compare outcomes of a vancomycin e-learning tool with a standard didactic email
intervention.

7.3.3 Aims of this study

The aims of this study were to assess the VI e-learning tool versus standard email update
for: (1) effects on health professionals’ vancomycin knowledge; and (2) effects on quality
of vancomycin use measured by both vancomycin plasma trough levels and approvals for
use recorded on a computerised clinical decision support system (CDSS) (Guidance
Group, 2013).
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7.4 Methods

This comparative pre-post intervention study took place in ISLHD (intervention site;
1000 total beds; 700 acute beds) and SESLHD (comparator site; 1500 total beds; 1200
acute beds), located in New South Wales (NSW), Australia (Figure 7.1). These health
districts cover a geographic area of 6,331 km2 and have an estimated population of 1.17
million, reaching from central Sydney to 3 h drive south (New South Wales Health,
2010). The districts’ 14 hospitals range from small rural facilities to large tertiary
metropolitan hospitals. The comparator site was selected due the following: a shared
information technology platform with the intervention site; geographical proximity, and
existing clinical and professional networks.

Figure 7.1: Map of intervention and comparator sites
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7.4.1 Pre-and post-intervention vancomycin knowledge survey

An anonymous web-based survey was created using Survey Monkey® (SurveyMonkey
Inc, Palo Alto, CA) to determine pre-intervention experience/confidence and knowledge
of vancomycin use among nurses, doctors and pharmacists across two health districts
(Bond et al., 2017). A four-point Likert scale was used to determine levels of experience
and confidence relating to knowledge questions on dosing, administration and monitoring
of vancomycin (Table 6.1). Post-intervention, a second survey with the same questions
was sent to the intervention and comparator sites. User testing indicated that preintervention survey would take around two minutes to complete and the post-intervention
surveys would take three minutes, since additional user feedback was sought on the VI
and comparator email. Requests for survey participation are included as Figure 7.2 and
Figure 7.3. A survey question on resources used to answer the survey was also analysed.
“Dear health professional (nurse, doctor, pharmacist),
Please take two minutes to complete a brief knowledge survey on the dosing,
administration and monitoring of vancomycin.
This survey will help us to develop a vancomycin learning module targeted to your
needs at SESLHD and ISLHD Hospitals.
https://www.surveymonkey.com/s/vancomycin
We would be grateful for your time to answer 10 quick questions.
Thank you”
Figure 7.2: Pre-intervention survey request emailed to staff at intervention/ comparator
sites
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Dear colleague,
Please take 3 minutes to complete this second survey on the anti-MRSA antibiotic
vancomycin. We would love to know if the VI/vancomycin email update was useful,
and how we can improve antibiotic education in the future. Answers will remain
confidential.
To complete the survey please click: https://www.surveymonkey.com/r/vancomycin
Thanks!”
Figure 7.3: Post-intervention survey request emailed to staff at intervention/ comparator
sites

7.4.2 VI and clinical email update

Educational content was developed locally for the VI on dosing, administration and TDM
of vancomycin (Antibiotic Expert Groups, 2014; Society of Hospital Pharmacists of
Australia Publications Reference Group, 2015). The learning objectives of the VI for
target users (nurses, doctors and pharmacists) were to improve knowledge of vancomycin
dosing, administration and TDM. The VI (ISLHD) (Bond and Crowther, 2015) depicted a
case study involving interaction between a patient and a health professional, both played
by professional actors. The user interface consisted of video clips interspersed with
interactive question and answer scenarios (Table 6.2). User testing indicated that the VI
would take approximately 10 minutes to complete. An email (taking 2-3 minutes to read)
with the same clinical content and learning objectives was developed as a comparator
intervention (Figure 7.4). To allow for the differences in the two media, there were some
minor variations in clinical content between the VI and email that related to
administration of vancomycin.
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Release and advertisement of the VI (email, newsletters, link on intranet homepage) to
the intervention site occurred on 27 July 2015. The clinical email update was then sent to
nurses, doctors and pharmacists at the comparator site (Figure 7.4). Following completion
of the second survey, the VI website was also advertised to the comparator site.
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“Dear health professional (nurse, doctor, pharmacist),
There have been some important updates to the adult guidelines for dosing,
administration and monitoring of intravenous vancomycin, commonly used for the
treatment and prevention of infections caused by MRSA.
Please see below for the key points:

DOSING
A loading dose is recommended, particularly in patients with serious infections who
are critically ill. A dose of 25-30 mg/kg is appropriate in most situations.
For maintenance doses of vancomycin in an average weight patient (70kg):
Creatinine clearance

Starting maintenance

Timing of trough

(mL/min)

dosage

plasma level

more than 90

1.5 g 12-hourly

before the fourth dose

60 to 90

1 g 12-hourly

before the fourth dose

20 to less than 60

1 g 24-hourly

before the third dose

less than 20

1 g 48-hourly

48 hours after the first
dose

-

For intermittent dosing of vancomycin, an appropriate maintenance dose is 15-20

mg/kg (actual bodyweight). Use the Cockcroft-Gault formula or online calculator to
approximate creatinine clearance.

ADMINISTRATION
Vancomycin should be administered by slow infusion at a rate of 10 mg/min.

MONITORING
-

The recommended trough level for vancomycin is 15 to 20 mg/L for most

infections.
-

Before interpreting the result, check that the timing of the trough sample was

appropriate (i.e. before the last dose was given). In patients receiving vancomycin
12hrly, do not wait for the trough concentration result before giving the next scheduled
dose.
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Adjustment of vancomycin dosage in adults:

Trough

Dosage adjustment

plasma level
less than 10

Increase dosage by adjusting either the dose or the dose interval.

mg/L
10 to 14

For patients with uncomplicated infection who are clinically

mg/L

improving, maintain current dosage. For patients with complicated
infection, increase dosage by adjusting either the dose or the dose
interval to achieve a trough concentration of 15 to 20 mg/L.

15 to 20

Maintain current dosage.

mg/L
21 to 25

Maintain current dosage, or reduce dosage by adjusting either the

mg/L

dose or the dose interval, or withhold dose.

more than 25

Withhold dose until trough concentration is less than 20 mg/L and

mg/L

seek expert advice.

For any questions please contact …”
Clinical content based on Therapeutic Guidelines: Antibiotic, Version 15 (Antibiotic
Expert Groups, 2014).
Figure 7.4: Clinical email update sent to staff at the comparator sites

7.4.3 Vancomycin trough plasma levels and approvals on the CDSS

Vancomycin plasma levels from a four month period before and a two month period after
the VI and comparator email were analysed to determine changes in the proportion of
levels in the therapeutic range. The post-intervention period was limited to two months in
order to conclude prior to the annual intake of new junior doctors. Criteria for dose
adjustment were as follows: (1) 0-9 mg/L, increase dose; (2) 10-14 mg/L, maintain or
increase dose depending on severity of infection and clinical status; (3) Maintain current
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dose (4) 20-25 mg/L, maintain or reduce dose depending on severity of infection and
clinical status; (5) >25 mg/L, withhold dose until trough level less than 20 mg/L and seek
expert advice (Antibiotic Expert Groups, 2014). The number of vancomycin levels as a
proportion of the total number of vancomycin CDSS approvals was also analysed to
determine frequency of vancomycin use. Pharmacy dispensing software did not allow for
patient-level data on vancomycin dispensing to be analysed, as vancomycin was
distributed as ward stock in some hospitals. Hence, vancomycin CDSS approvals were
used as a surrogate indicator for total vancomycin use.

7.4.4 Outcome measures

We compared total vancomycin knowledge survey scores pre- and post-intervention,
within and between intervention and comparator sites. The number of vancomycin levels
in the therapeutic range, the median number of vancomycin levels and ratio of
vancomycin levels to CDSS vancomycin approvals between sites were also analysed.

7.4.5 Statistical analyses

Chi-square and Fisher’s exact tests were used for proportions. For continuous data,
normality was assessed using a Skewness/Kurtosis statistic (D'Agostino et al., 1990). A
skewed distribution was denoted by p<0.05. Kruskal-Wallis and follow up Wilcoxon
rank-sum tests were used to investigate between effects with non-normal distributions.
Multivariate analysis was performed to examine influential factors (profession, site, preor post-intervention) on correct survey responses. Statistical analyses were performed
using Stata statistical software: Release 14 (Statacorp LP, College Station, TX, USA).
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7.4.6 Ethics

Ethics approval was granted by the Joint UOW and ISLHD Health and Medical Human
Research Ethics Committee (EC00150), approval number HE15/005 (Appendix F). The
VI website contained a disclaimer that anonymous data collected from the video could be
used for research purposes.

7.5 Results

7.5.1 Vancomycin knowledge survey

The response rate to the pre-intervention survey was 27% (577 responses from 2147
email recipients). The response rates by profession were 24% (236/967) for nurses, 25%
(271/1070) for doctors and 64% (70/110) for pharmacists (p<0.001); previously reported
(Bond et al., 2017). Post-intervention, there were 177 survey responses (8% response
rate), comprising 88 nurses, 69 doctors and 20 pharmacists (p<0.001).

Univariate analysis demonstrated that pre-intervention, there was a higher median survey
score for the comparator site (median 3/5; IQR 2-4; mean 2.85) than for the intervention
site (2/5; IQR 1-3; mean 2.51; p=0.01). Post-intervention survey scores were also higher
for the comparator site (median 3/5; IQR 2-4; mean 3.3) than for the intervention site
(median 3/5; IQR 2-4; mean 2.71; p=0.06).
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The median knowledge survey score for nurses increased post-VI (p<0.001; Table 1). No
significant differences pre- and post-VI were observed for doctors, pharmacists or for
combined health professionals. At the comparator email site, the median knowledge
survey score increased post-intervention for combined health professionals (p=0.02) and
for doctors (p=0.04).

7.5.2 Resources used to answer survey questions

To the question, “Did you refer to any resources to answer these questions?,” 595/754
(79%) participants responded “no”. Out of those 595, 424 (71%) self-reported that they
guessed some or all of the answers, whereas 171 (29%) reported that they knew the
answers. The remaining 159/754 (21%) respondents self-reported that they referred to
resources for answering the questions. The resources quoted were local guidelines
(49/159 [31%]) and the Australian Medicines Handbook or Therapeutic Guidelines:
Antibiotic (110/159 [69%]).
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Table 7.1: Pre- and post-intervention median knowledge survey score, n (IQR)
Profession

VI intervention site
Pre; n=278

Post; n=107

Comparator email site
p

Pre; n=299

Post; n=70

value
2/5 (1-2)

2/5 (1-3)

Mean: 1.67

Mean: 2.35

3 (2-4)

4 (2-4)

Mean: 3

Mean: 3.29

5 (4-5)

4 (4-5)

Mean: 4.24

Mean: 3.89

Total

2/5 (1-4)

3/5 (2-4)

score

Mean: 2.51

Mean: 2.71

Nurse

Doctor

Pharmacist

<0.001

0.28

0.40

0.24

p
value

2 (1-3)

3 (2-4)

Mean: 2.30

Mean: 2.71

3 (2-4)

4 (2-4)

Mean: 2.83

Mean: 3.29

5 (4-5)

5 (4-5)

Mean: 4.39

Mean: 4.27

3 (2-4)

3 (2-4)

Mean: 2.85

Mean: 3.3

0.17

0.04

0.87

0.02

7.5.3 Multivariate analysis of knowledge survey scores

Several factors were associated with an increased knowledge survey score. Compared
with nurses, pharmacists (regression coefficient 1.93; 95% confidence interval 1.63-2.23;
p<0.001) and doctors (coeff 0.89; 95% CI 0.70-1.09; p<0.001) had increased likelihood
of a higher survey score. Post-intervention survey participation was also associated with a
higher score (coeff 0.41; 95% CI 0.20-0.62; p<0.001) than pre-intervention. Referring to
online resources was associated with a higher score compared with responses where
participants self-reported that they knew or guessed the answers (coeff 0.98; 95% CI
0.75-1.20; p<0.001). The comparator site was not significantly associated with increased
likelihood of higher survey scores (coeff 0.16; 95% CI -0.02-0.34; p=0.08).
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7.5.4

Vancomycin TDM

From 1 January to 30 April 2015 there were 429 vancomycin trough plasma levels taken
at the intervention site (ISLHD; 1000 beds) and 1571 levels for the comparator site
(SESLHD; 1700 beds). During the post-intervention period 1 December 2015 to 31
January 2016, there were 151 levels reported at the intervention site and 316 levels at the
comparator site. As shown in Table 7.2, there were no significant post-intervention
differences in the proportion of vancomycin levels in the sub-therapeutic (0-9mg/L),
therapeutic (10-14, 15-20, 21-25 mg/L) or supra-therapeutic (>25 mg/L) ranges. There
were increases in the number of levels in the high-therapeutic range (20-25 mg/L) at both
sites; however, those differences did not reach statistical significance. There were no
significant pre-post intervention differences in median vancomycin levels at the
intervention site or comparator site (Table 7.2).
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Table 7.2: Pre- (4 months) and post-intervention (2 months) vancomycin plasma trough
levels for intervention and comparator sites, n (%)
Trough level (mg/L)

VI intervention site

Comparator email site

Pre

Post

p

Pre

Post

p

n=429

n=151

value

n=1571

n=316

value

0-9 (sub-therapeutic)

48 (11)

17 (11)

0.98

259 (16)

50 (16)

0.77

10-14 (low therapeutic)

91 (21)

28 (19)

0.49

362 (23)

62 (20)

0.18

15-20 (therapeutic)

168 (39)

54 (35)

0.46

515 (33)

98 (31)

0.54

21-25 (high therapeutic)

72 (17)

36 (24)

0.06

260 (17)

66 (21)

0.06

>25 (supra-therapeutic)

50 (12)

16 (11)

0.73

175 (11)

40 (13)

0.44

18 (13-21)

17 (13-22)

0.62

16 (12-21)

Median trough level

17 (12-22) 0.14

(IQR)
VI, Vancomycin Interactive; IQR, interquartile range.

7.5.5 Vancomycin trough plasma levels compared with vancomycin CDSS
approvals

The proportion of vancomycin trough levels to vancomycin CDSS approvals at the
intervention site decreased from 429/399 pre-intervention (1.1 levels for every
vancomycin approval) to 151/196 post-intervention (0.8 levels/approval). At the
comparator site, the proportion of vancomycin levels to vancomycin CDSS approvals
decreased from 1571/399 pre-intervention (3.9 levels/approval) to 314/199 postintervention (1.6 levels/approval).
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7.6 Discussion

7.6.1 Principal findings

This study compared the educational effect of an interactive web-based e-learning tool
with a comparator email update. Altogether, the e-learning tool did not result in improved
knowledge survey scores or clinical vancomycin use when compared to the email.
However, the e-learning tool was associated with improved survey scores among nurses,
whereas the comparator email update was associated with improved scores among
doctors. Multivariate analysis showed that survey scores did not differ between the
intervention and comparator sites. Not unexpectedly, pharmacists and doctors had higher
overall knowledge scores than nurses due to the greater number of questions considered
relevant to those groups. Participants who referred to web-based resources while
completing the survey had higher survey scores than those who did not.
Concerningly, only about one third of pre- and post-intervention vancomycin levels taken
at both sites fell within the recommended therapeutic range of 15-20 mg/L. This figure
rose to 73% when the ranges 10-14 mg/L, 15-20mg/L and 21-25 mg/L were combined,
which includes all potential recommended therapeutic ranges (Antibiotic Expert Groups,
2014). The proportion of vancomycin levels to CDSS approvals decreased at both sites,
perhaps signifying a reduction in the ordering of unnecessary levels, or shorter
vancomycin courses requiring fewer levels. A greater proportion of levels/approvals was
observed at the comparator site in both pre- and post-intervention phases, which may
have resulted from differences in acuity between sites.
In previous studies, strategies for improving the clinical use of vancomycin have included
use of loading doses (Li et al., 2012), implementation of guidelines (Swartling et al.,
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2012), education (Phillips et al., 2016; Coleman and Wilson, 2015; Dib et al., 2009), and
clinical decision support systems (Hamad et al., 2015; Crowley et al., 2007; Melanson et
al., 2013). None of those educational interventions incorporated a web-based e-learning
tool, and the predominant methodology was uncontrolled pre-post intervention at single
hospital sites. One study has reported development of a serious game to improve general
antimicrobial prescribing but it did not focus on vancomycin (Castro-Sanchez et al.,
2014). A review of educational games for health professionals emphasised the need for
more research with improved study methodology (Akl et al., 2013). Our study differed in
its multisite approach, comparison of e-learning tool with a standard email intervention,
and targeting of multiple health professional groups.

7.6.2 Interpretation of results

The difference in efficacy between the VI (improved nurses’ scores) and the email
(improved doctors’ scores) may have arisen from nurses’ increased familiarity and
engagement with online learning modules, whereas for doctors a didactic learning style
may be more suitable. Additionally, the short time to read a clinical update email may
have been more convenient for doctors. Referring to resources was associated with
improved survey scores, which emphasises the importance of guideline access in the
clinical setting. Some aspects of our study design may be applicable to facilities where
there are geographic barriers to use of face-to-face education, such as rural and regional
hospitals. Some improvements to the structure of the VI through greater application of
serious game methodology are proposed (Table 7.3), including more interactivity, scoring
and competition (Graafland et al., 2014; Thompson, 2012). Those features could result in
a greater level of user acceptance and effectiveness.
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7.6.3 Study limitations

There were some underlying differences in baseline vancomycin knowledge between
intervention and comparator sites as detected in the univariate analysis; however, those
did not retain significance in the multivariate analysis. Also, the total number of
vancomycin levels at the comparator site was considerably higher, which may be due to
differences in case mix (number of acute beds), antimicrobial use and background
educational culture. However, the proportion of satisfactory levels (i.e. those in
therapeutic range) did not differ between the sites. Furthermore, similar sizeable
reductions in the number of vancomycin levels ordered were experienced at both sites.
Some of this reduction may have been associated with seasonal variation of vancomycin
use, although unlike other antibiotics, vancomycin is not typically associated with strong
seasonal variation (Australian Commission on Safety and Quality in Health Care, 2015).
The low response rate to the post-intervention survey limited the power of pre-post
intervention comparisons. Potential reasons for this reduction include the perception of
staff that the post-intervention survey request concerned the pre-intervention survey,
despite clarifications that were provided in the email title and text, and appropriate
advertisement in staff newsletters. We note that the proportions of different health
professionals were similar in the two time periods. In addition, the denominator included
all targeted health professionals including those not involved in the day-to-day clinical
use of vancomycin, which is likely to have reduced the response rate.
The higher scores from the post-intervention survey may have resulted from participant
bias; i.e. only more experienced and enthusiastic staff may have responded to the second
survey. Time-dependent bias may also have influenced some of the improvement in
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survey scores, whereby increased time in a clinical role may have resulted in greater
knowledge of vancomycin use over the study period. A crossover design might have
partially alleviated this factor, but was not possible in our case due to the rotation of
junior doctors between the two sites.
There were some minor variations in clinical content between the VI and email; however,
they related only to administration of vancomycin and references used for development of
content were the same for both interventions. Participants who referred to guidelines
while completing the survey attained higher scores than those who did not. Although this
was unavoidable in a pragmatic study, it was still a desirable outcome as those
participants were using recommended national or local guidelines. The time to complete
the e-learning tool (10 minutes) was longer than the email update (2-3 minutes); the
duration of the email may have been more appropriate in a busy clinical context. As
reported in our previous study (Bond et al., 2017), there was low uptake of the VI during
the study period, and we did not measure the number of comparator emails read by staff.
There may have been some word of mouth leakage of the VI to the comparator site;
however, study data collection was completed prior to the junior doctor rotation. Given
the use of paper medications charts, the number of CDSS approvals was used as a
surrogate for vancomycin prescribing. We did not examine quality measures of
vancomycin use such as time to first therapeutic level, levels obtained at steady-state, or
clinical outcomes associated with the intervention; further research aims to examine these
effects. Linkage of survey-participant responses was desirable but was not achievable
within the ethical requirement for an anonymous survey. Based on those limitations and
the mixed results of our study, we propose a checklist that, subject to validation, may
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improve the likelihood of demonstrating significant effects from an e-learning tool (Table
7.3).

Table 7.3: Proposed development and evaluation checklist for health professional elearning tools
Perform qualitative research prior to design to determine learning needs of the target
group
Target clinical content to a specific health professional group
Apply a theoretical educational framework to include serious game design elements
such as entertainment, interactivity, scoring, and competition
Use identifiable surveys where possible to allow individual linkage of pre- and postintervention survey results
Allow for sufficient time post-intervention to collect data on knowledge and user
acceptability
Limit time required to complete the application (<5 minutes) in the context of a busy
clinical environment and acknowledging competing education priorities
Improve access to the e-learning tool through open access websites, development of the
tool as an app and shortcuts through the local intranet
Record pre- and post-intervention data that can suggest both effectiveness and noneffectiveness, including quantitative clinical outcomes
Develop a comprehensive advertisement and dissemination plan, to include email,
social media, newsletters, hospital grand rounds, quick links on hospital computers
Optimise search engine capacity
Select appropriate site for comparison with the e-learning tool
Comprehensive beta-testing by target end users
Collect relevant from the e-learning tool’s data feed
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7.6.4 Conclusions

Different health professional groups can be educated by using different targeted learning
approaches. Significant challenges can be experienced during design and evaluation of
comparative e-learning research. Further studies should aim to improve structural
elements of e-learning tools and enhance evaluation through an approach governed by a
newly proposed checklist.
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8 General discussion
8.1 Preamble

The research in this thesis by journal article compilation has extended current knowledge
of antimicrobial stewardship. The three primary aims were achieved during the course of
this research project. Firstly, an educational approach to improving antimicrobial use was
developed and evaluated at the individual, department, hospital and health district level.
Prevention of infection, treatment of infection and a serious adverse effect of
antimicrobial use were presented to demonstrate the value of this approach. Secondly,
AMS education and evaluation strategies applicable to multisite and rural and regional
settings were developed. Clinically meaningful outcome measures were targeted, such as
duration of antimicrobial therapy, LOS and mortality. Thirdly, technology for improving
ASPs was developed, implemented and evaluated, including: a CDSS to enhance
education and reporting, use of email in research and development of a web-based elearning tool for education of health professionals. The results suggest that: common
educational methods can be used to improve hospital antimicrobial use across different
clinical settings and organisational levels; patient-related outcomes should be measured in
addition to processes when evaluating AMS interventions; and technological innovations
can enhance the effectiveness of ASPs.

This concluding chapter provides an overview of project findings, followed by an outline
of the implications, strengths and limitations of this work. Recommendations for future
research are presented, followed by the thesis conclusions.

8.2 Overview of findings

Improving antimicrobial use in humans forms an important part of the Australian national
strategy to address AMR (Australian Government, 2015). Hospital AMS initiatives
should be targeted towards high-use areas, such as surgical prophylaxis and treatment of
common infections such as CAP (Duguid and Cruickshank, 2010; Australian
Commission on Safety and Quality in Health Care, 2015). In Chapter 2, an educational
approach was employed to discontinue prophylactic gentamicin use for insertion and
removal of urinary catheters in orthopaedic surgery patients. Use of gentamicin in this
setting was considered inappropriate according to national guidelines (Antibiotic Expert
Group, 2010), but was an embedded practice at the time of intervention. The requirement
for peer education and review, and the potential for medico-legal considerations to
influence behaviour change among senior doctors were outlined in this chapter.

CAP remains a leading cause of hospitalisation and death worldwide (Postma et al.,
2015). Inappropriate use of antimicrobials for the treatment of CAP can result in
emergence of resistant pathogens such as MRSA (Paterson, 2004). Chapter 3 reported an
approach for improving antimicrobial treatment of CAP that included use of timely
measurement and feedback to individual clinicians via email, education at departmental
meetings, and auditing of compliance with guidelines. Based on those interventions, a
reduction in median duration of CAP therapy was demonstrated, driven by shorter
courses of oral antimicrobials. Excessive duration of therapy is one of the most common
reasons for inappropriate antimicrobial use in Australia (Australian Commission on
Safety and Quality in Health Care, 2015), so this was targeted in addition to initial choice
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of therapy. Furthermore, a significant reduction in the inappropriate use of the broad
spectrum antibiotic ceftriaxone was demonstrated.

As inappropriate use of antimicrobials for prevention and treatment of infections can
result in adverse effects such as HCA-CDI, a project examining the relationship between
AMS and CDI was conducted (Chapter 4). The purpose of this chapter was to determine
whether the combination of a health district-wide ASP and a targeted education and
feedback initiative would result in a reduction in HCA-CDI rates. In addition, the burden
of HCA-CDI in terms of LOS and hospital costs was investigated. Although a reduction
in monthly HCA-CDI rates was observed using ITS analysis, this did not reach statistical
significance. A case-control analysis showed that there was a significant burden on the
patient in terms of additional length of hospital stay related to HCA-CDI, and also a cost
burden for the health service. These findings reinforce the importance of developing
AMS strategies to reduce HCA-CDI, including a reduction in inappropriate antimicrobial
use (Leffler and Lamont, 2015).

As most of the available literature on AMS outcomes is derived from tertiary
metropolitan hospitals (Schuts et al., 2016), there is an evidence gap for programs that
can be applied to rural and regional facilities, and multiple hospitals. Chapter 5 reported
AMS outcomes from two neighbouring health districts with varying resource levels. A
shared strategy of antimicrobial education and restriction was facilitated by a centrally
deployed CDSS, demonstrating that technology can be used to support AMS in hospitals
with disparate size and locations (Baysari et al., 2016). Antimicrobial use, costs, HCACDI, infection-related LOS and mortality were selected as outcomes; those have been
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previously reported in the published literature (Baysari et al., 2016). Significant changes
to patterns of antimicrobial use were observed, along with reductions in antimicrobial
costs and HCA-CDI. Although LOS and mortality were not substantially reduced when
compared with background rates, these were included as important balancing measures
that may have been negatively impacted by changing patterns of antimicrobial use (Davey
et al., 2013; Davey et al., 2017). Some of the initial impact of the shared program
diminished over time, suggesting that ongoing novel approaches to AMS education may
be required. One such approach in the form of an e-learning tool was described in
Chapters 6 and 7.

The challenges of providing continuing health professional education, such as increased
clinical demands, resource limitations and competing mandatory online training modules,
are further exacerbated in health districts with multiple hospitals spread across a wide
geographic area. Use of newer technological approaches to education may provide a
solution. Chapter 6 described the design and implementation of a novel educational
approach for improving knowledge on use of the anti-MRSA antimicrobial vancomycin.
As an online e-learning tool, this approach was well received by users and offered an
alternative to resource-intensive face-to-face education. It became evident from survey
data that there were shortcomings in clinical vancomycin knowledge, particularly among
nurses and doctors. Those shortcomings have provided opportunities to further explore
vancomycin education strategies.

Chapter 7 examined the e-learning approach to education, through comparison with an
email update to clinicians. Post-intervention knowledge survey scores increased for
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nurses following the e-learning tool, but were not significantly different for doctors or
pharmacists. This suggests that nurses may be better suited to receiving antimicrobial
education in this format. The comparator email was associated with an increase in
knowledge survey scores among the total participant group and among doctors. This
probably arose from both the shorter time requirement and the didactic nature of the
educational e-mail. Those survey participants who used educational resources to answer
questions achieved higher scores than those who did not refer to resources. Pharmacists
were more likely to achieve higher survey scores than doctors and nurses, thus they are
well placed to facilitate additional targeted education to those professional groups. No
significant differences were observed at the intervention and comparator sites pre- and
post-intervention of therapeutic vancomycin plasma levels.

8.3 Implications

The research described in this thesis has a number of implications. It provides a model for
evaluation of an ASP across a rural and regional health district comprising multiple
hospitals. Where there are existing political or professional links between hospital sites,
the reported quality improvement methodology is pragmatic and transferable to different
clinical settings. For example, the research methodology described in Chapter 2 relates to
orthopaedic surgery, but could just as easily be applied to other specialties where there is
inappropriate antimicrobial prophylaxis. Equally, Chapter 3 relates to CAP, but could be
applied to other common treatment indications with clear guidelines and evidence for
appropriate antimicrobial use, such as cellulitis or UTIs.
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AMR is a real and present global threat to human health (World Health Organisation,
2011). Thus, there is a requirement for culture change in organisations, with the ultimate
aim of improving patient outcomes through better antimicrobial use. The work contained
in this thesis provides realistic methods for achieving change in culture. Furthermore,,
sharing of AMS expertise across hospitals and health districts resulted in improved equity
of program resources, such as those projects reported in Chapters 4, 5 and 6.

A current educational strategy for improving clinical knowledge relating to vancomycin
has been provided on an open and free website for any person or organisation around the
world who wants to use it (Chapters 6 and 7). The sharing of research methods, data and
expertise forms part of the culture within Australian AMS networks.

8.4 Strengths

The research described in this thesis has addressed a knowledge gap in antimicrobial
stewardship, namely how to successfully implement a strategy for education and
evaluation across multiple hospitals sites, incorporating smaller rural and regional
hospitals. Different clinical aspects, with a strong grounding in the literature, were
addressed in the chapters, and the use of technology was investigated as a means of
overcoming barriers to antimicrobial education. In addition, educational approaches were
targeted at different organisational levels, including individual, departmental, hospital,
health district, and multiple health districts.

Constructed as a thesis by journal compilation, common themes were present through the
chapters, and current standards for evaluation methodology were used where appropriate.
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An example is ITS analysis, the quasi-experimental evaluation technique described in
Chapters 4 and 5.

The reporting of meaningful outcomes is an aspect of current AMS research that requires
improvement (Schuts et al., 2016; Davey et al., 2017). Additionally, there is a shortage of
standard definitions for outcome measures (Moehring et al., 2017), which creates a
barrier to pragmatic AMS research. Although process measures such as antimicrobial use
patterns and costs are useful in describing the effectiveness of interventions, the focus
should primarily be on patient safety. In this way, AMS becomes firmly embedded within
the framework of clinical governance. Outcome measures selected for inclusion in this
research project broadly align with a recent expert consensus, based on: association with
improved antimicrobial prescribing, improved patient care, utility in targeting AMS
efforts, and feasibility for monitoring within an eMR (Moehring et al., 2017). Markers of
patient safety were reported in all of the individual research projects: renal function and
SSI rates in Chapter 2; 30 day readmission rate and mortality in Chapter 3; CDI and LOS
in Chapter 4; CDI, infection related LOS and mortality in Chapter 5; and vancomycin
therapeutic levels, as a measure of both treatment effectiveness and drug toxicity in
Chapter 7. Chapter 6 reported design and implementation of an e-learning tool, and
therefore did not address patient-related outcome measures.

Meaningful statistical significance was achieved in some components of all of the studies.
Where possible, qualitative measures were also described (Chapters 3, 4 and 6).
Examples included email feedback and qualitative survey responses. This allowed for a
more comprehensive understanding of the cultural drivers of hospital antimicrobial use.
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8.5 Limitations

Detailed descriptions of limitations relating to the individual research projects were
provided in Chapters 2, 3, 4, 5, 6 and 7. There were some overarching limitations, often
inherent to pragmatic clinical research projects.

Small sample sizes potentially compromised statistical significance and may have
hampered applicability of results to similar populations. The uncontrolled before-andafter intervention study designs necessarily constrained conclusions about the impact of
interventions on outcomes. Conclusions on the effect of changes in antimicrobial use on
patient outcomes were also impacted by the existence of a complex health system with
multiple external confounders, such as community-acquired infections, variations in drug
acquisition costs and infection control practices. The retrospective study methodology in
Chapter 5 was used as a pragmatic way of assessing outcomes of AMS, where a
prospective study would have been unachievable due to parallel clinical commitments
during the implementation phase. Antimicrobial resistance was not included as an
outcome measure for this research project as a longer ASP timeline would be required to
effect meaningful changes to resistance patterns (Yong et al., 2010).

Multisite methodology was one of the strengths of this research with the exceptions of
Chapters 2 and 3 where clinical data were only presented from the tertiary referral
hospital. This was despite attempts by the candidate to collect data at one or more of the
smaller sites. Lack of on-site personnel, and a busy clinical load prevented adequate data
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collection. The methodology for those studies remains applicable to a multisite approach,
as described in suggestions for future research (Section 8.6).

In the research related to the VI (Chapters 6 and 7), the pre- and post-intervention surveys
were not linked, limiting the statistical analysis to grouped comparisons. Also, low survey
response rates, particularly post-intervention, hampered conclusions about the
effectiveness of the VI. This project was also the only one to compare different
educational methods, those being an e-learning tool and an email (Chapter 7).

Assessing the appropriateness of prescribing of antimicrobials according to the
recommendations in the Australian Therapeutic Guidelines: Antibiotic (Antibiotic Expert
Group, 2010) was an important part of this research. Midway through the research, a new
version of the Therapeutic Guidelines: Antibiotic was released (Antibiotic Expert Groups,
2014). However, there were no changes to the recommendations for antimicrobial use
related to the projects described in Chapters 2, 3 or 4. Chapter 5 was a retrospective
analysis based on the 2010 version of the guidelines, and Chapters 6 and 7 were
constructed around clinical content that was derived only from the 2014 version.

8.6 Suggestions for future research

This research demonstrated changes in antimicrobial use patterns over time, and the effect
on patient outcome measures. A number of questions have arisen that can guide further
research. The effect of AMS on patterns of antimicrobial resistance at various
organisational levels presents novel research opportunities, particularly in the multisite,
non-metropolitan setting. As the majority of study methodologies were uncontrolled,
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there is also an opportunity to conduct studies with design features that include
prospective data collection and randomisation, and further multisite research that can
capture data from the smaller rural hospitals. An emerging area in AMS is mixed methods
research, whereby qualitative components provide a deeper insight into the effectiveness
of interventions and help to inform quantitative evaluation. This would be of particular
use in assessing technological advances. There is also the potential to further explore
much sought after outcome data such as clinical cure rates and mortality.

8.7 Conclusions

With the increasing prevalence of antimicrobial resistance, there is an urgent need to
develop ways to improve use of antimicrobials in humans. In hospitals, where patients are
treated for severe and complex infections, antimicrobial stewardship offers a system for
improving patient outcomes while addressing antimicrobial resistance at a broader level.
In that context, this research has achieved the following meaningful contributions:
(1) An educational model for discontinuing unnecessary gentamicin use in the setting of
orthopaedic surgery was implemented without evident harm to patients.
(2) An intervention leading to a significant reduction in antimicrobial duration of therapy
for patients with community-acquired pneumonia, without any negative impact on 30-day
readmission rates and mortality.
(3) The burden of Clostridium difficile infection as a consequence of antimicrobial use
was shown by significant increases in patient length of stay and hospital costs.
(4) A multisite educational model resulted in significant improvements in antimicrobial
use and was associated with reductions in Clostridium difficile infection, infection-related
lengths of stay and mortality.
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(5) An innovative educational method in the form of the Vancomycin Interactive elearning tool identified that different educational strategies can be suited to particular
health professionals. Through addressing barriers to traditional educational methods, this
freely available online e-learning tool offers a potential model for future antimicrobial
education.
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9 Appendices
Appendix A

Literature search methodology

An initial search for the available literature, using a censorship date of 30 June 2013 was
employed using the following strategy on Pubmed:
((antimicrobial[ti] OR antifungal[ti] OR antibiotic[ti]) AND (utilisation[ti] OR
utilization[ti] OR usage[ti] OR stewardship[ti] OR "management team"[ti]) OR
"antimicrobial use"[ti] OR "antibiotic use"[ti] OR "antifungal use"[ti]) OR (("antibacterial agents"[MeSH] OR "antifungal agents"[MeSH]) AND "Physician's Practice
Patterns"[MeSH]).
As an “antimicrobial stewardship” MeSH term was not available, the search strategy from
the recent Cochrane review by Davey and colleagues (2013) was analysed to determine
the most closely related MeSH terms, which included “anti-bacterial agents’, “anti-fungal
agents” and “Physician's Practice Patterns”. Searches for antiviral agents and other
antimicrobials were excluded from this literature review.
Literature for this review was searched for using the following hierarchy (University of
Illnois at Chicago, 2013): meta-analyses and systematic reviews; randomised controlled
trials; cohort studies; case-control studies; case series, case reports; editorials, expert
opinion.
Subsequent searches for the subtopics within the review were analysed from within this
search strategy, with a recent review article on each topic acting as a check for
completeness of the review. The majority of studies in this field were of low quality

according to the evidence pyramid, mainly consisting of uncontrolled observational
before-and-after studies. A 2013 Cochrane review identified 507 full text articles on the
improvement of antibiotic prescribing in hospital inpatients (Davey et al., 2013). Of these,
300 were excluded on the basis of the study design, which included inadequate time
series analyses and uncontrolled before-and-after studies. Some of these studies were
included, because their structure provided insight into the type of projects that were
carried out as part of this thesis.

Search terms used for Chapter 2 were: “orthopaedic surgery”, “orthopedic surgery”,
“surgical prophylaxis”, “antimicrobial/s”, “antibiotic/s”, “antimicrobial stewardship”,
“antibiotic stewardship”, “urinary catheter/s”, “catheter-associated bacteriuria”, “urinary
tract infection/s”, and “prophylaxis”.

Search terms used for Chapter 0 were: “community-acquired pneumonia”, “antimicrobial
stewardship”, “antimicrobial/s”, and “antibiotic/s”.

Search terms used for Chapter 4 were: “Clostridium difficile”, “antibiotic/s”,
“antimicrobial/s”, “proton pump inhibitor/s”, “length of stay”, “health costs”,
“antimicrobial stewardship”, and “antibiotic stewardship”.

Search terms used for Chapter 5 were: “antimicrobial/s”, “Clostridium difficile”, “length
of stay”, “health costs”, “multisite”, “multi-site”, “mortality”, “antimicrobial
stewardship”, and “antibiotic stewardship”.
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Search terms used for Chapters 6 and 7 were: “nursing education”, “pharmacy
education”, “medical education”, “continuing education”, “vancomycin”, “antimicrobial
stewardship”, “online learning”, and “serious game”.

References
Davey, P, Brown, E, Charani, E, Fenelon, L, Gould, IM, Holmes, A, Ramsay, CR,
Wiffen, PJ & Wilcox, M 2013. Interventions to improve antibiotic prescribing
practices for hospital inpatients. Cochrane Database Syst Rev, 4, CD003543.
University of Illnois at Chicago 2013. Evidence-based practice in health sciences
[Online]. Chicago: UIC. Available from: http://ebp.lib.uic.edu/nursing/node/12
[Accessed 13th October 2013].

239

Appendix B

Ethics materials and data collection form reported in Chapter 2.
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Orthopaedic surgical prophylaxis project data collection form
Bed

Name

MRN

Opn

Surgeon
and Reg

OpDate

MSU

Cr

Cr

Preop

Pre

Pst

(MRSA?)
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Date

ABx –

ABx –

In/Pre

Out/Post

(Wt)

Appendix C

Ethics materials and data collection form reported in Chapter 0.
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CAP project data collection form
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1a. Patient audit number: _______

1b. MRN: ___________ 1c. Site: ________

2. Initials (eg. JoSm): First _ _ Last _ _
3a. Date of birth: __________________
4a. Arrival date: ________

3b.

Sex:

M

4b. Arrival time:________

F

4c. Admitted: Y

N U

Exclusion criteria:
< 18 years of age
Immunosuppressed (HIV positive or concurrent chemo/immunosuppressant therapy)
Cystic fibrosis
Bronchiectasis
Exacerbation of COPD or asthma if not involving pneumonia
Suspected or confirmed tuberculosis
Aspiration or hospital-acquired pneumonia
Discharged from hospital within the previous 14 day period
Patients transferred from another hospital
5.
Placement after ED: Discharge
Other
Doctor’s diagnosis:
Unknown

Pneumonia

Dr’s assessment of severity: Mild

HITH Ward

Chest infection

Moderate

CAP confirmed on Chest X-ray report:
Unknown

Yes

ICU/HDU

Transfer

Other: _____________

Severe
Equivocal

Unknown
No

Not done

SMART-COP severity score (on first observations):
Result

Score

S
M
A
R

systolic BP < 90mmHg (2 points):
multilobar involvement (1 point):
albumin < 35g/L (1 point)
respiratory rate 25br/min or more (30br/min in
>50yrs) (1 point)
T
tachycardia 125bpm or more (1 point)
C
confusion (acute) (1 point)
O
Oxygen low- PaO2<70 (<60 for over 50yrs)
O2 sat 93% or less (90% or less for > 50 yrs)(2
pts)
P
pH < 7.35 (2 points)
SMART-COP score (greater than or equal to 5 =
severe)
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Symptoms: Cough – Y N U
Dyspnoea – Y N U

Sputum – Y N U

Severity score documented: Y N Unknown
_________________
Sputum sample taken: Yes
Sputum result:

No

Fever – Y N U

Which score/result:

Unknown

Pathogen(s)_____________

Negative

Contaminated

Allergies/Adverse drug reactions ________________________________
Type of reaction: _____________________________________________
Antibiotics given prior to ED (or “none”): __________________________________
Initial antibiotic regimen
Antibiotic
Dose

*

Frequency Correct, Route Right
Low,
drug?
High,
*
Unclear

ID/micro
approved?

Completely, Partially, Not at all, Unclear

Antibiotic: who ordered it:
EDJMO Unk

AMO AMO'sReg AMO'sJMO EDCons EDReg

Who charted it:
EDJMO Unk

AMO AMO'sReg AMO'sJMO EDCons EDReg

Medication changed by team: Yes No Unk
____________________

Date: _______ To what:

20a. Total duration ABx in hospital: _______ days
________ days
21a. Discharge date: _______
____________

20b. Days of ABx given at D/C:

21b. Date of death (if applicable):

22. Final diagnosis/es: __________________________________________________
23.Comments:____________________________________________________________
________________________________________________________________________
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Appendix D

Ethics materials and data collection form reported in Chapter 4.
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Clostridium difficile project data collection form
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1a. Patient audit number: _______

1b. Site: ________

2a. Initials (eg. JoSm): First _ _ Last _ _

2b. MRN: ___________

3a. Date of birth: __________________

3b. Sex:

4a. Date admitted: __________________

4b. Date discharged: __________________

5a. Admitting consultant: _________________________
___________________
6a. Date of diagnosis: ___________________
_______________

M F Other

5b. Unit:

6b. Micro Episode no.

7a. Was C. diff diarrhoea the reason for admission? Y / N / U
7b. If NO, reason: ______________________________________________
8. Date of discharge for most recent admission (if applicable): ___________________
9. Primary classification:
weeks of discharge)

home

a. HCA-inpatient b. HCA-outpatient definite (within 4

c. HCA-O probable (4-8 weeks) d. HCA-O possible (8-12 weeks)
f. Community

e. Nursing

10. If health care associated: a. Hospital of likely origin ______________b. Ward:
___________
c. Consultant: ________________________
______________________

d. Unit:

11. Potential risk factors
Y/N/U
indication/procedure if Yes
a. Current PPI use
_____
_______________________________
b. Current H2 antagonist
_____
_______________________________
c. Antiperistaltic use
_____
_______________________________
d. GI surgery within 30 days
_____
_______________________________

Drug + dose +

12. Co-morbidities
Y/N/U
a. Current malignancy
_____
_______________________________
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b. Immunosuppressive drugs
_____
_______________________________
c. Immunosuppressive illness
_____
_______________________________
13. Other important risk factors / co-morbidities / contributory factors
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
________________________________________________
14. Current antibiotic use
a. Antibiotic use at time of diagnosis
Y/N/U
b. Name of antibiotic
IV/Oral
Dose/Frequency/Duration
Indication
_______________
______
______________________
______________
_______________
______
______________________
______________
_______________
______
______________________
______________
_______________
______
______________________
______________
15. Previous antibiotic use
a. Antibiotic use 1 month prior to diagnosis Y / N / U
b. Name of antibiotic
IV/Oral
Dose/Frequency/Duration
Indication
_______________
______
______________________
______________
_______________
______
______________________
______________
_______________
______
______________________
______________
_______________
______
______________________
______________
c. If off antibiotics at diagnosis, date last antibiotic stopped:
__________________
16. Initial Treatment
a. Drug
IV/Oral
Dose/Frequency/Intended duration
_______________
______
_____________________________
_______________
______
_____________________________
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Date started
__________
__________

_______________
______
_____________________________
17a. Did AMS recommend changing treatment?
17b. AMS-recommended treatment
a.
Drug
IV/Oral
Dose/Frequency/Intended duration
_______________
______
_____________________________
_______________
______
_____________________________
_______________
______
_____________________________

__________

Y/N/U
Date started
__________
__________
__________

18. Were other antibiotics withdrawn within 48 hours of diagnosis?
a. Completely (stat) b. Completely (< 48hrs) c. Partially d. Changed e. Not at
all f. Unknown
19a. ICU required? Y / N / U
20. Mortality
a. 7 days: Alive / Died / Unk
Alive / Died / Unk

19b. Surgery required? Y / N / U

b. Discharge: Alive / Died / Unk

c. 30 days:

21. Comments
________________________________________________________________________
________________________________________________________________________
________________________________________________________________________
____________________________________________________________
________________________________________________________________________
____________________
Please return to Stuart Bond, Pharmacy, 4222 5646 or pager #263
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Appendix E

Ethics materials reported in Chapter 5.
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Appendix F

Ethics materials reported in Chapter 6 and Chapter 7.
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